The effect of highly active antiretroviral therapy on Human Papilloma Virus Infection and Cervical Dysplasia in women living with HIV by Zeier, Michele D.
  
 
The Effect of Highly Active Antiretroviral Therapy on 
Human Papilloma Virus Infection and Cervical Dysplasia 
in Women Living With HIV 
 
 
 
 
 
by 
Dr Michèle D. Zeier 
MB ChB (Stell) 
B Med Sci (Stell) 
Dissertation presented for the degree of 
Doctor of Philosophy (PhD) 
Internal Medicine 
 
In the Faculty of Health Sciences  
University of Stellenbosch 
 
 
 
 
 
 
PromotHrs   
Prof Jean B. Nachega 
Prof Matthys H. Botha 
$SULO201 
 
  
 
 Declaration 
 
By submitting this thesis electronically, I declare that the entirety of the work contained therein is 
my own, original work, that I am the sole author thereof (save to the extent explicitly otherwise 
stated), that reproduction and publication thereof by Stellenbosch University will not infringe any 
third party rights and that I have not previously in its entirety or in part submitted it for obtaining 
any qualification. 
 
 
April 2014 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2014 Stellenbosch University 
 
All rights reserved 
Stellenbosch University http://scholar.sun.ac.za
 2 | P a g e  
 
Table of Contents 
SUMMARY ...................................................................................................................................6 
LIST OF ABBREVIATIONS .................................................................................................. 11 
CHAPTER 1:   INTRODUCTION ......................................................................................... 12 
CHAPTER 2:    LOW-GRADE CERVICAL DYSPLASIA IN WOMEN LIVING WITH 
HIV ............................................................................................................................................... 22 
Introduction .................................................................................................................................................. 22 
Materials and Methods ................................................................................................................................. 22 
Results .......................................................................................................................................................... 26 
I. Baseline Demographics and Clinical Characteristics ........................................................................... 26 
II. Progression of LSIL ........................................................................................................................... 28 
III. Persistence of SIL .......................................................................................................................... 31 
Discussion ..................................................................................................................................................... 34 
CHAPTER 3:   HIGH-GRADE CERVICAL DYSPLASIA IN WOMEN LIVING 
WITH HIV .................................................................................................................................. 38 
Introduction .................................................................................................................................................. 38 
Materials and Methods ................................................................................................................................. 39 
Results .......................................................................................................................................................... 41 
I. Baseline Demographics ...................................................................................................................... 41 
II. Excision Treatment Failure ................................................................................................................ 43 
III. Post excision Recurrence ............................................................................................................... 46 
Discussion ..................................................................................................................................................... 48 
CHAPTER 4:   CERVICAL HPV INFECTION IN WOMEN LIVING WITH HIV .... 52 
Background .................................................................................................................................................. 52 
Introduction ............................................................................................................................................... 52 
Human Papilloma Virus Infection in HIV Uninfected Women .................................................................... 52 
HPV Infection in HIV infected women ....................................................................................................... 55 
Latency and Reactivation of HPV ............................................................................................................... 56 
Monitoring HPV infection .......................................................................................................................... 58 
Antiretroviral Therapy and HPV infection .................................................................................................. 61 
Methods ........................................................................................................................................................ 64 
Stellenbosch University http://scholar.sun.ac.za
 3 | P a g e  
 
Results .......................................................................................................................................................... 70 
Patient Demographics................................................................................................................................. 73 
Frequency of Detection of HPV genotypes ................................................................................................. 75 
HPV Prevalence in Study Subjects ............................................................................................................. 76 
Association of HPV subtype detection with Cytopathology Results ............................................................. 78 
Association of HPV subtype detection with HSIL ....................................................................................... 80 
Influence of cART status on HPV infection ................................................................................................ 82 
Influence of Time Since cART first started on HPV infection ..................................................................... 84 
The Influence of CD4 count on HPV infection ............................................................................................ 86 
Discussion ..................................................................................................................................................... 88 
CHAPTER 5:  CERVICAL HIV INFECTION AND HPV DETECTION ...................... 95 
Background ................................................................................................................................................... 95 
Methods ........................................................................................................................................................ 98 
Results ........................................................................................................................................................ 100 
Exploratory descriptive analysis: HIV-RNA and -DNA results .................................................................. 100 
Association of plasma HIV-RNA level with Cervical HIV-DNA Proviral Load ......................................... 105 
Association ART Status with Cervical HIV-DNA Proviral Load ............................................................... 106 
Association Time since ART Started with Cervical HIV-DNA Proviral Load ............................................ 107 
Association of Cervical HIV-DNA Proviral Load with HPV Detection ..................................................... 108 
Association of Multiple HPV Detection with Cervical HIV-DNA Proviral Load ....................................... 109 
Discussion ................................................................................................................................................... 110 
CHAPTER 6:  FINAL CONCLUSIONS ............................................................................. 113 
REFERENCES......................................................................................................................... 118 
APPENDICES .......................................................................................................................... 131 
 
 
  
Stellenbosch University http://scholar.sun.ac.za
 4 | P a g e  
 
List of Figures 
 
 
Figure 1 Most prevalent cancer by country- females ..................................................................................... 12 
Figure 2 Cervical Cancer Estimates 2008 ...................................................................................................... 13 
Figure 3 Progression of HPV infection in the cells of the Cervix .................................................................. 14 
Figure 4 Poster announcing global GAVI expansion of HPV vaccine access ................................................ 16 
Figure 5 Numbers of Patients attending the IDC clinic, Tygerberg Hospital, for ART. ................................. 18 
Figure 6 Number of procedures performed annually at the Colposcopy Clinic, TBH. ................................... 18 
Figure 7.  Comparative age distribution (percentage of total TBH HIV ARV women) with history of LSIL 
and HSIL on cytology report ......................................................................................................................... 19 
Figure 8 Time line of a patient in the study of persistence. ............................................................................ 26 
Figure 9 Kaplan-Meier Plot for Progression-Free Status, According to HIV Groups .................................... 29 
Figure 10 Survival of  Persistence of SIL, for HIV positive group according to when ART started in relation 
to first LSIL diagnosis ................................................................................................................................... 33 
Figure 11 SIL Recurrence-free survival After Excision Biopsy ..................................................................... 46 
Figure 12 HPV prevalence world-wide .......................................................................................................... 53 
Figure 13 Prospective Study enrolment ......................................................................................................... 71 
Figure 14 Percentage of Pap Smears reported as no endocervical cells present ............................................. 72 
Figure 15 Total Number of HPV Genotype Detections During Follow-up Time ............................................ 76 
Figure 16 Independent Association of all HPV types with Abnormal Cytopathology (Unadjusted) ............... 78 
Figure 17 Independent Association of all HPV types with Abnormal Cytopathology (Adjusted) .................... 79 
Figure 18 Independent Association each HPV type with HSIL, unadjusted .................................................. 80 
Figure 19 Independent Association each HPV type with HSIL, Adjusted ...................................................... 81 
Figure 20 Association of cART Treatment status with detection of HPV16 compared to other HPV types .... 83 
Figure 21 Association of months since cART was first started with detection of HPV16 compared to other 
HPV types ...................................................................................................................................................... 85 
Figure 22 Association of CD4<200 with detection of HPV16 infection, compared to other HPV types .......... 87 
Figure 23 Early host invasion by HIV ........................................................................................................... 96 
Figure 24 HIV-1 Region detected by the proviral DNA qPCR assay .............................................................. 99 
Figure 25 Number of Observations at observation points for quarters 1-10 after cART was first started. .... 100 
Figure 26 Log plasma HIV-RNA level at each quarter after cART first started. .......................................... 101 
Figure 27 Distribution of Log Plasma HIV-RNA Level Results at observation points for quarters 1-10 since 
cART was first started. ................................................................................................................................. 101 
Figure 28 Cervical HIV-DNA pVL at each quarter after cART first started. ............................................... 102 
Figure 29 Distribution of Log Cervical HIV-DNA pVL at observation points  for quarters 1-10 since cART 
was first started. ........................................................................................................................................... 102 
Figure 30 Effect of cART on log plasma HIV-RNA levels vs cervical HIV-DNA pVL ................................. 103 
Figure 31 Correlation of visit log plasma HIV-RNA with log cervical HIV-DNA ........................................ 104 
Figure 32 Subjects with negative HIV-DNA pVL observations and corresponding detectable plasma HIV-
RNA levels ................................................................................................................................................... 104 
 
  
Stellenbosch University http://scholar.sun.ac.za
 5 | P a g e  
 
List of Tables 
 
 
Table 1 Comparison: Cervical Smear Results ................................................................................................ 19 
Table 2 Demographic and Clinical Characteristics ........................................................................................ 27 
Table 3 Factors associated with Progression of LSIL to HSIL for All Women in Cohort .............................. 28 
Table 4 Impact of Excision of LSIL on Progression, According to HIV Groups ............................................ 29 
Table 5 Risk Factors for Progression of LSIL for HIV positive Women ........................................................ 30 
Table 6 Factors that Influence Clearance of  LSIL in All Women in Cohort ................................................. 31 
Table 7 Impact of Excision of LSIL on Clearance, According to HIV Groups .............................................. 32 
Table 8 Factors that Influence Clearance of  LSIL in HIV Infected Women ................................................. 33 
Table 9 Demographic and Clinical Characteristics of Women who underwent Excision Biopsy treatment .... 42 
Table 10 Factors Influencing Excision Treatment Failure for All HIV groups ............................................. 44 
Table 11 Factors Influencing Treatment Failure for HIV positive Women ................................................... 45 
Table 12 Factors Associated With Post Excision Recurrence of  SIL in All Women ...................................... 47 
Table 13 Factors Associated With Recurrence of  SIL in HIV Positive Women ............................................. 48 
Table 14 Relative contribution of HPV16 in increasing severity of cervical dysplasia and cancer ................. 54 
Table 15 Summary of Studies investigating the effect of cART on cervical or anal HPV Infection................ 63 
Table 16 Demographic and Clinical Characteristics: Prospective Study ........................................................ 74 
Table 17 HPV types Most Detected Per Patient during follow-up time........................................................... 77 
Table 18 Association of cART treatment status with detection of all HPV subtypes ....................................... 82 
Table 19 Association of cART treatment status with detection of All HPV Infection ..................................... 82 
Table 20 Association of cART Treatment status with detection of HPV16 ..................................................... 82 
Table 21 Association of months since cART first started with detection of all HPV subtypes ......................... 84 
Table 22 Association of months since cART first started with detection of all HPV subtypes ......................... 84 
Table 23 Association of months since cART first started with detection of HPV16 infection ......................... 84 
Table 24 Association of CD4<200 with detection of all HPV subtypes ........................................................... 86 
Table 25 Association of CD4<200 with detection of All HPV Infection ......................................................... 86 
Table 26 Association of CD4<200 with detection of HPV16 infection ........................................................... 86 
Table 27 Association of plasma HIV-RNA level with Cervical HIV-DNA pVL >1.0/copies/106 cells ........... 105 
Table 28 Association of plasma HIV-RNA level with Cervical HIV-DNA pVL >2.0/copies/106 cells ........... 105 
Table 29 Association of plasma HIV-RNA level with Cervical HIV-DNA pVL>3.0/copies/106 cells ............ 105 
Table 30 Association of ART Status with Cervical HIV-DNA pVL>1.0/copies/106 cells............................... 106 
Table 31 Association of ART Status with Cervical HIV-DNA pVL >2.0/copies/106 cells .............................. 106 
Table 32 Association of ART Status with Cervical HIV-DNA pVL>3.0/copies/106 cells............................... 106 
Table 33 Association of Months since cART started with Cervical HIV-DNA pVL>1.0/copies/106 cells ...... 107 
Table 34 Association of Months since cART started with Cervical HIV-DNA pVL >2.0/copies/106 cells ..... 107 
Table 35 Association of Months since cART started with Cervical HIV-DNA pVL >3.0/copies/106 cells ..... 107 
Table 36 Association of Cervical HIV-DNA pVL with Detection of Any HPV Type..................................... 108 
Table 37 Association of Cervical HIV-DNA pVL with Detection of any HR HPV Type ............................... 108 
Table 38 Association of Cervical HIV-DNA pVL with Detection of HPV 16 and/or HPV 18 ....................... 108 
Table 39 Association of Number of HPV types with Cervical HIV-DNA pVL .............................................. 109 
  
Stellenbosch University http://scholar.sun.ac.za
 6 | P a g e  
 
Summary 
 
Title 
The Effect of Highly Active Antiretroviral Therapy on Human Papilloma Virus Infection and Cervical 
Cytological Abnormalities in Women Living With HIV 
 
Background 
Human Papillomavirus (HPV) infection causes cervical cancer. The prevalence of HPV-related 
dysplastic lesions is significantly higher in patients co-infected with the HI virus and thought to be 
linked to possible more persistent HPV infection. There is, however, conflicting evidence as to 
whether treatment of Human Immunodeficiency Virus (HIV) infection with antiretroviral agents may 
influence cervical HPV infection and the behaviour of Squamous Intraepithelial Lesions (SIL). 
 
Aims 
To examine the effect of the initiation of combination antiretroviral therapy (cART) on: 1) the 
persistence of cervical Low-grade SIL (LSIL); 2) The progression of cervical LSIL to High-Grade 
SIL (HSIL); 3) The effectiveness of excision treatment of HSIL 4) HPV genotypes detected, in HIV-
infected and uninfected women at the Infectious Diseases Clinic and the Colposcopy Clinic, 
Tygerberg Teaching Hospital, Cape Town, South Africa. 
 
Design and Methods 
We conducted  a retrospective cohort analysis of 1720 women with LSIL  of the survival of 
progression-free-time or time-to-clearance. Time to progression or persistence was compared 
according to HIV status, antiretroviral treatment and CD4 count. In another retrospective cohort 
analysis, we investigated the effectiveness of excision treatment in 1848 women who underwent 
LLETZ or CKC biopsy was used. Logistic regression and survival analysis were used to compare 
excision treatment failure and recurrence-free time between groups according to HIV status, 
antiretroviral therapy and CD4 count. 
 
To investigate the effect of antiretroviral therapy on the cervical HPV infection, 300 HIV-infected 
women were prospectively enrolled and followed at 6-monthly interval. Cytological testing and 
cervical HPV sampling were done at each visit.  Biopsy of suspicious lesions and excision treatment 
were done at colposcopy clinic according to standard a protocol.  The Roche Linear array HPV 
genotyping test was used for HPV detection. Generalized Estimating Equation (GEE) multivariate 
analysis was applied to investigate the effect of cART on the detection of HPV infection, while 
adjusting for time-dependent covariates such as CD4 count, sexual activity and excision treatment. 
The effect on each HPV type was then also compared to the effect on HPV16. 
 
Results 
Overall, we found that there was no difference between the progression of LSIL to HSIL by HIV 
status. However, among HIV-infected patients, those who started ART before first LSIL had a 
significantly lower risk for progression (HR 0.66, 95% CI 0.54-0.81). CD4 count did not have an 
impact on the risk for progression. We also found lower persistence of SIL in the HIV uninfected 
group (HR 0.69, 95% CI 0.57-0.85) and that cART was independently associated with decreased 
persistence of LSIL. On the other hand, a higher CD4 count at the time of first LSIL was not 
associated with lower persistence of the lesion. 
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HIV infected women with HSIL experienced much higher excision treatment failure than uninfected 
women (53.8% vs. 26.9%, p<0.001). Factors that improved outcome were higher CD4 count and 
complete excision. 
 
cART reduced the risk of detection of any HPV type by 47% (OR 0.53, 95% 0.49-0.58, p<001). 
When adjusted for covariates, time of exposure to cART and CD4 had a stronger effect.  Every month 
of cART exposure reduced the risk detection of any HPV type with 7%.  The effect was also 
significant on HPV16 alone (OR 0.93, 95% CI 0.90-0.95). All non-oncogenic subtypes were 
influenced similarly or more strongly than HPV16, as well as oncogenic HPV52. Only one oncogenic 
subtype HPV subtype, HPV39, was influenced marginally less (ratio of OR 0.95, CI 0.90-0.99, 
p=0.04).   
 
There was an increased risk for any HPV detection at CD4 count<200 (OR 1.63, 95% CI:1.50-1.77), 
but when adjusted, the time of cART exposure again remained the strongest predictor of risk (OR 
0.94, 95% CI:0.93-0.95). 
 
Conclusion 
cART impact the outcome of cervical HPV infection by increasing clearance, decreasing progression 
of LSIL and recurrence after excision treatment. This effect is time dependent and also associated 
with CD4 count. Specifically, HPV16 detection risk is also reduced by cART, and all HPV types are 
influenced at least as much as HPV16, except possibly HPV39. It seems that increased cervical HIV-
proviral load is associated with HPV detection risk, and both are lowered by cART time.  
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Opsomming 
Titel 
Die Effek van Kombinasie Antiretrovirale Terapie op Menslike Papilloomvirusinfeksie en Servikale 
Sitologiese Abnormaliteite in Menslike Immuniteitsgebrekvirus-geïnfekteerde Vroue 
 
Agtergrond 
Menslike Papilloomvirusinfeksie (MPV) veroorsaak servikale kanker. Die prevalensie van MPV-
verwante displastiese letsels is betekenisvol hoër in pasiënte wie ook met Menslike 
Immuniteitsgebrekvirus (MIV) geïnfekteer is en dit word gereken dat dit te wyte is aan meer 
persisterende  MPV infeksie. Daar is egter teenstrydige bewyse oor of die behandeling van MIV 
infeksie met antiretrovirale (ART) middels die infeksie met MPV en die gedrag van Plaveisel 
Intraepiletiële letsels (PIL) kan beïnvloed. 
 
Doelwitte 
Om die effek van die inisiasie van kombinasie ART op: 1) die persistering van Laegraadse PIL 
(LPIL); 2) die progressie van servikale LPIL na hoëgraadse PIL (HPIL) 3) die sukses van 
eksisiebehandeling van HPIL; 4) MPV genotypies waarneembaar, in MIV-geïnfekteerde vroue by die 
Infeksiesiektekliniek en die Kolposkopiekliniek,Tygerberghospitaal, Kaapstad, Suid-Afrika, te 
ondersoek. 
 
Studie-ontwerp en Metodes 
`n Retrospektiewe kohort-analise op 1720 vroue met LPIL van die oorlewing van progressive-vrye 
tyd en tyd tot opklaring van PIL is gedoen. Tyd tot progressie of opklaring is vergelyk na aanleiding 
van die pasiënt se MIV status, behandeling met antiretrovirale terapie en CD4-telling. In nog `n 
retrospektiewe kohort-analise is die effektiwiteit van eksisiebehandeling in 1848 vroue wie LLETZ or 
Kouemeskonus eksisie ondergaan het, ondersoek. Logistiese regressie en oorlewingsanalise is 
toegepas om die voorkoms van onsuksesvolle uitkoms en tyd sonder herhaling van letsels tussen 
groepe te vergelyk na aanleiding van MIV status, ART en CD4-telling. 
 
Om die effek van antiretroviral therapie op servikale MPV infeksie te ondersoek, is 300 MIV-
geïnfekteerde vroue opgeneem in `n prospektiewe studie en sesmaandeliks opgevolg. Sitologiese en 
MPV servikale smere is met elke besoek geneem. Biopsies van verdagte letsels en eksisiebehandeling 
is by die Kolposkopiekliniek gedoen volgens die standaardpraktyk. Die Roche Linear Array HPV 
Genotyping toets is gebruik vir MPV deteksie. Algemeen-beraamde vergelyking (GEE) 
meerveranderlike analise is toegepas om die effek van die anti-MIV terapie op die teenwoordigheid 
van MPV op die serviks te ondersoek. Die aangepaste effek is ook getoets deur die CD4-telling, die 
seksuele aktiwiteits- en eksisiebehandelingstatus by elke besoek in ag te neem. Die effek op elke 
MPV genotipe is laastens dan ook vergelyk met die effek op ‘n spesifieke basislyn genotype; in 
hierdie geval was MPV16 gekies. 
 
Resultate 
Daar was geen statisties beduidende verskil tussen die progressie van LPIL na HPIL na aanleding van 
HIV status nie, maar pasiënte wie met ART begin het voordat hulle vir die eerste keer met LPIL 
gediagnoseer was, het ‘n laer risiko gehad vir progressie (HR 0.66, 95% VI 0.54-0.81). Daar is ook 
gevind dat dit onafhanklik van die CD4 telling was. Die persistering van PIL was laer in die MIV 
negatiewe groep (HR 0.69, 95% VI 0.57-0.85), maar ook hier was antiretrovirale behandeling 
geassosieer met verminderde persistering. Weer eens was daar nie ‘n verband met die CD4 telling nie. 
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MIV-geinfekteerde vroue met HPILwas baie meer geneig tot gefaalde eksisiebehandeling (53.8% 
teenoor  26.9%, p<0.001). Verbeterde uitkoms was geassosieer met ‘n hoër CD4-telling en ‘n eksisie 
wat as volledig beskryf was. ART wat reeds voor die eksisiebehandeling begin was, het nie die risiko 
vir onsuskesvolle uitkoms statisties beduidend verminder nie, maar het egter die risiko vir herhaling 
van letsels na die eksisie sterk verlaag. 
  
ART het die kans dat enige MPV tipe waargeneem sou word, met 47% verlaag (OR 0.53, 95% VI 
0.49-0.58, p<001). Wanneer aangepas vir ander faktore, was die tyd wat verloop het sedert ART 
begin was, sowel as vir die CD4 telling, sterker. Vir elke maand sedert ART begin was, het die kans 
dat enige MPV tipe waargeneem word, met 7% verminder.  `n Soortgelyke effek is op HPV16 alleen 
gevind (OR 0.93, 95%, VI 0.90-0.95). Die effek was net so sterk of sterker op alle subtipes. Slegs een 
onkogeniese subtipe, MPV39, was gering minder beïnvloed (ratio van OR 0.95, VI 0.90-0.99, 
p=0.04).   
 
Die kans vir waarneming van enige MPV subtype is hoër wanneer die CD4 telling laer as 200 selle/ɥl 
is (OR 1.63, 95% VI: 1.50-1.77), maar wanneer aangepas, was die tyd van ART weer eens die sterkste 
voorspeller van MPV infeksie (OR 0.94, 95% VI:0.93-0.95). 
 
Gevolgtrekkings 
ART verbeter die uitkoms van servikale infeksie met MPV deur progressie en persistering van LPIL 
en herhaling van PIL na eksisie te verminder. Die effek is tydsafhanklik en word ook deur die CD4 
telling beïnvloed. Die kanse dat MPV16 spesifiek waargeneem word, word ook deur ART verminder, 
en all MPV tipes ondervind dieselfde of groter verlaging van waarnemingsrisiko as MPV16, behalwe 
miskien MPV39. Ons kon aandui dat verhoogde teenwoordigheid van servikale MIV verband hou met 
die risiko vir die waarneming van MPV infeksie, en beide word verminer deur die tyd waarmee die 
pasiënt met ARV terapie behandel is.  
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Chapter 1:   Introduction 
 
Cancer of the Cervix in South Africa and World-Wide 
 
Figure 1 Most prevalent cancer by country- females 
 
 
http://www.cancerresearchuk.org/cancer-info/cancerstats/world/ 
 
At an incidence rate of 26.8 per 100,000 population, cancer of the cervix is the second most 
common cancer in Southern African women (1). It is also the biggest cause of cancer death in 
South African women (1, 2). The region has the third highest cervix cancer mortality rate in 
the world, after Eastern and Western Africa, (1) (Figure 1). The lifetime risk of cervical 
cancer in South Africa has been reported as 1 in 26 (3) (Figure 2).  
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Figure 2 Cervical Cancer Estimates 2008  
World Age-Standardised Incidence and Mortality Rates per 100,000 Population, Females, World Regions 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/world/ ) 
 
World Region Incidence Rate Mortality Rate  
 
Eastern Africa 34.5 25.3 
Western Africa 33.7 24 
Southern Africa 26.8 14.8 
South-Central Asia 24.6 14.1 
South America 24.1 10.8 
Middle Africa 23 17 
Central America 22.2 11.1 
Caribbean 20.8 9.4 
South-Eastern Asia 15.8 8.3 
World 15.3 7.8 
Central and Eastern Europe 14.7 6.2 
Eastern Asia 9.6 3.9 
Northern Europe 8.4 2.5 
Southern Europe 8.1 2.5 
Western Europe 6.9 2 
Northern Africa 6.6 4 
Northern America 5.7 1.7 
Australia/New Zealand 5 1.4 
Western Asia 4.5 2.1 
 
 
Prevention and Detection of Cancer of the Cervix 
 
Cancer of the Cervix is a largely preventable disease. Detection and treatment of dysplastic 
pre-cancer lesions through screening programs is implemented internationally. Screening is 
done, and has been for many years, by performing a Cytological evaluation, or Papanicolaou 
(Pap) smear, at regular intervals. This procedure is easily performed by Health Care workers 
and can be performed after minimal training under even basic health service levels. When a 
low-grade abnormality (low-grade squamous intraepithelial lesion or LSIL) is detected on the 
Pap smear, it may safely be followed with a repeat smear after two years in order to exclude 
progression to a more severe high-grade lesion (high-grade squamous intraepithelial lesion or 
HSIL). If a high-grade lesion is detected, however, referral for colposcopy evaluation by a 
trained physician is necessary. A biopsy of abnormal-looking areas is done and if the high-
grade dysplasia is confirmed, the area needs to be excised to prevent further progression to 
cervical cancer. Regression of high-grade pre-cancer lesions occurs seldom. Figure 3 
represents a diagrammatic summary of the corresponding cytological and histological lesions 
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associated with the pathogenesis of cervical cancer. Sadly, access to screening facilities is 
most limited in the most underdeveloped regions in the world, which is reflected by the 
higher prevalence rates of cervical cancer in the same areas. 
 
Figure 3 Progression of HPV infection in the cells of the Cervix  
(Reproduced with permission from (4)) 
 
 
 
 
Cervical Cancer Screening Programme in South Africa 
 
For HIV-uninfected or of unknown HIV status, the current National Guideline for Cervical 
Cancer Screening recommends three Pap smears for every woman – one every ten years, 
commencing after the age of 30 years  (5). For women known with HIV disease and not yet 
eligible for Antiretroviral Treatment (ART), however, The South African Antiretroviral 
Treatment Guidelines recommend yearly Pap screening (6). 
 
The management of abnormal Pap smears according the National Guideline for Cervical 
Cancer Screening is identical regardless of HIV status. HSIL is always referred to the nearest 
Colposcopy clinic for evaluation. For LSIL and Atypical squamous cells of undetermined 
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significance (ASCUS) results, the smear is repeated after one year. If it persists, colposcopy 
evaluation is then recommended.  
 
Tygerberg Hospital still has a lower threshold for HIV positive women who have LSIL and 
recommends colposcopy examination after the first abnormal smear. This is based on 
evidence that cervical cytology may not be sufficient in HIV infected women as diagnostic 
tool:  they were found to be at high risk for underlying CIN II/III on colposcopy examination 
when diagnosed with a single cytological diagnosis (7). This is however not widely 
implemented outside our institution, and this approach still deserves validation. 
 
Human Papilloma Virus Infection and Cervical Cancer 
 
Cervical cancer is caused by oncogenic Human Papilloma Virus (HPV) infection (8). HPV is 
a small double stranded DNA virus that infects epithelial cells and can cause 
hyperproliferation of these cells. Cervical HPV infection is asymptomatic and easily 
transmitted. It is the most frequent viral sexually transmitted disease. The virus can exist in 
most of the anogenital region and it is likely that transmission during sexual intercourse is not 
prevented by the use of male condoms (9-15). 
 
Before technological advances enabled researchers to identify the aetiology of cervical 
cancer, the focus of research was on environmental and socioeconomic factors as causative 
agents. The progression from HPV infection to dysplasia and eventually invasive cancer is a 
slow process. In the HIV negative patient, mild dysplasia as well as moderate dysplasia 
almost always regresses spontaneously. 
 
HPV Vaccine 
 
There is currently no registered vaccine for the prevention of HIV infection. On the other 
hand, the development of HPV vaccines has been a modern success story. There are currently 
two non-infectious recombinant prophylactic HPV vaccine options with proven efficacy 
against some HPV strains. Gardasil ® (by Merck) targets subtypes 6, 11, 16 and 18  (16) and 
Cervarix ® (by GlaxoSmithKline) subtypes 16 and 18 (17). Both vaccines protect against the 
two subtypes that are responsible for over 70% of cervical cancer cases and 50% of high 
grade cervical lesions, and Gardasil ® protects against 93.5% to 96% of persistent HPV 
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infection, HSIL, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia 
(VAIN) and genital warts  (18). The impact of the nine valent vaccine currently in 
development will have an even larger impact, and is expected to prevent 90% of all invasive 
cervical cancer (19). Vaccination is aimed at the age group 9-12 years old, to occur before 
sexual debut. 
 
Although cost factors currently restrict HPV vaccination programmes world-wide, the recent 
announcement of drastic price reductions of both registered vaccines will see some African 
countries implement national rollout programmes by 2014. By 2020, the Global Alliance for 
Vaccines and Immunisation (GAVI) hopes to protect 30 million girls in 40 countries (20) 
(figure 4). Unfortunately, due to logistic factors, no catch-up vaccination effort can be 
expected, and the full cancer preventative effect may not be visible in South Africa for the 
next 20 years. 
 
 
 
Figure 4 Poster announcing global GAVI expansion of HPV vaccine access 
http://www.gavialliance.org/library/news/press-releases/2013/hpv-price-announcement 
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HPV Infection in HIV infected women 
 
The National HIV prevalence amongst women in South Africa according to the 2006 
antenatal survey stands at 29.1 % (21). HIV infection causes gradual weakening of cellular 
immune function and leaves women vulnerable to co-infection with diseases such as 
Tuberculosis (TB), and certain cancers, including vulval and cervical cancer (22). Even 
though cervical cancer has been reported as occurring at a younger age in HIV infected 
women, the burden of untreated HIV disease and high Acquired Immune Deficiency 
Syndrome (AIDS) mortality when antiretroviral therapy was not accessible, even led a 
reduction in the prevalence of cervical cancer reported in some areas (23). 
 
Now, in the era of improved survival of women living with HIV infection due to the better 
access to combination antiretroviral therapy (cART), an expected re-emergence of cervical 
cancer cases has not yet been documented. Furthermore, women on ART programmes for 
some years have been reported to have fewer abnormal smears than those recently initiated. 
Could this be due to cART? And if cART provides protection (clearance and/or decrease 
likelihood of progression to HSIL), is this due to or mediated by the reconstitution of the 
immune status, as can be measured by the CD4 T-cell count? 
 
Investigations at Tygerberg Hospital 
 
The Infectious Diseases Clinic (IDC) was established in 1993 under the Department of 
Internal Medicine. It is located on the eighth floor of Tygerberg Hospital (TBH) and has 
approximately fifty associated staff members, either on a full-time or part-time basis. Initially 
it treated mostly patients with sexually transmitted diseases and Tuberculosis, but as the HIV 
epidemic grew in the Western Cape, by 1996 most patients seen were referred for 
management of their HIV infection. From 1997 to 2011, it has also served as a site for 
Industry-driven pharmaceutical studies, in order to provide antiretroviral therapy to affected 
patients.  On the 6 January 2004 it became the first site to provide this cART as part of the 
Government Rollout Programme of Antiretroviral Treatment in the Western Cape. Since 
then, the IDC has initiated more than 3000 patients on cART (figure 5). 
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Figure 5 Numbers of Patients attending the IDC clinic, Tygerberg Hospital, for ART. 
The Colposcopy Clinic is located on the third floor of Tygerberg Hospital and falls under the 
Gynaecological Oncology Unit of the Department of Obstetrics and Oncology. The number 
of procedures performed at the clinic (biopsies) or referred from the clinic (hysterectomies) is 
depicted in Figure 1.6. There has been an increase in the number of biopsies since 2004, due 
to a combination of factors, which include the population growth in referral areas, but 
certainly, the number of HIV infected women who were referred for colposcopy evaluation 
also increased dramatically. 
 
 
Figure 6 Number of procedures performed annually at the Colposcopy Clinic, TBH. 
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We investigated the prevalence of cervical dysplasia in HIV positive women at Tygerberg 
Hospital in a pilot cross-sectional study in July 2007 and analysed the cytology smear and 
histopathology records of 648 HIV-positive females on the ARV programme at the IDC.  
Only 295 (45.6%) were found to have cytology or pathology results on record at the hospital. 
This was ascribed to the recommendation at the time that all women, regardless of HIV 
status, undergo the first Pap screening at the age of 30 years. The results of those women who 
had undergone screening were compared to those of prevalence survey done in Tygerberg 
Hospital Antenatal Clinic in 1996 which analysed 4762 cytology results done over a six 
month period (Study1)  (24), as well as to a multicentre South African Prevalence study from 
2003 (Study2) (25). Of the 295 TBH ARV women, 80 evaluated patients (27.1%) were found 
to have LSIL lesions (ASCUS or CIN I), 87 (29.5%) HSIL lesions (CIN II or CIN II) and 9 
(3.1%) had carcinomas. These figures are compared to Study1 and Study2 (table 1). 
  Table 1 Comparison: Cervical Smear Results 
Comparison: Cervical Smear Results: Percentage of Patients  (Median Age) 
 Study 1:  1996 Study 2: 2002 HIV ARV Group: 2007 
Normal 83.99% Not reported 38,2% (36,5) 
LSIL 2.66% (25,6) 2.42% (33,1) 27.1 % (34.1) 
HSIL 0.84% (30,8) 1.8 % (38,0) 29.5 % (35,7) 
Invasive CA 0.02 % (not reported) 0.47 % (51,3) 3.1 % (42.8) 
 
 
 
Figure 7.  Comparative age distribution (percentage of total TBH HIV ARV women) with history of LSIL 
and HSIL on cytology report 
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The cross-sectional design of our investigation which relied on retrospective data routinely 
collected through medical records with substantial missing data, as well as the tertiary nature 
of our Tygerberg Hospital (tertiary referral hospital), increase the likelihood of a selection 
bias towards overrepresentation of LSIL and HSIL and could account for the differences with 
Study 1 and 2. In support of a possible selection bias, a large number of women treated for 
HIV infection at Tygerberg Hospital (56.6%) had a recent history of LSIL and HSIL, and 
these numbers appeared to be much higher than the largely HIV uninfected comparative 
group from 1996.  Despite the above limitation leading to possible overestimation of the true 
prevalence rates, these results could also suggest the possibility of additional factors that 
could account for the high prevalence rates of LSIL, HSIL and cervical cancer observed such 
as failure of cervical cancer screening programmes. 
 
Indeed, improving Pap smear screening initially met with logistical problems. Health Care 
systems in South Africa are fragmented and services within institutions are generally not 
duplicated. Because Pap smear screening was at the time available at different locations 
within and outside the hospital, albeit on different days, we were not allowed to perform Pap 
smear screening at the IDC. Furthermore, patients were not willing or able to attend further 
appointments other than their ART dispensing visits, as they were either too ill, too poor or to 
overburdened from attending ART and TB appointments. 
 
We therefore initiated a more patient friendly service, largely funded through this research 
project, but not exclusive to study participants, whereby all women who attended the IDC 
could undergo Pap smear screening when reporting for cART initiation. This contributed to 
the improvement of Pap screening coverage to include 96% of our female patients. Since 
2012, Pap smear screening has now become part of the standard protocol for all women 
diagnosed with HIV infection, and most women who present to the IDC now have already 
had their first Pap smear test done at the referring clinic. 
 
Furthermore, during our initial pilot study, we noticed that many women who had been 
diagnosed with cervical dysplasia had not met their appointments at Colposcopy Clinic for 
evaluation and excision treatment as indicated. Some were even unaware of their prior 
screening result. We therefore decided at the IDC to include cervical dysplasia as an HIV 
related disease in the Clinic management database data capture sheet (an example is attached 
as appendix 1) and for this diagnosis also to be automatically included in the electronically 
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generated patient referral letter (appendix 2). Lastly, but importantly, the funding made it 
possible to purchase a third and new Colposcope for the Department of Gynaecology which 
shortened waiting times for appointments. 
 
The improved cooperation and collaboration between the IDC and the CC not only led to a 
“better deal” for patients, such as fewer visits with combined appointment dates, but enabled 
us to continue towards finding the answers to the most pertinent question we had regarding 
HIV infected women:  can we expect an increase in cervical cancer cases within the next few 
years, or will the treatment with antiretroviral agents mitigate or prevent an increase? 
 
In our attempt to answer this question, we rephrased it and refer to the important aspects of 
cervical dysplasia - the precursor disease of cervical cancer- in women living with HIV 
disease:  
1. What is the effect of cART on low-grade cervical dysplasia?  Can it lower the risk of 
progression to higher grade (pre-cancer) disease?  Chapter 2 describes a retrospective 
study investigating Progression and Persistence of low-grade disease. It compares 
these outcomes in HIV diagnosed and undiagnosed women, and investigates the 
impact of cART on these outcomes in HIV diagnosed women separately. 
2. What the effect of cART on excision treatment of high-grade cervical dysplasia? Can 
cART reduce the risk of recurrence of cervical dysplasia after excision treatment? 
Chapter 3 describes a retrospective study of women who underwent excision biopsy 
treatment of high-grade disease. It compares the excision treatment failure rate and 
post excision recurrence in HIV infected women with women not diagnosed with 
HIV. It also describes the impact of cART on these outcomes in HIV infected women 
separately. 
3. What is the impact of cART on cervical HPV genotype infection? Is this effect, or 
lack thereof, able to explain the answers to questions 1 and 2? A prospective study 
which enrolled women initiating cART is contained in Chapter 4.  
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Chapter 2:    Low-Grade Cervical Dysplasia in Women Living with HIV 
 
Introduction 
 
As discussed in the first chapter, cervical cancer is caused by Human Papillomavirus (HPV) 
infection. Most HPV infections clear within months in women with normal immune status. 
Progression of Low-grade SIL to pre-cancer (high-grade SIL) or cancer can however occur 
and is linked to persistent infection with one or more high-risk oncogenic types of Human 
Papillomavirus (HPV) (26-28).  
 
There is evidence that women who are co-infected with HIV develop cervical cancer at a 
younger age. Possible reasons are an increased persistence of genital HPV infection due to 
weakened immune system (29-32) and a resulting higher risk for progression of LSIL to 
high-grade lesions (33).  Prior to 2010, when we initiated our own investigation, there were 
few reports of an association of cART with a reduction in the burden of HPV and SIL (34-
36). These studies had however been done in low HIV prevalence settings.  
 
To investigate the factors that influence the persistence and progression of low-grade cervical 
intraepithelial lesions, we did a large retrospective cohort study that compared these 
outcomes in a setting of high HIV prevalence. We needed to confirm in our study population 
that there is an altered course of LSIL outcomes in HIV infected compared to uninfected 
women. Specifically, we were also interested to know if there is an association between the 
behaviour of cervical lesions with the antiretroviral treatment status of women living with 
HIV infection.  
Materials and Methods 
Study Design, Population, Setting and Outcomes Definition 
This retrospective cohort analysis used electronic records of 3,963 women who attended the 
Colposcopy Clinic and Infectious Diseases Clinic located in Tygerberg Hospital, Parow, 
Western Cape during the period July 2004 to July 2009.  Explanatory and outcomes variables 
such as histopathology and cytology data as well as information regarding use of 
antiretroviral therapy were collected from 1 January 1992 to 31 December 2010, extracted 
anonymously and linked to a study-specific identifier. Demographic data such as age and race 
were included.  
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For the analysis of progression and persistence of intraepithelial lesions we identified 1960 
cases that had a low-grade cervical intraepithelial lesion (LSIL) as first abnormal smear. Of 
these women, 1720 (87.8%) had follow-up available. Women who had a HSIL at first 
abnormal smear were not included.  We defined progression of LSIL as the detection of 
HSIL. Only women with a follow-up visit >24 weeks after the first LSIL were used for the 
analysis. Clearance was defined as two serial normal cytology results at least 4 weeks apart. 
 
Women were assigned to one of three groups. A patient was taken to be HIV positive if there 
was evidence that an HIV Enzyme-linked immunosorbent assay (ELISA) test or rapid test 
was performed, or a HIV viral load determination done that had virus detected. HIV negative 
status was taken as a negative ELISA or rapid test. If there was no evidence of HIV testing, 
the patient’s status was taken as HIV unknown. The choice of HIV group was made according 
to the status as known at first LSIL, as this was the most common point at which a patient’s 
status was identified. It was decided, in view of the retrospective nature of the study and lack 
of repeat HIV tests in the majority of women included, not to disregard the HIV unknown 
status group in this analysis, as the possibility existed that women not tested could represent 
women who were considered of very low risk for contracting HIV, whereas women who 
were tested negative, possibly represented a group considered at risk for HIV infection and 
were therefore tested but not re-tested during follow-up. Combination antiretroviral therapy 
(cART) was defined as the study subject receiving at least three antiretroviral medications and 
for the purpose of the study is equivalent to HAART (highly active antiretroviral therapy). 
Virological failure was defined as two consecutive HIV viral load determinations of >1000 
copies/ml at least 4 weeks apart. 
 
Squamous abnormalities were classified as LSIL, HSIL or cancer according to the Bethesda 
Classification System.  Cytology was performed with routine Papanicolaou (Pap) smear.  For 
the purpose of the analysis, ASC-US and Atypical squamous cells –low-grade (ASC-L) were 
grouped with LSIL, and Atypical squamous cells – cannot exclude HSIL (ASC-H) grouped 
with HSIL.  The quality of cytology was assessed by determining the percentage of smears 
with endocervical cells present.  Conventional Pap smear screening was in use for most of the 
time as the span of this study, but this has been previously found to be just as effective as 
liquid-based cytology in detecting abnormalities (37). Cytology was read by a cytopathologist 
and checked by a second cytopathologist, as per usual procedure in our institution. 
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In our setting, referral of HIV positive women for colposcopy evaluation is encouraged after 
the first abnormal smear. If a lesion suspicious of a high grade abnormality is visualized 
during colposcopy evaluation, a diagnostic biopsy is performed. If the biopsy confirms a high 
grade abnormality- that is CIN II or more on histology - an excision procedure is performed. 
Excision is by Large Loop Excision of Transformation Zone (LLETZ) under local 
anaesthesia in an outpatient setting. Cold knife Cone Excision (CKC) is performed in cases 
where there are either suspected early invasive carcinoma or adenocarcinoma in situ or large 
lesions or distorted anatomy not suitable for LLETZ. There is a move towards a see-and-treat 
approach: excision treatment may be performed at the first visit if the colposcopy appearance 
is suggestive of high grade histology (CIN II or above). In young women, where there is still 
a wish for future pregnancy, confirmatory biopsies are required before LLETZ or CKC. 
 
Pathology was considered to be more specific than cytology and the histology result was used 
if a smear was performed on the same day.  Excision treatment in this analysis refers to the 
surgical removal of the cervical lesions with the loop electrosurgical excision (LLETZ or 
LEEP), cold-knife cone (CKC or conisation), or hysterectomy.   
 
In this study, we compared the survival of LSIL without progression to HSIL here referred to 
as progression-free time, and the survival of LSIL or higher lesion without clearance of the 
lesion as persistence of SIL.  Our study was approved by the Stellenbosch University Human 
Research Ethics Committee (ref nr N11/01/007). Due to the fact that this study was a 
retrospective cohort analysis from an anonymous database (without patient identifiers), 
exemption for obtaining informed consent was granted. 
 
Statistical Analysis 
STATA Version 11 was used for the statistical analysis.   The t- test was used to compare the 
significance of the difference between the mean ages of women of HIV positive and 
unknown HIV status with the HIV negative group. Other group characteristics were 
compared using two-tailed chi square tests. Survival analysis of progression-free time of low-
grade cervical lesions, or for persistence of SIL used the Kaplan Meier method and log-rank 
test to compare the HIV status groups. Multivariable Cox regression was applied to identify 
independent risk factors for disease progression or persistence. Covariates investigated were 
age, the type of excision treatment performed and the duration of cART received. The effect 
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of excision treatment in this study applies only if the treatment was not done at the last visit:  
if excision was done at last visit, it is considered only as a histological observation and not as 
a therapeutic procedure.  
 
For both the analysis of progression and the analysis of persistence, the time 0 was taken as 
the first date that LSIL was detected. The end point for progression free- time was taken as 
the first date that the patient had a HSIL or higher lesion detected (event), or the last date that 
the patient was progression-free (censored if last date of follow-up). Concluding from our 
earlier definition of excision treatment effect on progression, a patient was classified as not 
having undergone excision treatment if it was performed on or after the day of first diagnosis 
of progression (HSIL or higher), as this would be on or beyond the end point of the 
progression end point. This automatically implies that, in our analysis of progression-free 
time, we adjusted for excision treatment performed for the indication of LSIL and not if done 
for HSIL. Figure 2.1.a provides an example of a time line of a patient in the study of 
progression-free time. 
 
 
 
 
 
 
 
Figure 2.1.a. Time line of a patient in the study of progression-free time. If an excision was performed at the 
time point “Excision A”, it was considered a therapeutic procedure. If it was performed at time point 
excision B, it was not. 
 
For analysis of persistence of LSIL, the end point was taken as the last date any SIL was 
detected as the event, if followed by a normal smear, or the last date that the patient had SIL 
detected, and censored if still present at last follow-up. The term persistence means the same 
as a lack of clearance for the purpose of this study.  
 
The analysis of progression and the analysis of persistence were conducted separately and a 
patient who developed HSIL was also considered as experiencing persistence (non-
clearance) of SIL. Regarding the effect of excision treatment on persistence of SIL, a patient 
LSIL LSIL LSIL HSIL ExcisionB ExcisionA LSIL 
Time 0: 
first LSIL 
End point: 
Progression event 
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was therefore regarded as having undergone the procedure if the date thereof was between 
time zero and before (but not on) the end point date, regardless of the indication of LSIL or 
HSIL. Figure 2.1.b provides an example of a time line of a patient in the study of persistence. 
 
 
 
 
 
 
 
 
Figure 8 Time line of a patient in the study of persistence. 
If an excision was performed at the time point “Excision A” or at time point Excision B”, it was considered a 
therapeutic procedure. 
 
The same methods were followed for a separate analysis of the effects of antiretroviral 
treatment and CD4 count within the HIV positive status group.  
 
Results 
 
I. Baseline Demographics and Clinical Characteristics 
 
Table 2 provides demographics data by HIV status. The mean age of women first diagnosed 
with LSIL for all three HIV status groups was compared and the HIV unknown status group 
found to be slightly older.  The follow-up time in HIV-infected women compared to HIV-
uninfected women was shorter. The quality of Pap smears performed on the HIV positive 
group was found to be marginally inferior to the other groups as measured by the presence of 
endocervical cells.  Of the total smears that had endocervical cell (EC) presence reported,  in 
the HIV positive group the percentage of smears with EC not present was higher at 19.1%, 
compared to 15.6% in HIV negative (p=0.006) and 18.2% in the HIV unknown status groups 
(p=0.05).  HIV positive women did not undergo more excision of LSIL during the follow-up 
period after first LSIL, and the number that did undergo excision of LSIL was small for all 
HIV groups. 
  
LSIL LSIL LSIL HSIL ExcisionB ExcisionA LSIL 
Time 0: 
first LSIL 
End point: 
Persistence (censored) 
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Table 2 Demographic and Clinical Characteristics 
 
   
                                                            
Total HIV negative 
n (%) 
HIV unknown 
  n (%) 
p-
value1 
HIV positive 
 n (%) 
p-value2 
 
Age at First LSIL 
(mean,SD)             
1720 33.1±10.14 35.6±11.10 0.006 32.5±7.73 0.34 
Ethic Group3 
Black 
Mixed Race 
Total 
 
520 
1200 
1720 
 
19 (9.5) 
181 (90.5) 
200 (100) 
 
31 (6.6) 
441 (93.4) 
472 (100) 
 
0.19 
 
470 (44.9) 
578 (55.2) 
1048 (100) 
 
<0.001 
Follow-up Time4 
(median,IQR) 
 
1720 
 
26.8 (14.9-49.0) 
 
31.4 (13.2-56.4) 
 
0.17 
 
17.5 (5.4-35.6) 
 
<0.001 
CD4 count at first LSIL5 
0-199 
200-349 
≥350 
Total with CD4 
available 
 
 
 
 
693 
 
 
 
N/A 
 
 
 
N/A 
 
 
 
N/A 
 
241 (34.8) 
213 (30.8) 
239 (34.5) 
693 (100) 
 
 
 
N/A 
ART duration 
None 
Started Before LSIL 
Started After LSIL 
Total 
 
 
 
 
1048 
 
 
 
 
N/A 
 
 
 
 
N/A 
 
 
 
 
N/A 
 
433 (41.3) 
185 (17.7) 
430 (41.0) 
1048 (100) 
 
 
 
 
N/A 
Excision of LSIL6 
Performed 
Not performed 
Total 
 
226 
1494 
1720 
 
28 (14.0) 
172 (86.0) 
200 (100) 
 
88 (18.7) 
384 (81.3) 
472 (100) 
 
0.15 
 
110 (10.6) 
938 (89.4) 
1048 (100) 
 
0.15 
1   t-test compares significance between means and Chi-square significance between two proportions (HIV 
unknown to HIV negative group) 
2   t-test compares significance between means and Chi-square significance between two proportions (HIV 
positive to HIV negative group) 
3   Number of  patients with LSIL and ethnic group known as Mixed Race or Black (% of Ethnic Group) 
4   From First LSIL to date of first progression or last follow-up, in months, for women  who had at least  24 
week follow-up available 
5   Done in year of first LSIL, for HIV infected women who had CD4 count available 
6   Includes all method of excision (excision biopsy and hysterectomy) of LSIL 
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II. Progression of LSIL 
 
Association of Progression of LSIL with HIV status 
Overall, there was no difference between HIV groups as to progression of LSIL to HSIL.  
Progression was observed in 94/200 (47.0%) of HIV negative women compared to 226/472 
(47.9%) of women HIV unknown status (p=0.83) and 447/1048 (42.7%) of HIV positive 
women (p=0.26). Time to progression from LSIL to HSIL was found to be not different for 
HIV-infected compared to uninfected women (Figure 9, Log-rank:  p=0.120). Cox regression 
showed no increased risk for progression from LSIL to HSIL by HIV status in both univariate 
and multivariate analysis, after adjusting for the effects of age and whether excision treatment 
was performed or not (Table 3). 
 
Table 3 Factors associated with Progression of LSIL to HSIL for All Women in Cohort 
 
 Univariate analysis Multivariate analysis 
Variable HR  (95%CI) p-value HR  (95%CI) p-value 
HIV Status 
Negative 
Positive 
Unknown 
 
1.00 
1.15  (0.92-1.44) 
0.98  (0.77-1.25) 
 
- 
0.22 
0.89 
 
1.00 
1.11  (0.88-1.38) 
0.96  (0.75-1.22) 
 
- 
0.38 
0.75 
Age at first LSIL 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
 
1.00 
1.16  (0.91-1.47) 
1.55  (1.22-1.97) 
1.67  (1.29-2.14) 
1.10  (0.81-1.48) 
1.55  (1.16-2.07) 
 
- 
0.23 
<0.001 
<0.001 
0.54 
0.003 
 
1.00 
1.18  (0.93-1.50) 
1.55  (1.22-1.96) 
1.83  (1.42-2.35) 
1.28  (0.95-1.73) 
2.12  (1.58-2.88) 
 
- 
0.18 
<0.0001 
<0.0001 
0.10 
<0.001 
Excision of LSIL‡ 
Not performed  
Performed 
1.00 
0.10  (0.60-0.16) 
- 
<0.001 
1.00 
0.09  (0.06-0.16) 
- 
<0.001 
‡ Excision includes all method of excision ( excision biopsy and hysterectomy) done during follow-up 
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Figure 9 Kaplan-Meier Plot for Progression-Free Status, According to HIV Groups 
Log Rank Test: X2=4.233, p=0.12 
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Association of Progression of LSIL with Excision Treatment 
Excision of the LSIL during follow-up did however impact on progression of the lesion. In a 
breakdown of the HIV groups, most women who underwent excision without a history of a 
prior HSIL lesion did not subsequently progress to HSIL and this was true for all groups by 
HIV status. For women who did not undergo excision treatment, progression was similar for 
the HIV groups (Table 4). Cox regression analysis confirmed decreased risk for progression 
if LSIL was excised. Adjusting for HIV status and age, there remains a strong association 
between the rate of progression and whether excision treatment was performed (Table 3).  
 
Table 4 Impact of Excision of LSIL on Progression, According to HIV Groups 
 HIV negative HIV unknown p-value* HIV positive p-value** 
Excision Performed‡ 
Progression 
No Progression 
Total 
 
0 (0.0) 
28 (100.0) 
28 (100) 
 
8 (9.1) 
80 (90.9) 
88 (100) 
 
0.20 
 
7 (6.4) 
103 (93.6) 
110 (100) 
 
0.34 
No Excision Procedure‡ 
Progression 
No Progression 
Total 
 
94 (54.7) 
78 (45.3) 
172 (100) 
 
218 (56.8) 
166 (43.2) 
384 (100) 
 
0.65 
 
440 (46.9) 
498 (53.1) 
938 (100) 
 
0.07 
Total 200 472  1048  
‡Excision includes all method of excision- excision biopsy and hysterectomy 
* Fisher’s exact test to compare significance between two proportions (Comparing HIV unknown  to HIV negative group) 
** Fisher’s exact test to compare significance between two proportions (Comparing HIV positive to HIV negative group 
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Association of Progression of LSIL with cART 
Progression was observed in 62/185 (33.5%) of HIV positive women who had started 
antiretroviral therapy before the first LSIL on smear, compared to 186/433 (43.0%) of 
women who received no ART (p=0.023) or 192/430 (44.7%) of women who initiated ART 
after the first LSIL (p=0.01).   In the multivariate Cox regression model,  there was a 
decreased risk for progression (HR 0.66, 95% CI 0.54-0.81) for the HIV positive patients  if 
ART was started before first LSIL, and this association remained strong when adjusted for 
age and whether excision treatment was performed (Table 5). 
 
Table 5 Risk Factors for Progression of LSIL for HIV positive Women 
  
 Univariate analysis Multivariate analysis 
Variable HR  (95%CI) p-value HR  (95%CI) p-value 
Age at first LSIL 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
 
1.00 
1.19  (0.89-1.62) 
1.34  (1.00-1.82) 
1.57  (1.14-2.17) 
1.01  (0.67-1.53) 
1.62  (1.07-2.46) 
 
- 
0.23 
0.06 
0.006 
0.96 
0.02 
 
1.00 
1.30  (1.96-1.76) 
1.47  (1.08-2.01) 
1.82  (1.32-2.51) 
1.23  (0.81-1.87) 
1.90  (1.25-2.90) 
 
- 
0.09 
0.01 
<0.001 
0.34 
0.003 
Duration of ART 
None 
Pre-First LSIL 
Post-First LSIL 
 
1.00 
0.67  (0.55-0.83) 
0.90  (0.68-1.20) 
 
- 
<0.001 
0.49 
 
1.00 
0.66  (0.54-0.81) 
0.90  (0.67-1.20) 
 
- 
<0.001 
0.47 
CD4 count at first LSIL 
0-199 
200-349 
≥350 
 
1.00 
1.08  (0.81-1.44) 
0.94  (0.71-1.24) 
 
- 
0.60 
0.67 
- - 
Virological Failure 
No 
Yes 
 
1.00 
1.18  (0.84-1.65) 
 
- 
0.35 
- - 
Excision of LSIL‡ 
Not performed  
Performed 
 
1.00 
0.10  (0.05-0.21) 
 
- 
<0.001 
 
1.00 
0.09  (0.04-0.19) 
 
- 
<0.001 
‡ Excision includes all method of excision ( excision biopsy and hysterectomy) done during follow-up 
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III. Persistence of SIL 
Association of Persistence of LSIL with HIV status 
Persistence was observed in 669/1048 (63.8%) of HIV positive women (p<0.001) and 
137/472 (29.4%) of women of unknown HIV status (P=0.13) compared to 70/200 (35.0%) of 
HIV negative women, respectively. 
 
Table 6 Factors that Influence Clearance of  LSIL in All Women in Cohort 
 
 Univariate analysis Multivariate analysis 
Variable HR  (95%CI) p-value HR  (95%CI) p-value 
HIV Status 
Negative 
Positive 
Unknown 
 
1.00 
0.66  (0.54-0.81) 
1.14  (0.93-1.40) 
 
- 
<0.001 
0.21 
 
1.00 
0.69  (0.57-0.85) 
1.09  (0.89-1.34) 
 
- 
<0.001 
0.39 
Age at first LSIL 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
 
1.00 
1.01  (0.80-1.27) 
1.32  (1.05-1.66) 
1.45  (1.13-1.85) 
1.60  (1.24-2.08) 
2.16  (1.67-2.80) 
 
- 
0.96 
0.02 
0.003 
<0.001 
<0.001 
 
1.00 
1.01  (0.80-1.28) 
1.33  (1.06-1.67) 
1.41  (1.10-1.79) 
1.44  (1.11-1.87) 
1.81  (1.39-2.35) 
 
- 
0.91 
0.01 
0.006 
0.006 
<0.001 
Excision of LSIL‡ 
Not Performed 
Performed 
 
1.00 
1.58  (1.33-1.88) 
 
- 
<0.001 
 
1.00 
1.39  (1.16-1.65) 
 
- 
<0.001 
‡ Excision includes all method of excision ( excision biopsy and hysterectomy) done during follow-up 
 
 
Association of Persistence of LSIL with Excision Treatment 
 For women of HIV negative or unknown status, persistence of LSIL was strongly influenced 
by excision treatment, with few experiencing persistence of LSIL after such treatment. For 
HIV positive women, however, excision had a smaller effect on persistence. With or without 
excision of LSIL, persistence was much more common amongst HIV positive women than 
for the other groups (table 7). 
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Table 7 Impact of Excision of LSIL on Clearance, According to HIV Groups 
 
 HIV negative HIV unknown p-value* HIV 
positive 
p-
value** 
Excision Performed‡ 
Persistence 
Clearance 
Total 
 
2 (7.1) 
26 (92.9) 
28 (100) 
 
12 (13.6) 
76 (92.7) 
88 (100) 
 
0.51 
 
50 (45.5) 
60 (54.5) 
110 (100) 
 
<0.001 
No Excision Procedure‡ 
Persistence 
Clearance 
Total 
 
68 (39.5) 
104 (60.5) 
172 (100) 
 
125 (32.5) 
259 (67.5) 
384 (100) 
 
0.12 
 
619 (66.0) 
319 (34.0) 
938 (100) 
 
<0.001 
Total 200 472  1048  
‡Excision includes all method of excision- excision biopsy and hysterectomy 
* Fisher’s exact test to compare significance between two proportions (Comparing HIV unknown  to HIV negative 
group) 
** Fisher’s exact test to compare significance between two proportions (Comparing HIV positive to HIV negative group 
 
 
 
Association of Persistence of LSIL with cART 
If cART was started before the first diagnosis of LSIL, clearance was improved. Clearance 
was observed in 141/433 (32.6%) of HIV positive women who did not receive ART, 
compared to 164/430 (38.1%) of women who started ART after the first LSIL (p=0.09) and 
76/185 (41.1%) of women who had started ART before the first LSIL (p=0.04). This was 
confirmed with survival analysis (figure 10). In the multivariate Cox regression model, HIV-
infected women who started ART before first LSIL had an improved clearance (HR 1.71, 
95% CI 1.29-2.27) compared to women not on ART and if excision treatment was performed 
(HR 1.39, 95% CI 1.05-1.83) (table 8).   
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Table 8 Factors that Influence Clearance of  LSIL in HIV Infected Women 
 
 Univariate analysis Multivariate analysis 
Variable HR  (95%CI) p-value HR95%CI p-value 
Age at first LSIL 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
 
1.00 
1.14  (0.82-1.59) 
1.44  (1.03-2.00) 
1.51  (1.06-2.16) 
1.58  (1.04-2.39) 
1.76  (1.12-2.76) 
 
- 
0.44 
0.03 
0.02 
0.03 
0.02 
 
1.00 
1.10  (0.79-1.54) 
1.37  (0.98-1.92) 
1.46  (1.02-2.08) 
1.48  (0.97-2.25) 
1.60  (1.02-2.53) 
 
- 
0.56 
0.07 
0.04 
0.07 
0.04 
Duration of ART 
None 
Pre-First LSIL 
Post-First LSIL 
 
1.00 
1.80  (1.36-2.38) 
0.79  (0.63-0.99) 
 
- 
<0.001 
0.04 
 
1.00 
1.71  (1.29-2.27) 
0.77  (0.61-0.97) 
 
- 
<0.001 
0.03 
CD4 count at first LSIL 
0-199 
200-349 
≥350 
 
1.00 
0.77  (0.56-1.05) 
1.00  (0.75-1.33) 
 
- 
0.10 
0.99 
- - 
Virological Failure 
No 
Yes 
 
1.00 
0.58  (0.39-0.87) 
 
- 
0.008 
- - 
Excision of LSIL‡ 
Not Performed 
Performed 
 
1.00 
1.49  (1.13-1.96) 
 
- 
0.005 
 
1.00 
1.39  (1.05-1.83) 
 
- 
0.02 
‡ Excision includes all method of excision ( excision biopsy and hysterectomy)done during follow-up 
 
 
Figure 10 Survival of  Persistence of SIL, for HIV positive group according to when ART started in relation 
to first LSIL diagnosis 
Figure 2.2.   
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Discussion 
 
Most previous studies have investigated the effect of HIV infection on incidence of SIL and 
HPV infection, and have found higher occurrence of both in HIV infected women. In these 
studies, the proportion of women with LSIL at baseline was small, or included only women 
with normal cytology (38-40) (41, 42).  We were however interested in the behaviour of 
LSIL in HIV infected women compared to HIV uninfected women, and specifically the risk 
of progression of LSIL. Such an analysis by Nappi in a cohort of 150 women found the risk 
for progression 4-5 times higher than for HIV uninfected women (33).  In contrast, Denny, 
from Cape Town, examined the risk for progression in a study of 400 HIV infected women 
(of whom 137 had LSIL at baseline) and found percentage of women with progression very 
low (4% over 3years) and similar to that for HIV uninfected women; over 30% of women 
started ART within 2 years of participation in the study. Adjustments for ART initiation were 
not made due to delayed availability of ART in state-sponsored programmes and the small 
numbers involved(43).   In our study, we also found no overall difference in progression of 
LSIL to HSIL between HIV infected and uninfected groups before adjusting for other 
covariates and therefore decided to further investigate the effect of CD4, ART and excision 
treatment on progression and persistence in our HIV infected women separately.  
 
As for the effect of CD4 count, most previous reports have concluded that a decrease in CD4 
count could be linked to higher incidence of HPV infection and/or SIL (41-45). With regards 
to progression of LSIL, Nappi and Schuman found higher occurrence of progression with 
lower CD4 counts(33, 38), and Omar, who enrolled 225 HIV infected women with LSIL, 
reported decreased risk for progression if the CD4 count was over 500 cells/ɥl(46). Our 
study, as a retrospective cohort, investigated the real-life scenario of availability of CD4 
counts in HIV infected women - these are seldom repeated if already done in the preceding 6 
months. Since fewer than 20% of women in our cohort had CD4 count above 500 cells/ɥl, we 
decided to group CD4 as is currently under negotiation for initiation of ART per national 
treatment protocol from 200 to 350 cells/ɥl, and found it had no predictive value as to 
progression or persistence of SIL. 
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We were therefore still intrigued as to the apparent lack of difference of progression of LSIL 
between our HIV status groups, and if cART could have contributed in reducing risk for the 
HIV infected women. The results of previous studies have been contradictory. Numerous 
reports showed no effect of cART on the HPV infection or SIL pattern (33, 39, 45), but 
others indicated reduced SIL occurrence or progression and persistence of LSIL when 
receiving cART. Of note, a more recent report by Omar of over 1000 HIV infected women in 
Soweto, South Africa (of whom 225 had LSIL at baseline) found that ART protected against 
LSIL progression.  We found a similar ART-reduced hazard for LSIL progression compared 
to their study in our more than 1000 LSIL-diagnosed HIV infected women (0.66 versus their 
0.72) (46). This finding concurs also with the Minkoff findings already in 2001, and again in 
2010, as well as the small cohort of Heard in 1998 (34, 35, 47). 
 
The question remained whether excision treatment in women with LSIL played a role in 
preventing progression or persistence of LSIL. Although the number of women who 
underwent excision of LSIL was small but similar for all groups, the decision to do excision 
was based on colposcopy appearance and therefore could have contributed to the prevention 
of progression and/or persistence. This was indeed the case- none of the HIV uninfected 
women who underwent excision treatment experienced progression, and the effect was 
similar for HIV infected women.  The effect of excision was however smaller on persistence 
in HIV infected women than HIV uninfected women.  We therefore included the effect of 
excision of LSIL in our multivariate analysis of progression and persistence, and still found a 
decrease in the risk for both progression and persistence with ART use; the influence of CD4 
remained not significant. 
 
To interpret the results of our findings, the conditions under which women entered study have 
to be understood. The current local management protocol preselected women who have had 
LSIL for at least one year, as they would have only been referred for colposcopy after a 
repeat LSIL.  This may explain the high progression of LSIL in the HIV uninfected group- 
previous prospective studies which included HIV uninfected women have shown a much 
lower risk for progression of CIN I lesions (48). 
 
We expected women of unknown HIV status to be of low risk for HIV infection and therefore 
not tested, or of normal to high risk but to have declined HIV testing, and that their risk for 
persistence to be somewhat between the HIV infected and uninfected groups.  Unexpectedly, 
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the persistence risk for this group was similar to the HIV negative group, implicating similar 
risk for HIV acquisition than the uninfected group. Also, the risk for progression in HIV 
uninfected women was higher than for HIV infected women who had started ART before the 
first LSIL, and we relate it to the high prevalence of HIV infection in our communities. 
Women who were HIV negative at first LSIL, possibly did not remain so during follow-up 
time. Unfortunately, due to the retrospective nature of the study, we do not know to what 
extent subsequent acquisition of HIV infection could have contributed to the progression of 
LSIL in the HIV negative group, and it is something we would only be able to adequately 
answer in a prospective cohort study. We therefore advise at regular intervals re-testing of 
HIV negative women who present with cytological abnormalities. In our institution, facilities 
for HIV screening have dramatically improved and we expect an increased screening 
frequency in HIV negative women and women of HIV unknown status than was experienced 
during the study period. 
 
Overall, we found that there was no difference between the progression of LSIL to higher 
grade cervical dysplasia between the HIV groups.  Importantly, patients who started ART 
before first LSIL were associated with a significant decreased risk for progression. Of note, 
CD4 count did not have an influence on the risk for progression.  
 
We conclude that ART protects against progression of LSIL to HSIL and that this effect was 
independent of the CD4 count at which the LSIL was first diagnosed.  From this finding, we 
postulate that cART exposure –by the protection it offers- may partly be responsible for the 
overall perception that HIV infected women are not at higher risk for progression of LSIL to 
HSIL than HIV uninfected women.  However, one has to bear in mind that women who 
underwent regression of LSIL would not have been referred for colposcopy evaluation, and 
this selection bias may further explain the high rate of progression in the HIV uninfected 
women in this cohort. 
 
We also found persistence (absence of clearance of SIL) to be markedly increased in the HIV 
positive group.   ART was independently associated with improved clearance of LSIL. On the 
other hand, a higher CD4 count at the time of first LSIL was not associated with improved 
clearance of the lesion, but virological failure was associated with increased persistence. 
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Finally, it can be concluded that since the effect of cART is to reduce progression and 
persistence of LSIL, and because LSIL is caused by HPV of the cervical epithelium, the 
association of cART with the detection of HPV also warrants further investigation.   
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Chapter 3:   High-Grade Cervical Dysplasia in Women Living with HIV 
 
Introduction 
 
As described in Chapter 1, the development of cervical cancer depends on the persistence of 
oncogenic HPV and the progression of the associated low-grade lesions to more severe 
lesions. In our investigation of the progression and persistence of LSIL, we found that cART 
reduces the risk of both in HIV infected women, and that this is independent of the CD4 
count.  
 
Once progression of LSIL to HSIL has occurred, the lesion very seldom regresses, and the 
management of confirmed HSIL is always that of excision, regardless of the patient’s HIV 
status.  As such, the “see and treat” approach, which refers to excision treatment without 
histological confirmation in women who have completed their families, seems to rarely lead 
to overtreatment (49). 
 
In the background of increased persistence of LSIL in women living with HIV infection, 
which we have postulated is caused by more persistent HPV infection, it may be assumed that 
the success of the treatment of HSIL – excision treatment – will be also affected by HIV 
status and possibly even cART. 
 
Previous studies of excision treatment outcome of HSIL as described by Tate (50), Reimers 
(51), Massad (52) and Wright (53), have involved small cohorts of HIV positive women in 
low HIV prevalence settings. They found treatment failure very common at 36·2 to 73% in 
women affected by HIV. Treatment success was associated with higher CD4 count (50, 51, 
53), but not with antiretroviral treatment (51). Reimers also found an improved outcome with 
conisation (CKC) over loop excision (LEEP or LLETZ) for HIV infected women (51).  
 
Furthermore, as to the recurrence of lesions post excision, reports were also conflicting.  
Lesions observed after excision treatment were either mostly low-grade (52) or high-grade 
(51).  
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We therefore proceeded to investigate the factors that influence outcome of excision 
treatment and the recurrence of cervical intraepithelial lesions in a large cohort in our setting 
of high HIV/ HPV prevalence. Specifically, we were interested to find out if there exists 
again an association of HIV status with excision treatment failure, and if cART in HIV 
infected women could reduce recurrence of lesions after excision treatment. 
 
Materials and Methods 
Study population 
For this retrospective cohort analysis we extracted electronic records from our database of 
women who attended the Colposcopy Clinic at Tygerberg Hospital, Parow, Western Cape 
region of South Africa during the period July 2004 to July 2009.  We identified 1848 women 
for this analysis that underwent excision treatment of squamous intraepithelial lesions of the 
cervix and that had >24 weeks follow-up available. Women were assigned to one of three 
groups: HIV- infected, HIV- uninfected, or HIV status unknown. The choice of HIV group 
was made according to the status as known at the time of excision biopsy (EB).  
 
Regulatory Approvals 
The study was approved by the Stellenbosch University Human Research Ethics Committee 
(ref nr N11/01/007). 
 
Operational Definitions, Explanatory and Outcome Variables 
Histopathology and cytology data as well as information regarding use of antiretroviral 
therapy (ART) were extracted and anonymously linked to a study-specific identifier.  
Antiretroviral therapy exposure was defined as follows:  “ART started before EB” and “no 
ART” indicate the start time or absence of ART respectively. For the analysis of excision 
treatment failure, “after EB” means that ART was started during the first 365 days after EB; 
for the analysis of recurrence, it indicates that ART was started after EB but before end point 
of survival analysis. Baseline CD4 count was stratified in three groups according to the 
current South African guidelines for initiation of antiretroviral therapy: <200, 200-350 or 
>350 cells/ɥl. 
 
Squamous abnormalities were classified as LSIL, HSIL or cancer according to the 2001 
Bethesda Classification System(54). We again for the purpose of this analysis included 
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ASCUS in the LSIL category, and ASC-H as HSIL. Cytology evaluation was performed with 
routine Papanicolaou (Pap) smear. The quality of cytology was assessed by determining the 
percentage of smears with endocervical cells (EC) present. Pathology was considered to be 
more specific than cytology and the result of histology was used if a smear, performed on the 
same day, was of lesser severity. 
 
Excision biopsy refers to the surgical removal with the loop electrosurgical excision (LLETZ 
or LEEP) or the cold-knife cone (CKC or conisation) method. For completeness of excision, 
we set strict criteria at LSIL present at any margin to agree with previous reports (51). 
Excision treatment failure is the presence of at least CIN I (LSIL) at first follow-up visit. Post 
excision recurrence (at one year or later) refers to the proportion of the population with 
disease after EB at a given time.  
 
Statistical Analysis 
Mean or median and the interquartile range were calculated as a measure of spread of the 
baseline characteristics. The t- test was used to compare statistical significance of baseline 
continuous variables such mean ages of women by HIV status. Dichotomous baseline 
variables were evaluated using proportions and compared by performing two-tailed chi-
squared test. 
 
For the analysis of excision biopsy treatment failure, 1620 women out of the total 1846 in the 
cohort were selected as women who had the first post-excision follow-up evaluation within 
365 days. Logistic regression was used to evaluate the association of factors such as HIV 
status with excision treatment outcome. Of the 1620 women analysed, the 653 HIV infected 
women were analysed separately as well, using univariate and multivariate logistic regression 
to evaluate the association of each risk factor separately with treatment failure.  In the 
multivariate analysis the selected covariates were included because of clinical relevance. 
Subsequent excision and subsequent hysterectomy were not included in multivariate analyses 
of excision treatment failure because, although there was a strong association, the subsequent 
procedure was performed as a result of excision treatment failure and could not be considered 
a cause thereof. 
 
For survival analysis of recurrence-free time in the post-excision period we used the Kaplan-
Meier method and log-rank test to compare the HIV status groups. All 1846 women in the 
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cohort were included in the recurrence analysis. For the analysis the time 0 was taken as the 
date that the first excision biopsy treatment was performed. The end point for recurrence-free 
survival was taken as the first date that the patient had LSIL or higher (event). If there was no 
lesion after excision, the date of last follow-up evaluation (Pap or histopathology) during the 
post excision period was used (censored). Cox regression analysis was applied to investigate 
the influence of covariate factors such as excision type and completeness of excision. The 
analysis was also done separately for the 778 HIV infected women to further include the 
covariates CD4 count and ART. 
 
Results 
I. Baseline Demographics 
 
Table 9 provides demographics data by HIV Status. Of note, the quality of Pap smears 
performed on the HIV infected group was found to be marginally inferior (with the 
percentage of smears with no EC present higher at 19·1%), compared to 15·6% in HIV 
uninfected (p=0·006) and 18·2% in the HIV unknown status groups (p=0·05).  
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Table 9 Demographic and Clinical Characteristics of Women who underwent Excision Biopsy treatment 
 
 Total HIV neg 
 n (%) 
HIV unk 
 n(%) 
p-value1 HIV pos 
 n(%) 
p-value2 
Age at Excision Biopsy 
 (mean,SD) 
1848 37·3±10·19 38·2±9·99 0·14 34·1±7·39 <0·001 
Race3 
Black 
Mixed Race 
Other 
1848 
662 
1122 
64 
335 (100) 
59 (17·6) 
248 (74.0) 
28 (8.4) 
735 (100) 
98 (13·3) 
606 (82·5) 
31 (4.2) 
 
0·03 
778 (100) 
505 (64·9) 
268 (34·5) 
5 (0.6) 
 
<0·001 
Follow-up Time4 (median, IQR) 1848 1·24 (0·54-2·35) 1·52 (0·56-2·81) 0·008 1·31 (0·59-2·24) 0·22 
Excision treatment reported5 
Complete 
Incomplete 
Not Applicable6 
Not Stated 
Cannot be determined 
1848 
682 
790 
186 
77 
113 
335 (100) 
129 (38·5) 
128 (38·2) 
40 (11·9) 
13 (3·9) 
25 (7·5) 
735 (100) 
306 (41·6) 
279 (38·0) 
95 (12·9) 
21 (2·9) 
34 (4·6) 
 
0·57 
778 (100) 
247 (31·8) 
383 (49·2) 
51 (6·6) 
43 (5·5) 
54 (6·9) 
 
0·003 
Cytology:  LSIL 
Diagn Biopsy Result LSIL 
Diagn Biopsy Result HSIL 
331 
102 
229 
45 (100) 
15 (33·3) 
30 (66·7) 
97 (100) 
35 (36·1) 
62 (63·9) 
 
0·75 
189 (100) 
52 (27·5) 
137 (72·5) 
 
0·44 
Cytology:   HSIL 
Diagn Biopsy Result LSIL 
Diagn Biopsy Result HSIL 
310 
47 
263 
52 (100) 
5 (9·6) 
47 (90·4) 
151 (100) 
25 (16·6) 
126 (83·4) 
 
0·26# 
117 (100) 
17 (15·9) 
90 (84·1) 
 
0·34# 
Pre-excision diagnosis 
LSIL or less 
HSIL or higher 
1848 
615 
1233 
335 (100) 
104(31·0) 
231 (69·0) 
735 (100) 
226(30·8) 
509 (69·2) 
 
0·92 
778 (100) 
285 (36·6) 
493 (63·4) 
 
0·07 
Type of Excision 
CKC 
LLETZ 
1848 
146 
1702 
335(100) 
41 (12·2) 
294 (87·8) 
735 (100) 
71 (9·7) 
664 (90·3) 
 
0·20 
778 (100) 
34 (4·4) 
744 (95·6) 
 
<0·001 
Pre-excision diagnosis for CKC 
HSIL or higher 
LSIL or less 
146 
116 
30 
41 (100) 
36 (87·2) 
5 (12·8) 
71 (100) 
51 (72·5) 
20 (27·5) 
 
0·06# 
34 (100) 
29 (84·8) 
5 (15·2) 
 
1·000# 
Subsequent Excision7 
Performed 
Not Performed 
1848 
147 
1701 
335 (100) 
28 (8·4) 
307 (91·6) 
735 (100) 
48 (6·5) 
687 (93·5) 
 
0·28 
778 (100) 
71 (9·1) 
707 (90·9) 
 
0·68 
Subsequent Hysterectomy8 
Performed 
Not Performed 
1848 
249 
1599 
335 (100) 
67 (20·0) 
268 (80·0) 
735 (100) 
115 (15·6) 
620 (84·4) 
 
0·08 
778 (100) 
67 (8·6) 
711 (91·4) 
 
<0·001 
CD4 count at Excision Biopsy9 
<200 
200-350 
≥350 
Not available 
778 
131 
218 
230  
199 
N/A N/A N/A 
778 (100) 
131(16.8) 
218 (28.0) 
230 (29.6) 
199(25.6) 
N/A 
ART  
Started Before EB 
Started After EB 
No ART 
778 
244 
189 
345 
N/A N/A N/A 
778 (100) 
244 (31·4) 
189(24·6) 
345 (44·3) 
N/A 
Log Pre-ART viral load (mean, SD) 130 N/A N/A N/A 4.95±0.99 N/A 
1    t-test used to compare significance between means and Chi-square test used to compare significance between two proportions 
(Comparing HIV unknown  to HIV-negative group) 
2   t-test used to compare significance between means and Chi-square test used to compare significance between two proportions 
(Comparing HIV+ to HIV-negative group)   
3    significance of difference between Black and Mixed Race 
4     from EB to last FU date 
5   significance of difference between Complete and Incomplete 
6     there was no lesion seen on specimen 
7    Number of all Patients that underwent excision biopsy  (Percentage of HIV status group) 
8    Number of all Patients that underwent subsequent  EB hysterectomy (Percentage of HIV status group) 
#   value calculated with the Fisher’s exact test 
9    CD4 done in year of excision 
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II. Excision Treatment Failure 
Association of Excision Treatment Failure with HIV Status 
HIV infected women experienced markedly higher excision treatment failure than HIV 
uninfected women at first follow-up after excision biopsy treatment. Overall, treatment 
excision failed in 53·8% of HIV infected women (p<0·001) and 23·8% of women of 
unknown HIV status (p=0·31) compared to 26·9% of HIV uninfected women.  In cases 
where excision was reported as complete, treatment failure occurred in 41·1% of HIV 
infected women (p<0·001) and 11·7 % of women of unknown HIV status (p=0·38) 
respectively, compared to 14·9% of HIV uninfected women. Treatment failure for incomplete 
excisions was 65·9% for HIV infected women (p<0·001) and 34·5% for women who were of 
unknown HIV status (p=0·68) compared to 36·7% in HIV uninfected women. 
 
The results of univariate and multivariate logistic regression of excision treatment outcome in 
all women are listed in table 10. When adjusted for age, completeness of excision, excision 
type and excision result (a reflection of indication for the excision), HIV infection was 
associated with an increased risk for excision treatment failure (RR=3.66, 95% CI 2.67-5.01, 
p<0.001). 
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Table 10 Factors Influencing Excision Treatment Failure for All HIV groups 
 
 Total Univariate analysis Multivariate analysis 
Variable  HR (95%CI) p-value RR95%CI p-value 
Age at EB 1620 1·02  (1·00-1·03) 0·008 1·03  (1·02-1·04) <0·001 
Age at EB 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
1620 
108 
253 
333 
391 
244 
291 
 
0·67  (0·47-0·95) 
0·87  (0·63-1·20) 
0·83  (0·61-1·13) 
0·86  (0·61-1·22) 
0·64  (0·40-1·02) 
1·00 
 
0·03 
0·39 
0·25 
0·40 
0·06 
- 
- - 
HIV Status 
Neg 
Pos 
Unk 
1620 
309 
652 
659 
 
1·00 
3·18  (2·36-4·26) 
0·85  (0·63-1·16) 
 
- 
<0·001 
0·31 
 
1·00 
3·66  (2·67-5·01) 
0·87  (0·63-1·20) 
 
- 
<0·001 
0·39 
Excision Complete 
Yes 
No 
Not Stated 
Cannot Say 
NA‡ 
1620 
597 
703 
62 
99 
159 
 
1·00 
3·34  (2·62-4·25) 
1·88  (1·08-3·28) 
2·22  (1·42-3·48) 
1·48  (1·00-2·18) 
 
- 
<0·001 
0·03 
<0·001 
0·05 
 
1·00 
3·07  (2·37-3·97) 
1·60  (0·89-2·88) 
1·89  (1·18-3·03) 
1·57  (0·99-2·50) 
 
- 
<0·001 
0·12 
0·01 
0·06 
Pre-Excision Diagnosis 
LSIL 
HSIL 
Not Done 
CA 
1620 
561 
858 
186 
15 
 
1·00 
1·16  (0·92-1·44) 
1·13  (0·80-1·60) 
2·20  (0·76-6·15) 
 
- 
0·21 
0·48 
0·13 
- - 
Diagnostic Biopsy Result 
LSIL 
ND 
HSIL 
CA 
1620 
114 
1093 
411 
2 
 
1·00 
1·12  (0·75-1·69) 
1·26  (0·81-1·94) 
0·40  (0·01-16·7) 
 
- 
0·59 
0·31 
0·63 
- - 
Excision Type 
LLETZ 
CKC 
1620 
1495 
125 
 
1·00 
1·09  (0·75-1·59) 
 
- 
0·64 
 
1·00 
1·16  (0·76-1·78) 
 
- 
0·49 
Excision Result 
LSIL 
HSIL 
Normal 
CA 
1620 
264 
1211 
121 
24 
 
1·00 
1·22  (0·92-1·62) 
0·90  (0·56-1·43) 
2·03  (0·88-4·71) 
 
- 
0·16 
0·64 
0·10 
 
1·00 
1·11  (0·81-1·52) 
1·01  (0·59-1·73) 
1·90  (0·77-4·64) 
 
- 
0·53 
0·98 
0·16 
Subsequent EB* 
Not Performed 
Performed 
1620 
1457 
163 
 
1·00 
11·64  (7·55-18·0) 
 
- 
<0·001 
- - 
Subsequent 
Hysterectomy* 
Not Performed 
Performed 
1620 
1331 
289 
 
1·00 
3·98  (3·05-5·19) 
 
- 
<0·001 
- - 
‡Not applicable: no lesion 
*after 1 year 
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Association of Excision Treatment Failure with cART 
Looking at HIV infected women alone, the effect of already receiving cART before excision 
treatment was not significant, although a lower CD4 count was associated with increased risk 
(table 11). 
 
Table 11 Factors Influencing Treatment Failure for HIV positive Women 
 
  Univariate analysis Multivariate analysis 
Variable Total RR  (95%CI) p-value HR  (95%CI) p-value 
Age at EB 653 1·01  (0·99-1·03) 0·52 1·01  (0·99-1·03) 0·35 
Age at EB 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
653 
140 
138 
196 
78 
36 
65 
 
1·00 
0·56  (0·29-1·08) 
0·61  (0·32-1·16) 
0·61  (0·31-1·19) 
0·77  (0·38-1·59) 
0·60  (0·28-1·27) 
 
- 
0·08 
0·13 
0·15 
0·48 
0·18 
- - 
Excision Complete 
Yes 
No 
Not Stated 
Cannot Say 
NA‡ 
653 
210 
321 
28 
44 
48 
 
1·00 
2·73  (1·96-3·79) 
0·87  (0·42-1·81) 
1·36  (0·75-2·48) 
1·18  (0·65-2·13) 
 
- 
<0·001 
0·71 
0·32 
0·59 
 
1·00 
2·63  (1·87-3·69) 
0·80   (0·38-1·69) 
1·30  (0·71-2·40) 
1·13  (0·59-2·15) 
 
- 
<0·001 
0·56 
0·39 
0·71 
Pre-Excision Diagnosis 
LSIL 
HSIL 
Not available 
CA 
653 
296 
305 
50 
2 
 
1·00 
1·62  (1·18-2·24) 
2·01  (1·08-3·74) 
5·72  (0·14-237) 
 
- 
0·003 
0·03 
0·36 
- - 
Excision Type 
LLETZ 
CKC 
653 
625 
28 
 
1·00 
0·81  (0·40-1·63) 
 
- 
0·55 
 
1·00 
0·64  (0·31-1·33) 
 
- 
0·23 
Excision Result 
LSIL 
HSIL 
Normal 
CA 
653 
124 
491 
33 
5 
 
0·73  (0·51-1·04) 
1·00 
0·77  (0·41-1·45) 
2·02  (0·39-10·51) 
 
1·00 
- 
0·69 
0·40 
 
0·92  (0·63-1·35) 
1·00 
0·99  (0·49-2·01) 
2·05 (0·37-11·26) 
 
0·66 
- 
0·98 
0·41 
Subsequent EB*  
Not Performed 
Performed 
653 
570 
83 
 
1·00 
9·99  (4·73-21·08) 
 
- 
<0·001 
- - 
Subsequent Hysterectomy* 
Not Performed 
Performed 
653 
570 
83 
 
1·00 
4·60  (2·57-8·23) 
 
- 
<0·001 
- - 
CD4 
<200 
200-350 
≥350 
Not Done 
653 
105 
184 
200 
164 
 
2·50  (1·60-3·92) 
1·50  (1·03-2·18) 
1·00 
1·19  (0·82-1·75) 
 
<0·001 
0·03 
- 
0·36 
 
- 
 
- 
ART 
Started Before EB 
Started After EB 
No ART 
653 
199 
154 
300 
 
1·42  (1·02-2·00) 
1·62  (1·14-2·29) 
1·00 
 
0·04 
0·007 
- 
 
1·37  (0·96-1·94) 
1·58  (1·10-2·27) 
1·00 
 
0·08 
0·01 
- 
‡ Not applicable: no lesion 
*after 1 year follow-up 
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Lesion at Excision Treatment Failure 
At treatment failure the lesion detected was most likely to be LSIL in HIV infected compared 
to HIV-uninfected women. Of HIV infected women, 62·7% had LSIL, compared to 33·0% of 
HIV uninfected women (p<0·001). 
 
III. Post excision Recurrence 
 
Association of Recurrence with HIV Status 
More HIV infected women experienced recurrence of lesions after excision treatment than 
HIV uninfected women or women of unknown HIV status (figure 11).  
 
Figure 11 SIL Recurrence-free survival After Excision Biopsy 
(log rank p<0.001) 
 
 
 
  
HIV unknown HIV negative HIV positive 
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Association of Recurrence with HIV Status 
The results of univariate and multivariate survival analysis of post excision recurrence of 
lesions are listed in table 12. As can be seen, HIV uninfected women had a lower risk for 
recurrence, and this association remained after adjusting for age, excision type and 
subsequent excision. 
 
Table 12 Factors Associated With Post Excision Recurrence of  SIL in All Women 
 
 Total Univariate analysis Multivariate analysis 
Variable  HR  (95%CI) p-value HR  (95%CI) p-value 
Age at EB 1848 1·01  (1·00-1·01) 0·05 1·01  (1·00-1·01) 0·19 
Age at EB 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
1848 
128 
294 
447 
386 
275 
318 
 
1·00 
0·83  (0·60-1·15) 
0·90  (0·66-1·23) 
0·93  (0·69-1·26) 
1·14  (0·84-1·56) 
1·19  (0·88-1·62) 
 
- 
0·22 
0·90 
0·70 
0·38 
0·15 
- - 
HIV Status 
Neg 
Pos 
Unk 
1848 
335 
778 
735 
 
1·00 
1·86  (1·52-2·26) 
0·75  (0·60-0·93) 
 
- 
<0·001 
<0·001 
 
1·00 
1·95  (1·59-2·39) 
0·81  (0·65-0·99) 
 
- 
<0·001 
<0·001 
Excision Complete 
Yes 
No 
Not Stated 
Cannot Say 
NA‡ 
1848 
682 
790 
77 
113 
186 
 
1·00 
1·90  (1·42-2·54) 
1·37  (0·86-2·20) 
1·68  (1·25-2·25) 
1·39  (1·07-1·81) 
 
- 
<0·001 
0·51 
0·22 
0·69 
- - 
Excision Type 
CKC 
LLETZ 
1848 
146 
1702 
 
1·00 
0·99  (0·78-1·28) 
 
- 
0·96 
 
1·00 
1·08  (0·83-1·41) 
 
- 
0·54 
Excision Result 
LSIL 
HSIL 
Normal 
CA 
1848 
197 
1605 
9 
37 
 
1·00 
0·79  (0·51-1·23) 
1·02  (0·41-2·50) 
1·45  (0·88-2·38) 
 
- 
0·57 
0·80 
0·20 
- - 
Subsequent EB* 
Not Performed 
Performed 
1848 
1701 
147 
 
1·00 
3·19  (2·70-3·78) 
 
- 
<0·001 
 
1·00 
2·25  (1·89-2·67) 
 
- 
<0·001 
Subsequent Hysterectomy* 
Not Performed 
Performed 
1848 
1599 
249 
 
1·00 
2·79  (2·40-3·24) 
 
- 
<0·001 
 
1·00 
2·50  (2·12-2·95) 
 
- 
<0·001 
‡  Not applicable: no lesion 
*after 1 year follow-up 
 
Association of Recurrence with cART 
When looking at HIV infected women alone, cART that was started before excision treatment 
reduced risk for recurrence of lesions, even after adjusting for completeness of excision, 
excision type, and subsequent excision (HR 0.70, 95%CI 0.55-0.89, 95%, p=0.006) (table 
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13). The impact of cART that was started after excision treatment was not significantly 
different from the effect it had in women who never started cART. 
 
Table 13 Factors Associated With Recurrence of  SIL in HIV Positive Women 
 
  Univariate analysis Multivariate analysis 
Variable Total HR  (95%CI) p-value HR  (95%CI) p-value 
Age 778 1·00  (0·99-1·01) 0·93 1·00  (0·98-1·01) 0·47 
Age at EB 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
778 
48 
163 
232 
170 
94 
71 
 
1·00 
0·87  (0·58-1·30) 
0·75  (0·49-1·15) 
0·79  (0·52-1·21) 
0·89  (0·59-1·34) 
0·84  (0·54-1·31) 
 
- 
0·79 
0·32 
0·36 
0·69 
0·94 
- - 
Excision Complete 
Yes 
No 
Not Stated 
Cannot Say 
NA‡ 
778 
243 
394 
35 
52 
54 
 
1·00 
1·57  (1·05-2·32) 
0·76  (0·40-1·42) 
0·96  (0·65-1·44) 
1·27  (0·87-1·85) 
 
- 
<0·001 
0·21 
0·39 
0·37 
 
1·00 
1·41  (0·95-2·11) 
0·80  (0·42-1·49) 
0·90  (0·60-1·35) 
1·20  (0·82-1·75) 
 
- 
0·004 
0·41 
0·31 
0·41 
Excision Type 
CKC 
LLETZ 
778 
33 
745 
 
1·00 
1·17  (0·76-1·80) 
 
- 
0·47 
 
1·00 
1·24  (0·80-1·92) 
 
- 
0·35 
Excision Result 
LSIL 
HSIL 
Normal 
CA 
778 
100 
668 
2 
8 
 
1·00 
0·98  (0·45-2·13) 
0·82  (0·20-3·34) 
1·32  (0·53-3·29) 
 
- 
0·56 
0·62 
0·56 
- - 
Subsequent EB* 
Not Performed 
Performed 
778 
680 
98 
 
1·00 
2·17  (1·73-2·71) 
 
- 
<0·001 
 
1·00 
1·89  (1·49-2·38) 
 
- 
<0·001 
Subsequent Hysterectomy* 
Not Performed 
Performed 
778 
685 
93 
 
1·00 
2·30  (1·82-2·91) 
 
- 
<0·001 
 
1·00 
2·01  (1·55-2·60) 
 
- 
<0·001 
CD4 at EB 
<200 
200-350 
≥350 
Not Done 
778 
131 
218 
230 
199 
 
1·00 
0·94  (0·73-1·22) 
0·81  (0·62-1·05) 
- 
 
- 
0·68 
0·09 
- 
- - 
ART 
Started After EB 
Started Before EB 
No ART 
778 
189 
244 
345 
 
1·00 
0·80  (0·64-1·01) 
0·89  (0·72-1·10) 
 
- 
0·11 
0·92 
 
1·00 
0·70  (0·55-0·89) 
0·86  (0·69-1·06) 
 
- 
0·006 
0·78 
Virological failure 
Observed 
Not Observed 
No ART 
778 
89 
344 
345 
 
1.00 
0.96 (0.72-1.28) 
- 
 
 
0.79 
- 
- - 
Pre-ART HIV-RNA 130 1.22 (0.97-1.53) 0.09 - - 
‡ Not applicable: no lesion 
*after 1 year follow-up 
 
Discussion 
 
In this retrospective study we wanted to know if women living with HIV had worse outcome 
after undergoing excision biopsy treatment of SIL, and if cART protected against disease 
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recurring. We found that HIV infected women experienced much higher excision treatment 
failure than HIV uninfected women, but that failure occurred mostly as low-grade lesions. 
Factors that improved outcome were higher CD4 count and complete excision. Recurrence 
was much more common in HIV infected women than uninfected women. Importantly, 
initiating antiretroviral therapy before excision treatment reduced risk for recurrence. 
 
Treatment failure in HIV infected women was previously reported to be more LSIL (52), but 
Reimers found most (>70%) treatment failure lesions to be HSIL, regardless of the grade of 
lesions at the time of treatment (51). Like Reimers, we set the minimum lesion for treatment 
failure conservatively at CIN1, but found 62·7 % of lesions at treatment failure to be LSIL in 
the HIV infected women. We sought possible explanations for this difference in outcome, 
especially the timing of first follow-up visit and the influence of possible progression of LSIL 
to HSIL in the post-excision period. Reimers included all women who had an evaluation after 
excision treatment in her analysis, even if it occurred > 12 months. She did note, however, 
that “in most cases, the time from initial follow-up to failure occurred within the first year 
after the procedure”, and found higher risk for excision treatment failure for women with first 
follow-up after 6 months than if it had occurred before 6 months after excision procedure. In 
contrast, we only included women who had follow-up within 6-12 months post excision 
treatment. Early follow-up (<6 months) therefore would not have contributed to over 
diagnosing LSIL at treatment failure in our cohort. One would, however, consider it possible 
that the few women who were only evaluated after 6 months by Reimers contributed to their 
HSIL proportion of excision treatment failure, especially in their comparatively small cohort 
of 136 women.  
 
Others have previously already reported better excision treatment outcome with higher CD4 
count, (50, 51, 53) which we could confirm. We found no association of CD4 count with 
recurrence. The CD4 count is not only influenced by disease HIV disease progression; many 
conditions, amongst other concomitant diseases (e.g. the HPV infection) and medications 
may play a role. The CD4 count also may not accurately reflect the presence of CD4 cells at 
mucosal level. Further investigative studies that focus on cervical immunological factors, 
such as dentritic cell density, could be of more value.  
 
ART did not significantly reduce risk for excision treatment failure, which was not surprising 
for women who initiated cART only after the excision treatment procedure. The follow-up 
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time would have been too short.  More unexpected was the lack of protection it provided to 
women who had started cART before the excision treatment. A possible explanation could be 
found in the small number of women who were already on cART prior to the LLETZ/CKC. 
We had few women who had been treated with ART for longer periods and presented with 
HSIL as the indication for excision treatment. Indeed, as we (55) and others (46) have shown, 
the risk of progression of LSIL to HSIL is reduced by cART. It is possible that cART had 
protected women from progression of low-grade disease (46), thereby reducing the number of 
study subjects who had been treated with cART available for our analysis.   
 
ART was associated with a reduced risk for recurrence of lesions after excision treatment. 
Because our definition of recurrence refers to any lesion after one year, it again reflects the 
importance of the timing of the initiation of cART with the protection it may offer. 
 
The strength of this study lies in large sample size and the use of a combination of cytology 
and histopathology results in determining and comparing outcome of excision treatment of 
cervical intraepithelial lesions. Set in high HPV/HIV prevalence area, it describes the clinical 
scenario physicians and their patients are faced with in limited-resource countries.  
 
This investigation had some limitations. First, as for all observational data, our study may be 
subject to unknown confounding factors that we are not aware of and therefore were not 
controlled for in our multivariate models. Furthermore, the quality of cytology was inferior 
for the HIV group as measured by the percentage smears without EC present. Judging the 
completeness of a Pap smear, the presence of endocervical cells on cytological reporting is 
considered important, as cervical abnormalities usually occur in the region of the endo-
ectocervical junction. The presence of these cells is routinely used to compare quality of 
smears between groups of patients. If more patients in one group have incomplete smears 
(endocervical cells not seen), such as with the HIV infected group in this study, it means that 
cervical lesions could have been missed more often in the HIV infected group. Without the 
possible attenuation of effect, the results could have been more pronounced. 
 
For completeness of excision, we set strict criteria at LSIL present at any margin to agree 
with previous reports (51). Completeness overall was low, and also significantly less in HIV 
infected women. However, comparing only the excisions reported as either complete or 
incomplete, treatment failure still occurred more in HIV infected women. The higher 
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occurrence of incomplete excision in HIV infected women could have been due to extensive 
HPV infection in the immune deficient cervical milieu (56). 
 
Also, there was a selection bias toward HIV infected women entering care earlier. For HIV 
infected women, local guidelines request referral for colposcopy evaluation after their first 
LSIL. In addition, Pap screening is available free to all women over the age of 30 years, but 
HIV infected women qualify for this benefit regardless of age. The younger age at which HIV 
infected women underwent first excision treatment reflects referral policy but does not 
necessarily implicate faster progression of low-grade lesions. 
 
We included women of unknown HIV status in our analysis. The clinical significance of 
including the HIV unknown group is high. As can be seen in the total patient numbers, this 
group is larger than the HIV negative group. The reason is that HIV testing for the largest 
part of the study period was not routinely done for women with cervical dysplasia.  
Importantly, the study did not find increased risk for recurrence of SIL post excision in the 
HIV unknown status group compared to the HIV uninfected group. We think that women 
regarded by physicians as at risk for HIV infection were more likely to be tested, and that  
women not tested, were considered low- risk for acquiring HIV infection. Testing for HIV 
infection has become standard practice since 2009 for all women who attend the Colposcopy 
Clinic. 
 
Our data suggest that careful follow-up should be maintained after cervical excision 
treatment, especially in countries with high HIV/HPV prevalence. Women on ART may be 
expected to have overall better excision treatment outcome and this supports earlier initiation 
of ART than current guidelines stipulate in vulnerable communities. It also underlines the 
importance of HIV screening in all women with cervical dysplasia. 
 
In conclusion, we found that post excision disease occurs more as LSIL than as HSIL in HIV 
infected women, but that cART protects against this recurrence.  In chapter 2, we already 
described the impact of cART in reducing risk of progression and persistence of LSIL.  As 
our next step we needed to proceed to examine the effect of cART on the cause of low-grade 
cervical dysplasia, that being cervical HPV infection. 
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Chapter 4:   Cervical HPV Infection in Women Living with HIV 
 
Background 
 
Introduction 
 
We have described in the preceding chapters that cART reduces the risk for progression and 
persistence of LSIL. These findings have been confirmed by others (46, 57, 58). After 
excision of existing lesions, it also reduces risk of recurrence of SIL. We therefore wanted to 
proceed by doing a study which would investigate directly the effect of cART on cervical 
HPV infection. 
 
In order to plan a robust study with the best chance of an undisputable verdict as to the effect 
of cART, an understanding of HPV epidemiology was first required. This would enable us to 
choose the most appropriate detection method for the presence of cervical HPV infection. 
Also, we looked at previous studies done, specifically not only the outcomes achieved, but 
the success with which their outcomes have been duplicated by others. If not, we would try to 
identify possible reasons, and how these could be improved upon in our methodology. 
 
Human Papilloma Virus Infection in HIV Uninfected Women 
The progression from HPV infection to moderate and severe dysplasia and eventually 
invasive cancer is a slow process. In the Human Immunodeficiency Virus (HIV) uninfected 
patient, mild dysplasia as well as moderate dysplasia almost always regresses spontaneously, 
with 1% annual progression of mild cervical dysplasia to moderate or worse dysplasia. (59).  
Ninety per cent of women may clear HPV infection of the cervix within 60 months (60). 
Even infection with High-Risk (HR)-HPV clears naturally in most HIV uninfected women, as 
was recently again described by Kim et al in Korea (61)  HR-HPV types tend to persist 
longer, particularly HPV16, which can cause larger lesions (62), although some authors 
recently reported better HPV16 clearance rate than for HR- HPV types such as 31, 39 and 73 
(63).  
 
Before technological advances enabled identification of the viral aetiology of cervical cancer, 
the focus of research was on environmental and socioeconomic factors as causative agents. 
Although HPV infections resolve mostly spontaneously without causing symptoms, some 
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women develop cancer. In the past decade, an important aspect of cervical HPV infection in 
the pathogenesis of cervical cancer emerged: the persistence of HPV infection, especially 
type specific persistence (60, 64-67). 
 
More than 120 human strains of HPV have been identified.  Fifteen are classified as 
oncogenic types (68, 69). Literally hundreds of epidemiological studies of cervical HPV 
DNA genotype distribution have been done worldwide. It is therefore best to focus on meta-
analyses that summarize these findings. 
 
The first meta-analysis from 2005 which included only published studies of women with 
normal cervical cytology, found the overall HPV prevalence at 10.4%, with Africa highest at 
over 22%. HPV16 and -18 were the commonest subtypes observed, but their relative 
contribution was smaller for women with normal Pap smears than in women with CIN (70). 
 
Figure 12 HPV prevalence world-wide 
(Reproduced with permission from (4)) 
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On the opposite side of the spectrum of HPV related disease, in a meta-analysis of HPV 
genotypes associated with invasive cervical cancer (ICC) published in 2011, 79% of cancer 
was associated with only one genotype HPV, and in 56.6% of these cases it was HPV-16. 
Second most common was HPV-18 at 13.2%, followed by HPV-58 , -33, -45, -31, -52, -35, -
59, -39 and -56, each contributing 1% or more. Other subtypes represented less than one per 
cent of detections. This pattern was also found in African studies (71). 
 
A meta-analysis published in 2012 that combines the full spectrum of cervical disease, 
summarized the association of the different genotypes with the severity of disease.  They 
found the relative contribution of HPV 16/18/45 to the combined lower spectrum of cervical 
disease to remain stable,  but that HPV16 was detected significantly more in higher grades to 
cancer (table 14) (72). A large study combining the results of 8050 HIV uninfected women 
from Khayelitsha, Cape Town, also found HPV16 most common, with the other main 
contributors to CIN 2/3 to be HPV35 and HPV45 (73). 
 
 HPV16 HPV18 HPV45 
Normal/ASCUS 20.4% 8.4% 4.8% 
CIN1 27.1% 9.0%,   4.2% 
CIN2 39.8% 10.0% 5.0% 
CIN3 58.2% 7.4% 3.6% 
ICC 62.8% 15.7% 5.3% 
 
Table 14 Relative contribution of HPV16 in increasing severity of cervical dysplasia and cancer 
 
To summarize, of the 70 strains, HPV 16 and 18 are strongly linked with the development of 
invasive cervical cancer. Together they account for approximately 70% of invasive cancer 
(69). Specifically, HPV-16 causes larger and more persistent lesions (62), is less likely to 
regress (74) and more likely to cause squamous cell carcinoma of the cervix (75).  What 
needs to be remembered, that although HPV16 contributes most to cases of cervical cancer, 
the contribution of other genotypes to cervical dysplasia is substantial (76), and the behaviour 
of each genotype potentially varied. Added to this, prevention of HPV16 infection only 
would decrease risk of cervical cancer, but the impact on cervical dysplasia could be 
expected to be substantially smaller. 
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HPV Infection in HIV infected women 
In studies done internationally and in South Africa, HIV positive women have been found to 
have higher incidence of Human Papilloma Virus infection (31, 77-84) and of recurrence 
thereof after treatment (85) than HIV negative women. The HPV prevalence in HIV infected 
South African women is among the highest ever reported at 95%,  (82), with the risk for HR-
HPV infection estimated at 5 times that of HIV uninfected women (86).  HIV positive women 
also have a higher risk for the development of invasive cancer and the cancer occurred at a 
younger age. It is thought to be due to persistence of HPV infection in HIV positive women, 
reactivation of latent HPV infection (77, 85) or reinfection from their male partners. HIV 
positive women may be more likely to be infected with HPV from their male partners than 
HIV negative women (87) .  
 
As to the HPV genotypes that most contribute to cervical cancer in HIV infected women, 
there seems to be geographic variation in reports. As in HIV-negative women, subtypes 16, 
18, 31, 13 and 45 were found to most likely to lead to cancer by certain investigative groups 
(81, 88), or just HPV-16 and -18 in an Italian study (89), or HPV-16  and HPV33 in Norway 
(90) . In Australia, HPV-16 and -52 and -58 were most common (91). A Brazilian study 
found HPV 16, -18-, 61 and -53 to be most commonly detected in HIV positive women (92), 
and in Honduras HPV 16, 51, 84, 66, 39 were most common (93) .Clifford in the US found 
HIV positive women are less likely to harbour HPV 16 in HSIL (81), but more commonly 
have multiple HPV types, especially HPV 18, 33, 51, 52, 58, 11, 53, and 61 (88, 94).  
 
There seems to be variation of HPV genotype distribution and relative contribution to 
invasive cervical cancer also within the African continent. A meta-analysis of Medline listed 
studies showed  HPV-16 to be the commonest subtype in Africa, although no Sub-Saharan 
country study was included in this review (95). Numerous regional studies in Sub-Saharan 
Africa have however since been done. In Uganda HIV positive women were 4 times more 
likely to have cervical HPV infection (96), in Rwanda HPV-16 was most prevalent and 
persistent (97), and in Botswana, HPV-58 was more common than HPV-16, followed by 
HPV-39 in third place (98).  In another study done in Mozambique, no difference was found 
between HPV type detected in the cervical cancer between HIV negative and positive women 
(99).  
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Even within South Africa, there has been variation of reports of HPV genotype distribution 
amongst HIV infected women. The commonest types detected in HIV positive women in 
Johannesburg were HPV 16, 35, 53 and 18 (82). In Cape Town, HPV-16 was also still found 
to be the most common type, with HPV-18 only the fifth commonest (43). Nevertheless, no 
matter what company it seems to keep, HPV-16 features predominantly in all reports as 
having the strongest prevalence in those cases of cancer (100). The subtype distribution of 
HPV and the role of specifically HPV-16 in women living with HIV infection have not been 
investigated in the Tygerberg Hospital referral population. Also, what has to be kept in mind 
that over the years, HPV testing has become more expansive in their ability to detect the 
different genotypes, which contributed to the variation in and increasing number of genotypes 
reported to be associated with cervical disease.  
 
Apart from the role of specific HPV genotype infection in progression of cervical lesions to 
pre-cancer and cancer, the association of HPV infection with increasing immunosuppression 
caused by HIV infection has been reported in numerous studies. In a Johannesburg study of 
148 HIV infected women, 54% had abnormal smears (of which 66% LSIL and 33% HSIL), 
95% of the 148 women had HPV detected and 83% more than one subtype, with increased 
risk with CD4<200 (82). This was also seen in a Cape Town study, where abnormal cytology 
and high-risk HPV positivity were strongly correlated with low CD4 counts and high HIV 
viral loads  (43). The association of HPV infection with immunosuppression may be 
explained by the commitment of local immune mediators towards clearance of incident HPV 
infection, and that non-transient HPV infection was most associated with elevated levels of 
these immunological markers (101). In contrast to all these reports, Mbulawa in Cape Town 
grouped all HPV-HR types together, analysed outcomes in a Poisson regression model and 
found that no variables (such as CD4 count) except abnormal cytology had an impact on 
HPV clearance (84). 
 
Latency and Reactivation of HPV 
Just what happens when HPV is no longer detectable - or as authors mostly describe the 
phenomenon - the infection is “cleared”, is not certain. As with most DNA tests based on 
PCR technique, the level of detection is extremely sensitive. The question remains that if 
HPV-DNA is not detected, is it just because the number of copies of the virus has dropped to 
below the level of detection, or has the viral infection been completely cleared? A few studies 
have tried to explain other coincidental findings on the basis of clearance not always being 
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absolute, but with regression of HPV viral shedding to include presence of the virus in a 
latent, asymptomatic and undetectable state in the basal cells (102). 
 
In a study examining the association of incident HPV detection with immunological markers 
(CD4 count) and HIV-viral load,  there was a peak hazard ratio for HPV incident detection 
with the CD4 count <200 and HIV Viral Load over 100,000 copies/ml. Because this was also 
observed in women who were sexually inactive, the author postulated that increased detection 
of HPV in such instances could be due to reactivation from a latent state (103).  
 
A rapid rise in HPV detection within the first years of HIV infection, a period of intense 
immune modification, especially shortly after incident HIV infection, has also been 
described. The authors thought that local immune dysfunction after HIV acquisition may play 
a role in this increased detection of HPV. (104). 
 
Theiler et al went further to investigate reactivation events for five HPV genotypes. Prior 
exposure was determined by serologic testing and HPV shedding observed with PCR 
methods at 6 monthly intervals. The author found reactivation of latent HPV infection higher 
in HIV infected when compared with uninfected women, who had few reactivation events. 
The risk factor associated with reactivation was the CD4count <200. Total HPV shedding 
(reactivation plus recurrence) was 1.8 to 8.2 times higher in HIV infected than uninfected 
women (105). This finding has to be seen in the light that re-appearance of type-specific HPV 
is extremely rare in HIV uninfected women (106). 
 
A study published very recently was done in women in California, and here the authors do 
not report HIV status in the followed subjects. They found reappearance of HPV DNA in 
18% of women, that it was linked to sexual exposure, even in women without serological 
evidence of prior HPV exposure. Their explanation was that not all women who acquire 
HPV16 infection seroconvert, or that tests serological testing is still inadequate (107). This 
study is interesting, especially when read in together with the findings of Theiler, and we 
need to keep in mind that it is additionally possible that in immunocompromised women, 
there exists a possibly greater chance of insufficient development of memory immune 
responses to HPV16, leaving HIV infected women at greater risk for reinfection or 
redetection of HPV. 
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Although there is still paucity of proof as to whether HPV may persist in a latent state in the 
basal layer of the cervix, the possibility thereof may explain at least in some part the 
difficulty researchers are having in adopting definitions of persistence, clearance, and 
prevalence - especially in the immunocompromised population- from research done in the 
field of cervical dysplasia and cancer, in spite of expansion of the repertoire of definitions to 
include incident detection of HPV. 
 
Monitoring HPV infection 
There are a number of commercially available tests for detecting the presence of HPV, of 
which the Roche Linear Array is able to detect the larger number of genotypes: 
HPV DNA detection test 
1. Roche Linear Array HPV Genotyping Test 
This qualitative in vitro test uses amplification of target DNA by polymerase chain 
reaction (PCR) and nucleic acid hybridization and detects 37 anogenital HPV DNA 
types in cervical cells collected in PreservCyt® Solution. 
2. The Cobas4800® (Roche Molecular Systems, Pleasanton, CA) detects 12 HR-HPV 
types also with individual HPV-16 and HPV-18 detection. 
3. Hybrid Capture 2 (HC2) test (Qiagen, Gaithersburg, MD) is an amplification assay 
which uses a combination of antibody capture and chemiluminescent signal detection. 
It can detect 13 HR- and 5 LR-HPV types. 
 
HPV mRNA 
Apart from identifying persistent HPV infection with HPV-DNA screening tests and/or the 
specific genotype present on cervical smear, a more specific test has been developed which 
may predict the development of high grade lesions (108-110). These tests are flow cytometry-
based in-situ tests that identify the presence of HPV E6/E7 mRNA in intact ectocervical cells. 
Oncogenic genotypes of HPV over express E6 and E7 mRNA after integration of HPV into 
genomic DNA (111).The E6/E7 proteins inactivate two tumour suppressor proteins, p53 and 
pRb. Increasing levels of E7 mRNA appear to be associated with an increased risk of 
developing cervical cancer (112). 
 
The mRNA tests may be especially helpful in patients under the age of 30 years, when the 
prevalence of HPV infection is the highest, in identifying oncogenic activity in the HPV 
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subtypes most linked with dysplasia (113). Further application may be to triage women with 
normal cytology but positive HR-HPV to Colposcopy evaluation: a positive mRNA test 
relating to increased CIN2 risk. Also clinically validated for ASC-US triage, the negative 
predictive value of an mRNA test result for CIN2 or higher is 99% after ASC-US cytology, 
and the positive predictive value for CIN2 is between 8-14% (114). The mRNA detection 
tests do not however contribute diagnostically in cases of mild dysplasia or higher cytological 
abnormality (115). 
 
Commercially available tests for detecting mRNA include: 
1. PreTect Proofer Assay (NorChip AS, Klkkarstua, Norway) is a multiplex nucleic 
acid sequence based amplification (NASBA) can detect mRNA of five (5) HR 
subtypes. 
2. NucliSENS EasyQ™ HPV (bioMérieux Clinical Diagnostics, France) can detect 
mRNA of five (5) HR subtypes. 
3. APTIMA HPV Assay (Hologic Gen-Probe Incorporated, San Diego, CA) can 
detect mRNA of fourteen (14) HR subtypes. 
Although the potential value of mRNA for the detection of oncogenic activity exists, two 
factors excluded its use for monitoring cervical HPV infection in this study: the limited 
number of genotypes that may be detected, and that the focus of this study is the detection of 
specific HPV genotype infection and not that of the study of oncogenic activity. To put it 
more plainly: we were not just interested in the association of cART with certain oncogenic 
types, but with all types that could cause an abnormal Pap smear. 
 
HPV Viral Load 
Advances in molecular techniques have enabled scientists to not only detect the presence of 
HPV in cervical tissue, but also to quantify the amount of HPV shedding. There is an 
association of the level of cervical HPV shedding with patient age and the progression of 
cervical dysplasia. Cervical HPV viral loads are consistently higher in women under 25 years 
of age (116), with HPV viral load declining with increasing age. HPV viral load has in some 
reports been found to be significantly associated with degree of cervical lesions (83, 117). 
 
Specifically, HPV Type 16 and 18 viral load levels in cervical smears are higher in women 
with HSIL than with LSIL, even after excision treatment, in women aged 30-40 years. In 
younger women, a high HPV viral load can also be detected in some women with LSIL or 
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even normal cervix (118). Severely immunocompromised patients (CD4<100cells/ɥl) are at 
highest risk for high HR-HPV viral load and cytological abnormality (119). HR-HPV viral 
load may also be influenced by transmission from the sexual partner. A study previously 
showed that circumcised males have a lower prevalence of HPV-associated penile lesions 
(120). Supporting this, the risk for higher HPV viral load in the female partner has been 
found to be  reduced by circumcision intervention in the male partner, primarily for incident 
HPV infections, but not persistent HPV (121). 
The association of cervical HPV viral load with severity of cervical disease is still under 
investigation, however. A recent study saw no association of HPV viral load at baseline with 
progression to CIN3+, and the slight increase in those that did progress was not a significant 
change. What was interesting, though, was that the women who developed persistence of 
HPV infection- which is considered the most important factor contributing to risk for 
developing cervical cancer- had lower HPV viral loads, while clearance of the infection was 
associated with high cervical HPV viral load levels at baseline (122) . 
 
When the disease has progressed to invasive cancer, no correlation of pre-treatment HPV 
viral load with prognosis of early stage cervical carcinoma was found (123).  HPV-16 could 
however be detected in plasma of women with CIN III (16.7%), Cancer stage I (25%), Stage 
II (61.3%), stage III (74.3%), stage IV (100%). In this publication, the Clinical Stage was 
correlated with HPV 16 viremia. No association could be found for HPV 18 viremia and 
advancing stage of cancer (124). 
 
As with the detection of HPV mRNA in cervical tissue, monitoring the amount of HPV 
shedding from the cervix seems to have highest value in the study of progression of cervical 
dysplasia to cancer. Unfortunately, it would only be possible to monitor HPV viral load levels 
for one or two genotypes. The purpose of the study is to investigate the efficacy of cART to 
eliminate, or at least drive to below the level of detection, the HPV genotype population. In 
addition the aim is to compare the relative effect of cART on those subtypes, but not to focus 
on the amount of shedding of just one or two types. 
 
We have therefore chosen as most suitable for the purpose of this investigation, with proven 
high sensitivity for detection of the most HPV genotypes, the Roche Linear Array HPV 
Genotyping Test.  
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Antiretroviral Therapy and HPV infection 
Several studies that examined the effect of cART on cervical HPV infection - from as early as 
1998 - have been executed, and they reported some conflicting findings. Firstly, earlier 
studies used less sensitive HPV tests- based on all or none detection- that possibly could not 
detect the variety of genotypes that can be detected with tests more recently. Furthermore, 
HPV genotypes were often grouped together as HR-HPV. Most studies were based on 
confusing study end points that had been adopted from cervical dysplasia research. These 
endpoints were possibly also used in order to apply statistical methods available at the time 
(Xhi-square tests, logistic regression, and cox regression and survival analysis). These tests 
ignore the repeated measures effect, resulting in loss of statistical power by ignoring a large 
proportion of observations. Finally, some were done on very small cohorts; some had very 
few patients initiated on cART, or very few patients not exposed to cART. Most studies, but 
not all, failed to show an effect of cART on HPV infection, even if some could demonstrate 
an effect on SIL, or vice versa. 
 
One of the first studies was done in France. Early regression of cervical lesions was seen in 
49 women initiating ARV therapy, but clearance of the HPV infection was not always 
observed in those cases (47).  In another small study that enrolled 45 MSM, a high prevalence 
of anal HPV and high-grade SIL remained despite immune restoration under cART (125). 
When looking more specifically at incident HPV detection, two more recent study reports 
also failed to show a protective influence of cART (39, 126). One was focused on women 
with genital warts, the other included only adolescents (39). 
 
In contrast, in an observational study by the Minkoff group of women initiating cART, these 
women were 40% more likely to experience regression of their cervical lesions after 
adjustment for CD4 counts (34). ARV therapy was found to alter the course of HPV-related 
disease, reducing progression and increasing regression of lesions (34). Paramsothy et al 
included 537 women in their study and found that HAART was associated with improved 
HPV clearance in women with pre-existing cervical squamous intraepithelial lesions (Hazard 
ratio was 4.5, 95% CI 1.2-16.3), but not with abnormal Pap test regression. Also, it did not 
lead to improved clearance of HPV infection in women with normal Pap smears. (36). 
 
Similarly, another larger study was done by Konopnicki et al. Sustained suppression of HIV 
RNA plasma load for >40 months and CD4count >500 cells/ɥl for >18 months reduced risk 
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of HR-HPV persistence. The group did not distinguish between the different the HR-HPV 
genotypes in their analysis (127). 
 
Minkoff did another prospective study of 286 women which was published in 2010. His team 
again found that HAART use in women was significantly associated with a reduced burden 
of HPV infection and SIL. Specifically, there was a reduced prevalence (OR= 0.60 (0.44-
0.81), incident detection (HR=0.49 (0.30-0.82) and more rapid clearance of HPV positive SIL 
(HR 2.35, 1.07-5.18).  The effect was bigger if the women were adherent to the medication. 
He did not find a difference if a stricter definition of adherence, that of undetectable viral 
loads, was used for adherence. Minkoff did however apply frailty models instead of standard 
Cox proportional hazards models, but still used traditional definitions of prevalence, 
persistence and incident detection as outcomes.  In both the 2001 and 2010 studies, a PCR 
method was used. In the 2001 study, no distinction was made between the different 
oncogenic HPV subtypes as outcomes. Rather, the presence of any HR-HPV was seen as a 
positive outcome.  In the 2010 study, oncogenic and non-oncogenic groups were evaluated 
separately as two outcomes (35). Table 4.2 summarizes the methods applied in these reports. 
 
These conflicting findings, leading to a lack of consensus on the effect of cART on cervical 
HPV infection, therefore provided us with the impetus for this research question to be 
revisited. We decided to design a more robust study which enrolled women with a wide range 
of immunological as well as cervical cytological status, and to apply the most appropriate 
analytical method that utilizes maximum statistical power suited to the design of the study. 
We also chose to also evaluate the effect of cART on each individual HV genotype and not 
restrict ourselves to the overall effect on all HPV types together. 
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Table 15 Summary of Studies investigating the effect of cART on cervical or anal HPV Infection 
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Methods 
Study Design, Population, Setting and Outcomes Definition  
In this prospective study women known with HIV infection were approached for enrolment 
to the study if they were cART naïve or had recently (<1 month) initiated cART. Two study 
sites - both situated in Tygerberg Hospital, Parow, South Africa- were used.  The first site 
was the Infectious Diseases Clinic (IDC), a treatment centre for the management of HV 
infection, which includes provision of antiretroviral therapy. The second site was the 
Colposcopy Clinic (CC) of the Department of Obstetrics and Gynaecology. The twin 
enrolment approach was needed to ensure inclusion of study subjects already known with 
cervical dysplastic lesions, whilst also including women with normal cytology from the 
Infectious Diseases Clinic. Patients known with cervical or other cancers, however, were 
excluded, as were pregnant women. Each study site contributed approximately one half of 
study participants. Enrolment commenced November 2009 and ended October 2011. The 
study was approved by the Stellenbosch University Human Research Ethics Committee (ref 
nr N09/04/106). 
 
Follow-up visits were conducted twice yearly, either at the IDC, or both the IDC and the 
Colposcopy Clinic, depending on whether colposcopy evaluation and a procedure such as 
biopsy or excision treatment was indicated. At each visit, the medical history, including the 
obstetric history, sexual behaviour and substance (alcohol or drugs) use were recorded. 
 
A cervical Pap test was performed for each study subject at every visit, except on the days 
that a cervical biopsy was taken or an excision biopsy was done. Cytology and pathology 
were read by Pathologists according to standard protocol at the routine laboratory service 
located in Tygerberg Hospital. Classification of results was based on the 1988 Bethesda 
scoring system for cervical pathology:  normal, LSIL and HSIL. For simplification for 
statistical analyses, ASC-US and ASC-L were grouped with LSIL, and ASC-H was grouped 
with HSIL. For the analyses, a combination of Cytology and Pathology results were used, but 
Pathology that was performed on the same date was used in the case of conflicting results.  
 
Management of HSIL cervical lesions was not altered for the purpose of this protocol, but 
continued unchanged regardless of HIV status of the patient. We did, however, have a lower 
threshold for referral of LSIL for women known with HIV infection. Referral for colposcopy 
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evaluation occurred already after a single LSIL Pap smear result, whereas HIV uninfected 
women were only referred after the second abnormal smear showed LSIL or a higher lesion. 
If a suspicious lesion was seen on aceto white stain, a biopsy was taken to confirm or exclude 
HSIL. If confirmed, an excision biopsy treatment was scheduled at the next available 
appointment at Colposcopy Clinic, usually a week later. If the diagnostic biopsy excluded 
HSIL but showed LSIL, the Pap test would then be repeated 6 months later for the purpose of 
this protocol, and not two years later as would normally be standard for non-study 
participants. 
 
The decision to initiate antiretroviral therapy was not influenced by the study, but was based 
on the Government Protocol for the Initiation of Antiretroviral Therapy. In 2009, the protocol 
prescribed commencement of cART when the CD4 count dropped under 200 cells/ɥl. This 
was revised in 2010 to include initiation of cART when the CD4 decreased to under 350 
cells/ɥl in pregnant women and persons with Tuberculosis, and finally in 2012 again revised 
to recommend initiation in all persons with a CD4 count less than 350 cells/ɥl. The standard 
initiating regimen of antiretroviral therapy was stavudine, lamivudine and efvavirenz or 
nevirapine in 2009, but was changed to replace stavudine with tenofovir in April 2010. The 
Protease inhibitor, ritonavir boosted lopinavir, was and still is used only in the second-line 
regimen in almost all patients treated on this programme. 
 
Antiretroviral therapy use was recorded at each visit. Interruption of the prescribed regimen 
was ascertained by a combination of the pharmacy pickup and patient self-report methods. 
No distinction was made whether interruptions were physician or patient-initiated. 
 
Response to antiretroviral therapy was measured by testing the CD4 count at study enrolment 
and at each six monthly follow-up visit. A viral load determination was also done at baseline 
and is referred to as the viral set point. The Abbott m2000 RealTime HIV-1 Assay was used 
throughout the study and performed at the Department of Virology, NHLS, Tygerberg 
Hospital. For the patients that have commenced cART, the viral load test was repeated at six 
monthly intervals. If an unscheduled viral load test done between study visits was at a 
detectable level and higher than at the next study visit (for example in the case of suspected 
poor adherence not reported by the patient or revealed by missed pharmacy appointments), 
the higher value was used to reflect that viral replication was not suppressed for the time 
between study visits. 
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Cervical HPV samples were collected with a Cervexbrush® at baseline and 6 monthly 
intervals, placed in PreservCyt® (Hologic, Bedford, MA) solution and stored at -80deg 
Celsius for later analysis by Roche linear array, according to the manufacturer’s instructions. 
Specimen preparation was done using the AmpiLute Medica Extraction Kit which yields 
HPV target DNA and human HPV suitable for PCR amplification. The Master Mix reagent 
contains primers for the amplification of DNA from 37 HPV genotypes and of the ß-globulin 
gene. The test procedure performs target DNA amplification with AmpliTaq Gold DNA 
Polymerase, and AmpErase for further selective amplification. Genotyping was then 
performed by hybridization technique on the extracted DNA. Test strip results were read 
independently by the two molecular scientists. Both were blinded as to the ART and 
cytological status detected in any of the study subjects. Samples that were ß-globulin negative 
were excluded from the analysis. HR-HPV subtypes are HPV-16, 18, 26, 31, 33, 35, 39, 45, 
51, 52, 53, 56, 58, 59, 66, 68, 73, and 82. The rest of the HPV subtypes detected by the Roche 
array are considered LR-HPV and include HPV 6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 
71, 72, 81, 83, 84, CP6108 and IS39.  For simplification, we did not consider the probable 
HR types 67, 69 and IS39 in the HR group (68). A study subject was considered HPV 
positive if the specific HPV genotype was detected on a cervical sample.  The test results 
were reported keeping in mind the cross-reactions that occur: a positive test result for subtype 
33* means that HPV 33 is positive, but the presence of HPV 52 cannot be excluded; the same 
for HPV 35* and HPV 58*. 
 
Statistical analysis 
A SQL database (Microsoft SQL Server 2008) was created to capture, store and retrieve 
study data (Appendix 1-5). The database was securely stored on the University of 
Stellenbosch server with a double layered per-user defined password access system. Data 
extraction was done from an Access front end (Microsoft Access 2010).   Once extracted, the 
data were analysed using Microsoft Excel 2010, XLSTAT (version 2013.3.01) and Stata 
(version 11).  Baseline demographic variables were assessed using Pearson's χ2 or Fisher 
exact tests to compare proportions, and Student's paired-t tests to compare means between 
groups. 
 
For the purpose of this analysis, we defined antiretroviral treatment in two ways. For the first 
variable, time on cART, the cART start date was recorded and the time since first date of 
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administration calculated at each visit. This variable would not be influenced by adherence to 
the cART regimen. The cART treatment status variable was used as a binary variable to 
indicate if the patient was still using cART at a visit; never started or an interruption of more 
than one month were labelled  “not on treatment”  at that visit. 
 
Historically, analysis of the factors that influence detection of HPV subtypes, and this 
includes the influence of cART, were done using logistic regression or survival analyses. 
Unfortunately, artificial simplification of data always had to be done in order to 
accommodate these methods. Firstly, HPV infection outcomes had to be defined, mostly as 
HPV prevalence, HPV incident detection and HPV persistence (the time to clearance of an 
HPV test result following its initial detection, with clearance defined as the first or the first 
subsequent negative result). This simplification presents opportunity for bias and human 
error: for example how would the detection of a subtype, previously detected at baseline, not 
detected at two subsequent visits and then detected at the next, be defined?  Minkoff (35) 
used frailty models to evaluate incident detection and time to clearance, but the artificial 
diagnosis of both incident detection and clearance would duplicate the within-participant 
correlation already provided by the statistical method of analysis, namely that of different 
snapshots in time of the same study subjects. Frailty analysis already takes into account the 
presence or absence of the subtype at another time point and it is therefore not necessary to 
create these additional classifications of HPV detection outcomes. 
 
A second simplification was made in almost all of these analyses. Because of the multiple 
subtypes that are tested for, the subtypes were roughly grouped as any high-risk HPV (HR-
HPV). This implied that the factors that influence HPV infection are equal for all HR-
subtypes, ignoring possible differences between the subtypes and the effect of the presence of 
any HR-or LR-HPV subtype might have. LR-HPV types were mostly ignored.  A third and 
important simplification was that time-dependent factors were simplified or classified in 
order to include them as covariates in the analyses, thereby ignoring the statistical effect of 
repeated measurements on study subjects. For example, the time treated with cART was 
traditionally taken as <1yr, 2 yrs etc; sexual activity was stated as at baseline without taking 
into account that it might change during follow-up period; CD4 counts were taken as either 
baseline or pre-cART and ignored the effect of changes during follow-up. 
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Independent predictors of HPV detection before or after cART can be assessed by performing 
random effect modelling which controls for the fact that data collected include repeated 
observations measures of the same women over time and possibly multiple different HPV 
types. These multiple HPV subtypes presented separate outcomes which are possibly not 
equal: it is known that HPV16 causes most cases of cancer and larger and more persistent 
CIN lesions. Immunity conferred during infection with one subtype also may not confer 
complete immunity to another (128). The various other factors that influence outcomes may 
also not be independent from each other; cART status can be expected to have a strong 
association with HIV-RNA level.  
 
Time-to-event analyses were therefore performed using detection of HPV outcomes by 
performing frailty models which incorporate a random effect to adjust for within-participant 
correlation. Indeed, they are the most commonly used time-to-event method that permits the 
comparison of women with themselves (i.e. before and after cART initiation) and are 
therefore more appropriate for our study (129). All models were adjusted for excision 
treatment of cervical neoplasia and the CD4+ cell count, using time-dependent variables. 
Other time-dependent factors adjusted for in our models include: time on cART, cART 
treatment status and sexual activity. Age was included as a non-time dependent variable due 
to the limited follow-up time. P-Values reported were two-tailed and alpha level 5%.  
 
Approach to missing data 
Missing data are unavoidable under even the most strictly controlled studies. There are 
several methods to deal with missing data. A common approach is to exclude all observation 
sets with missing data points. We followed this approach as regards to the outcome variable 
(successful DNA sample) and included only observation sets from those visits that had 
complete HPV detection results available; four (4) of 1115 cervical specimens on which no 
DNA could be extracted were excluded from the analysis, even though it also led to the 
complete exclusion of one study subject (see Results). 
 
To deal with missing data from factors influencing the outcome variable, the data set was 
examined as to determine the type of missing points. All of the remaining 1111 data set 
variables were found to be complete, except for the HIV-RNA and CD4 count 
determinations.  The missing data points were not missing at random, but represented tests 
not done for very specific clinical reasons. In the case of the CD4 count test, this was not 
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done at time points between six monthly visits, as this value can be expected to vary very 
little in between visits. A commonly used approach was applied here by single imputation 
with the average of the preceding and following value. There were 27 such single imputations 
done of the total of 1111 for this variable, which is further discussed in the Results section.  
 
HIV-RNA plasma level determination presents a unique type of variable. In the time before 
cART is started, it behaves as a non-time dependent variable, with little log-variation. In 
clinical medicine this is called the viral set point. A HIV-RNA determination was therefore in 
our study done only once, prior to initiation of cART, and an assumption could be made that 
it would remain at viral set point value until the cART initiation date. Furthermore, this 
variable starts behaving like a time-dependent variable after cART is initiated, with a 
dramatic decrease in plasma HIV-RNA level which is only sustained for as long as the 
subject remains treatment adherent and the virus susceptible to the regimen. An HIV-RNA 
level was thus not done on days of supplemental cervical HPV sampling if the study subject 
remained on cART and remained adherent to the regimen. If the subject remained adherent 
between scheduled visits and the HIV-RNA level at the previous as well as the following 
visit was below the level of detection, a very strong assumption could be made that at the 
time point between the visits, the HIV-RNA level would also be undetectably low. Lastly, if 
the cART was interrupted for more than 30 days, another strong assumption could be made 
that the HIV-RNA level would have returned to the viral set point. 
 
The approach of blindly excluding observation sets with missing HIV-RNA levels would be 
highly inappropriate in this setting, as it would omit most observation sets of study subjects 
who have not started cART, leading to serious bias and loss of statistical power.  We 
therefore performed single imputations for missing HIV-RNA levels in the following 
manner: 
1. If the study subject had not started on cART, an assumption was made that the HIV-
level remained at viral set point. 
2. If the study subject had an undetectable HIV-RNA level at the visit before and after 
the visit with the missing HIV-RNA level, and remained adherent to the regimen 
throughout the time period in between, it was assumed that that HIV-RNA level was 
also undetectable. 
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3. If a study subject interrupted cART for more than 30 days prior to the missing data 
point, it was assumed that the HIV-RNA level had returned to viral set point. 
4. If none of the above could be applied, the observation data set was excluded from the 
analysis. 
There are other options for dealing with missing data points available in statistical software. 
Most have to be used with caution, especially in the case of data not missing at random, as in 
this study.  The most commonly used is that of multiple imputation. This method (in Stata the 
mi command) calculates and imputes values for the missing observations – the process is 
usually repeated 3-5 times, resulting in as many data sets. The desired analysis is then 
performed on each set, and the average of the parameter estimates with standard errors 
calculated. Of note, it is important to also include in the MI calculation all the variables that 
influence the imputed values (130). In the background of the systematic and intentional 
pattern of missing values in only two variables, namely that of CD4 count and HIV-RNA 
levels for HPV samples that were taken between scheduled dispensing visits, it was decided 
that substituted calculated values based on average predictors would be inferior to the 
expected value at that point- and concluded that single imputations that fit the rules described 
a nearest to accurate reflection of the maximum likelihood of those values. 
 
Results 
 
From November 2009 to October 2011, a total of 304 participants were enrolled to the study, 
of whom two were excluded from the analysis as having exceeded 30 days of cART exposure 
prior to enrolment (figure 13). One patient was consented but withdrew consent immediately 
after colposcopy evaluation. In total, 1115 HPV DNA specimens were received from 301 
patients of which four (4) no DNA could be extracted, including one patient who, having 
presented only the one time for evaluation, was then subsequently not included in the 
analysis. We therefore had 1111 specimens from 300 women which could be tested for HPV 
DNA.  
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Figure 13 Prospective Study enrolment  
Single imputation of missing values for CD4 counts and HIV-RNA levels were then 
performed, according to the rules stipulated in “Methods-Statistical Analysis-Missing Data”.  
For missing CD4 count values, 27 values were imputed, which represents 2.4% of the 1111 
data sets. The mean±SD of the imputed values were 360±147 (n=27) compared to the 371±199 
(n=1084) for non-imputed data. 
 
For missing HIV-RNA levels, applying the rules stipulated, 261 single imputations for 
subjects not on cART,  22 for subjects that had interrupted cART longer than 30 days, and 27 
imputations for subjects that were adherent to cART together with undetectable HIV-RNA 
levels at the preceding as well as at the following visit, were done. Ten (10) data sets were 
excluded because no assumption of value could be made, leaving 1101 data sets included in 
the analysis. The mean±SD of the imputed log values were 3.77±1.28 (n=310) compared to the 
2.61±1.83 (n=791) for non-imputed data. The higher mean of the imputed viral loads reflects 
the fact that most imputations were done for patients that had not yet initiated cART, and that 
imputing population-based cohort averages would have been inappropriate. Due to the 
clinical nature of HIV infection, the expected viral set point variation in each study subject is 
small, whereas large variations exist between subjects. Indeed, in our cohort, the viral set 
point varied from 29 copies/ml to 7.2 million copies/ml for the 290 out of the 300 women 
who had a viral load test done before initiating cART. Furthermore, conditions that could 
have caused a small variation in the viral set point, such as an AIDS-related illness, would 
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have been unlikely in the women who did not need to initiate cART.  We were therefore 
confident that our method for patient-based imputation was superior to averaged inputs, and 
we avoided serious bias based on exclusion of pre-cART- initiated visits. 
 
We analysed the quality of Pap smears throughout the study period and found that overall, the 
percentage of smears that did not contain endocervical cells, were 11% of the total of 1458 
cytology results. The quality of smears at the start of the study was similar to that seen with 
our previous analysis of LSIL and HSIL (Chapters 2 and 3) for HIV infected women,  at 
17%, and as study site personnel performed the follow-up Pap smears, the incomplete smears 
dropped to below 10% (figure 14). 
 
Figure 14 Percentage of Pap Smears reported as no endocervical cells present 
A biopsy from a single site can underreport the severity of a lesion (131, 132). Standard 
procedure was however used at Colposcopy clinic which was to take diagnostic specimens 
from more than one area on the cervix to improve sensitivity of the test. We were therefore 
confident that the sensitivity of diagnostic biopsy was high enough to consider it of 
overriding diagnosis in determining the cytopathology status of a patient. For this analysis, a 
combination of Cytology and Pathology results were used, but Pathology that was performed 
on the same date, was used in the case of differing results. 
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Patient Demographics 
 
We compared certain characteristics of women who were initiated on cART with those who 
were not initiated on cART, as to describe the differences in risk factors in our study cohort 
(Table 16). The differences that were found reflect the design of the study and the 
participants included. These include the reasons why cART was not initiated in the untreated 
group- a higher CD4 count at study enrolment and the lower viral set point. Besides being 
younger, the time from coitarche to study enrolment was also significantly shorter. The 
shorter follow-up time in the non-cART treated women may be another reason why cART 
was not started as these women possibly moved to another cART site to start their treatment. 
 
Other factors were more equally represented. The women not initiated on cART had a 
slightly lower history of smoking and alcohol use, and fewer reported abstinence from sexual 
intercourse at study baseline. Excision treatment during study follow-up was equal both in 
proportion, completeness and indication. Only one patient underwent cold-knife cone (CKC) 
excision treatment; the distinction as to the type of excision treatment was thus not included 
in the analyses of factors influencing cervical HPV infection. 
 
Exposure to cART was a sum of 98442 days for the 204 study subjects that were initiated on 
cART. All patients treated were initiated on standard regimen of non-nucleoside analogue 
reverse transcriptase inhibitor (NNRTI) -containing regimen. Only seven patients were 
exposed to a Lopinavir-containing regimen for a total of 2435 days during the study, which 
represents 2.48% of the total time of regimen exposure.  The type of cART regimen was 
therefore not included in analysis. 
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Table 16 Demographic and Clinical Characteristics: Prospective Study 
 
 Total ART 
 n (%) 
No ART 
 n(%) 
p-value1 
Age  (mean,SD) 300 35·9±9·26 31·4±7·75 <0·001 
Age study entry 
(years) 
 
 
15-24 
25-29 
30-34 
35-39 
40-44 
≥45 
300 
27      
79 
68 
46 
37 
43 
204 (100) 
11 (5·4) 
47 (23·0) 
45 (22·1) 
34 (16·7) 
30 (14·7) 
37 (18·1) 
96 (100) 
16 (16·7) 
32 (33·3) 
23 (24·0) 
12 (12·5) 
7 (7·3) 
6 (6·3) 
<0·001 
Ethnicity 
 
 
Black 
Mixed Race 
Indian 
300 
156 
143 
1 
204 (100) 
94 (46·1) 
109 (53·4) 
1 (0·5) 
96 (100) 
62 (64·6) 
34 (35·4) 
0 (0·0) 
 
0·01 
Time Coitarche to Enrolment (Sexual Age) (mean,SD) 286 18·0±8·99 14·5±7·06 <0·001 
Follow-up Time  
 
(mean,SD) 300 578±154.9 367 ±314.1 <0·001 
Life Time Sexual Partners  
1-3 
4-6 
>6 
300 
195 
85 
20 
204 (100) 
132 (64·7) 
59 (28·9) 
13 (6·4) 
96 (100) 
63 (65·6) 
26 (27·1) 
7 (7·3) 
0·92 
Partner Status  
Married/partner 
Abstinence>1 
year 
300 
217 
83 
204 (100) 
140 (68·6) 
64 (32·4) 
96 (100) 
77 (80·2) 
19 (19·8) 
0·04 
Ever Smoker  
Ongoing 
Previous 
Never 
300 
79 
32 
189 
204 (100) 
59 (28·9) 
28 (13·7) 
117 (57·4) 
96 (100) 
20 (20·8) 
4 (4·2) 
72 (75·0) 
0·005 
Ever Alcohol Use  
Ongoing 
Previous 
Never 
300 
36 
105 
159 
204 (100) 
21 (10·3) 
81 (39·7) 
102 (50·0) 
96 (100) 
15 (15·6) 
24 (25·0) 
57 (59·4) 
0·04 
Ever Substance Abuse  
Ongoing 
Previous 
Never 
300 
2 
25 
273 
204 (100) 
2 (1·0) 
20 (9·8) 
182 (89·2) 
96 (100) 
0 (0·0) 
5 (5·2) 
91 (94·8) 
0·24 
Excision treatment prior to study enrolment  
Yes 
No 
300 
26 
274 
204 (100) 
21 (10·3) 
183 (89·7) 
96 (100) 
5 (5·2) 
91 (94·8) 
0·14 
Excision treatment prior to enrolment Result  
Normal 
LSIL 
HSIL 
26 
3 
4 
19 
21 (100) 
2 (9·5) 
3 (14·3) 
16 (76·2) 
5 (100) 
1 (20·0) 
1 (20·0) 
3 (60·0) 
0·74 
Cytopathological diagnosis study enrolment 
 
 
Normal 
LSIL 
HSIL 
300 
98 
143 
59 
204 (100) 
84 (41·2) 
87 (42·7) 
33 (16·2) 
96 (100) 
14 (14·6) 
56 (58·3) 
26 (27·1) 
 
<0·001 
Cytopathological diagnosis ART initiation 
 
 
Normal 
LSIL 
HSIL 
204 
96 
75 
33 
204 (100) 
96 (47·1) 
75 (36·8) 
33 (16·2) 
NA NA 
Excision Treatment on Study  
Performed 
Not Performed 
300 
91 
209 
204 (100) 
64 (31·4) 
140 (68·6) 
96 (100) 
27 (28·1) 
69 (71·9) 
 
0·57 
Excision Treatment on Study Result  
Normal 
LSIL 
HSIL 
91 
3 
28 
60 
64 (100) 
3 (4·7) 
17 (26·6) 
44 (68·8) 
27 (100) 
0 (0·0) 
11 (40·7) 
16 (59·3) 
 
0·25 
Excision treatment on Study5 
Completeness 
 
Complete 
Incomplete 
Not Applicable6 
91 
35 
  33 
4 
64 (100) 
21 (32·8) 
24 (37·5) 
4 (6·3) 
27 (100) 
14 (51·9) 
8 (29·6) 
0 (0·0) 
 
0·37 
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Not Stated 
Cannot be 
determined 
6 
15 
5 (7·8) 
10 (15·6) 
1 (3·7) 
4 (14·8) 
CD4 count 
 
 
at study 
enrolment9 
at ART initiation 
300 
300 
204 
204 
209±128·0 
194±117·0 
96 
398±224·3 
NA 
 
<0·001 
NA 
CD4 at study enrolment 
 
 
<200 
200-350 
≥350 
300 
140 
80 
80 
204 (100) 
117 (57·4) 
61 (29·9) 
26 (12·8) 
96 (100) 
23 (24·0) 
19 (19·8) 
54 (56·3) 
<0·001 
CD4 at cART initiation  
<200 
200-350 
≥350 
204 
125 
61 
18 
204 (100) 
125 (61·3) 
61 (29·9) 
18 (8·8) 
NA  
Study Enrolment HIV-RNA  
<5,000 
5,000-50,000 
50,000-100,000 
100,000-500,000 
≥500,000 
ND 
300 
43 
97 
32 
79 
39 
10 
204 (100) 
19 (9·3) 
62 (30·4) 
23 (11·3) 
65 (31·9) 
30 (14·7) 
5 (2·5) 
96 (100) 
24 (25·0) 
35 (36·5) 
9 (9·4) 
14 (14·6) 
9 (9·4) 
5 (5·2) 
<0·001 
Study Enrolment Log HIV-RNA (mean,SD) 290 4·8±0·95 4·3±1·08 <0·001 
Days cART (mean,SD) 300 482 ±199.5 N/A  
 
 
Frequency of Detection of HPV genotypes 
 
Of a total of 40737 HPV genotype observations, 1101 for each genotype, there were 4455 
HPV positive detections.  The most frequently detected HPV genotype was HPV84, followed 
by HPV62 and HPV16. There were fewer than twenty detections of HPV40 and HPV64 
(Figure 15). 
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Figure 15 Total Number of HPV Genotype Detections During Follow-up Time 
 
HPV Prevalence in Study Subjects 
 
The prevalence of HPV types was calculated as the number of study subjects that ever had a 
positive detection of the subtype during the time of follow-up, as depicted in table 17. 
We tested 1101 samples for each of the 37 HPV genotypes. The most frequent oncogenic 
type was HPV16. Any High-Risk Type was detected at least once in 94.3% of patients during 
follow-up time. Only 18 (6.0%) of study participants had only one HR type, 115 (38.3%) had 
between two to four HR types, 25 (8,3%) women had ten or more HR types. Of the LR-types, 
the most common was HPV84, -62 and -66 (Table 17). 
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Table 17 HPV types Most Detected Per Patient during follow-up time 
 
HR-HPV type Number Percentage of 
Patients 
LR-HPV type Number Percentage 
of Patients 
HPV 16 127 42.3% HPV 84 183 61.0% 
HPV 51 112 37.3% HPV 62 145 48.3% 
HPV 59 111 37.0% HPV 66 106 35.3% 
HPV 58 108 36.0% HPV 53 92 30.7% 
HPV 35 97 32.3% HPV 61 90 30.0% 
HPV 39 83 27.7% CP6108 85 28.3% 
HPV 33 81 27.0% HPV 55 84 28.0% 
HPV 68 81 27.0% HPV 69 69 23.0% 
HPV 18 79 26.3% HPV 81 67 22.3% 
HPV 45 76 25.3% HPV 73 66 22.0% 
HPV 31 69 23.0% HPV 82 65 21.7% 
HPV 56 65 21.7% HPV 54 59 19.7% 
HPV 52 57 19.0% HPV 83 58 19.3% 
HPV 82 65 21.7% HPV 70 52 17.3% 
HPV26 21 7.0% HPV 71 50 16.7% 
   HPV   6 43 14.3% 
   HPV 42 40 13.3% 
   HPV 72 39 13.0% 
      
Any HR risk HPV Type Detected 287 94.3% 
Any Low Risk HPV Type Detected 284 94.7% 
No HPV Detected 2 0.7% 
HPV 16 and/or HPV 18 160 53.3% 
HPV 16 and HPV 18 46 15.3% 
Only one High-Risk type detected 18 6.0% 
High-Risk types- two to four 115 38.3% 
High-Risk Types- five to nine 129 43.0% 
High-Risk Types -ten or more 25 8.3% 
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Association of HPV subtype detection with Cytopathology Results 
 
Using a GEE population averaged model to test the association of any abnormal 
cytopathology result (compared to normal) separately for each HPV genotype, we found that 
HPV 16, -31, 33, -35 and -39 were significantly linked to abnormalities. Of the non-
oncogenic types, HPV 6 (OR 2.30, 95% CI 1.34-3.92, p=0.002), HPV42 (OR 2.93, 95% CI 
1.64-5.27, p<0.001), HPV70 (OR 2.19, 95% CI 1.35-3.57, p=0.002) and HPV84 (OR 1.39, 
95% CI 1.08-1.79, p=0.01) were significantly associated with abnormal cytopathology 
(Figure 16).  
 
Figure 16 Independent Association of all HPV types with Abnormal Cytopathology (Unadjusted) 
 
Result for HPV11 not shown,   95% CI too wide 
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When adjusting for age, CD4 count, days on cART and days since excision treatment, the 
association remained, but the time since excision was performed also had a strongly 
significant contribution. The time on cART and CD4 count did not (Figure 17). 
 
Figure 17 Independent Association of all HPV types with Abnormal Cytopathology (Adjusted) 
 
Result for HPV11 not shown,   95% CI too wide 
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Association of HPV subtype detection with HSIL 
Again using a GEE population averaged model to test the association of a HSIL  
cytopathology result (compared to LSIL or normal combined) separately for each HPV 
genotype, we found that HPV 16, -31, 33, -35, -39, -56, -58, -59 and -82 were significantly 
linked to HSIL. Of the non-oncogenic types, HPV 69, and -70 were significantly associated 
with HSIL (Figure 18). 
 
Figure 18 Independent Association each HPV type with HSIL, unadjusted 
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When adjusting for age, CD4 count, and days on cART, the association remained. The days 
since excision was not included, as this did not reach convergence: too few patients 
developed HSIL after having had excision treatment. The time on cART was significantly 
associated for each genotype except HPV16.  The association with CD4 count was not 
significant (Figure 19). 
Figure 19 Independent Association each HPV type with HSIL, Adjusted 
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Influence of cART status on HPV infection 
 
Association of cART treatment status with detection of all HPV subtypes 
During the unadjusted GEE population-averaged model analysis of the detection of any HPV 
genotype, and cART status (receiving cART or not) as only predictor, the risk for detection 
was reduced by 47% (table 18). 
Table 18 Association of cART treatment status with detection of all HPV subtypes 
 
Variable OR  (95%CI) p-value 
Receiving ART 0·53  (0·49-0·58) <0·001 
 
After adjusting for the other covariates, the time since cART was first started and the CD4 
count had a stronger effect. Other factors that had a significant influence were age, excision 
treatment and whether the patient was sexually active (table 19). 
Table 19 Association of cART treatment status with detection of All HPV Infection 
 
Receiving ART 0·95  (0·80-1·13) 0·59 
Age 0·99  (0·98-0·99) 0·003 
Months since cART first started 0·99  (0·98-0·99) 0·003 
Days Since Excision Treatment 0·99  (0·99-0·99) <0·001 
Sexually active 1·13  (1·01-1·26) 0·03 
CD4  count at visit 0·99  (0·99-0·99) 0·02 
Log HIV-RNA level 0·97  (0·99-0·99) 0.12 
 
Association of cART treatment status with detection of HPV-16 genotype 
For the analysis of the association of cART with the detection of HPV16, again using cART 
treatment status as primary predictor, the time since cART was first started and CD4 count 
were stronger predictors of risk of detection. Other covariates that influenced the outcome 
were age, excision treatment and whether the patient was sexually active (table 20). 
Table 20 Association of cART Treatment status with detection of HPV16 
 
Receiving ART 0·99  (0·84-1·17) 0·94 
Age 0·98  (0·97-0·99) <0·001 
Months since cART first started 0·93  (0·90-0·95 <0·001 
Days Since Excision Treatment 0·99  (0·99-0·99) <0·001 
Sexually active 1·12  (1·01-1·24) 0·04 
CD4  count at visit 0·99  (0·99-0·99) 0·001 
Log HIV-RNA level 0·97  (0·94-1·01) 0.12 
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The influence of cART on all HPV types was expressed as the ratio of the OR of HPV16.  Of 
the oncogenic types, only HPV52 was associated more strongly with cART treatment status 
than HPV16. Several non-oncogenic types were influenced more strongly by cART treatment 
status. No HPV genotype was influenced less than HPV16.  The ratio of the OR for HPV40 
and HPV 64 could not be interpreted as the number of observations was very low (Figure 20). 
Figure 20 Association of cART Treatment status with detection of HPV16 compared to other HPV types 
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Influence of Time Since cART first started on HPV infection 
 
Association of Time Since cART first started with detection of all HPV subtypes 
During the unadjusted GEE population-averaged model analysis of the detection of any HPV 
genotype, the risk for detection was reduced by 6.4% for each month since cART was started 
for the first time (table 21). 
Table 21 Association of months since cART first started with detection of all HPV subtypes 
 
Variable OR  (95%CI) p-value 
Months since cART first started 0·94  (0·93-0·94) <0·001 
 
After adjusting for the other covariates, the time since cART was first started and the CD4 
count still remained significant. Other factors that had a significant influence were age, 
excision treatment and whether the patient was sexually active (table 22). 
Table 22 Association of months since cART first started with detection of all HPV subtypes 
 
Months since cART first started 0·94  (0·94-0·95) <0·001 
Receiving ART 0·95  (0·80-1·13) 0·59 
Age 0·98  (0·98-0·99) 0·003 
Days Since Excision Treatment 0·99  (0·99-0·99) <0·001 
Sexually active 1·13  (1·01-1·26) 0·03 
CD4 count at visit 0·99  (0·99-0·99) 0·02 
Log HIV-RNA level 0·97  (0·94-1·01) 0.12 
 
Association of Time since cART first started with detection of HPV-16 genotype 
For the analysis of the association of time since cART first started with the detection of 
HPV16, again using months since the cART start date as primary predictor, the association 
with cART time and CD4 count was also significant. Other covariates that influenced the 
outcome were age, excision treatment and whether the patient was sexually active (table 23). 
Table 23 Association of months since cART first started with detection of HPV16 infection 
 
Months since cART first started 0·93  (0·90-0·95 <0·001 
Receiving ART 0·99  (0·84-1·17) 0·94 
Age 0·98  (0·97-0·99) <0·001 
Days Since Excision Treatment 0·99  (0·99-0·99) <0·001 
Sexually active 1·12  (1·01-1·24) 0·04 
CD4 count at visit 0·99  (0·99-0·99) 0·001 
Log HIV-RNA level 0·97  (0·94-1·01) 0.12 
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The influence of time since cART was first started (cART Time) on all HPV types was 
expressed as the ratio of the OR of HPV16.  Of the oncogenic types, the detection of HPV52 
and HPV73 was associated more strongly with cART Time than HPV16 was. Several non-
oncogenic types were associated more strongly with cART time, of which HPV6. Only 
HPV39 and HPV84 genotypes were influenced less than HPV16.  The ratio of the OR for 
HPV40 and HPV64 could not be interpreted, as the number of observations was very low 
(Figure 21). 
 
Figure 21 Association of months since cART was first started with detection of HPV16 compared to other 
HPV types 
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The Influence of CD4 count on HPV infection 
 
Association of CD4 count<200 with detection of all HPV subtypes 
During the unadjusted GEE population-averaged model analysis of the detection of any HPV 
genotype, and with CD4 count less than 200 as only predictor, the risk for detection was 
increased by 63% (table 24). 
Table 24 Association of CD4<200 with detection of all HPV subtypes 
 
Variable OR  (95%CI) p-value 
CD4<200 at visit 1·63  (1·50-1·77) <0·001 
 
After adjusting for the other covariates, the time since cART was first started was stronger. 
Other factors that had a significant influence were age, excision treatment and whether the 
patient was sexually active (table 25). 
Table 25 Association of CD4<200 with detection of All HPV Infection 
 
CD4<200 at visit 1·12  (1·00-1·23) 0·06 
Receiving cART 0·97  (0·82-1·15) 0·72 
Age 0·99  (0·98-0·99) 0·005 
Months since cART first started 0·94  (0·93-0·95) <0·001 
Days Since Excision Treatment 0·99  (0·99-0·99) <0·001 
Sexually active 1·13  (1·01-1·26) 0·03 
Log HIV-RNA level 0·98  (0·94-1·01) 0.17 
 
Association of CD4 count<200 with detection of HPV-16 genotype 
For the analysis of the association of CD4 count<200 with the detection of HPV-16, again 
using months since the cART start date as primary predictor, the association with the time 
since cART was first started was stronger. Other covariates that influenced the outcome were 
age, and whether the patient was sexually active (table 26). 
 
Table 26 Association of CD4<200 with detection of HPV16 infection 
 
CD4<200 at visit 0·69  (0·47-1·02) 0·94 
Age 0·98  (0·98-0·99) <0·001 
Receiving cART 0·98  (0·83-1·16) 0·82 
Months since cART first started 0·94  (0·93-0·94 <0·001 
Sexually active 1·15  (1·03-1·28) 0·01 
Log HIV-RNA level 0·98  (0·95-1·02) 0.32 
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The influence of CD4<200 on all HPV types was expressed as the ratio of the OR of HPV-
16.  Of the oncogenic types, HPV33,-35,-39,-58 -68 and -82, were associated more strongly 
with CD4<200. Several non-oncogenic types were influenced more strongly than HPV16, of 
which HPV6. Only HPV39 and HPV84 genotypes were influenced less than HPV16.  The 
ratio of the OR for HPV40 and HPV64 could not be interpreted as the number of 
observations was very low (Figure 22).  
Figure 22 Association of CD4<200 with detection of HPV16 infection, compared to other HPV types 
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Discussion 
 
We know that HIV disease increases the prevalence and persistence of cervical HPV 
infection and resulting cervical dysplasia.  Conversely, HPV infection of the cervix may 
increase the risk of HIV acquisition (133-138). The respective interactions are thought to be 
due to not only shared risk factors, but due to alteration of the systemic as well as cervical 
immunological milieu. In spite of registered effective vaccines for the prevention of infection 
with oncogenic subtypes HPV16 and -18, the effect of improved availability of HPV 
vaccination programmes will, in countries with highest burden of cervical cancer, not be felt 
for the next decade at least, as there will be no catch-up efforts attempted for adolescent girls. 
This is in spite of an assessment that including 12-15 year olds in a once-off effort may 
reduce the cumulative probability of HPV 16/18 prevalence at the age by age 35years by 
about 30% in medium to low-income countries (139).  HIV infection, on the other hand, is a 
largely manageable disease, and the question remains as to why a dramatic increase or re-
emergence of cervical cancer due to increasing longevity in HIV infected women has not 
become evident in countries with effective HIV treatment programs. 
 
To study the early effect of initiating antiretroviral therapy on cervical HPV subtype 
infection, we enrolled 304 women known with HIV infection in a prospective observational 
study at Tygerberg hospital. To ensure that women with varying levels of immune 
suppression and cervical dysplasia lesions were included, women were recruited from both 
the Infectious Diseases Clinic (IDC) – expected to contribute women with higher chance of 
more severe immune suppression but possibly also women with normal Pap smears-  and the 
Colposcopy Clinic, where women with cervical dysplasia would be seen but not necessarily 
with a degree of immunosuppression that would necessitate initiation of antiretroviral therapy 
within the following 18 months. 
 
Decision to start cART was purely per standard protocol and not influenced by cervical 
pathology. The difference in ethnicity found between women who initiated and those who did 
not, could be explained by the referral areas for the two clinics: the IDC serves mostly areas 
surrounding the hospital whereas the Colposcopy referral area reaches wider to include larger 
neighbourhoods with more Black residents. This also may tie in with the slightly lower active 
smoking, alcohol and other substance use in the women who did not need to initiate cART, as 
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these habits tend to be less prevalent in Black women in the respective referring areas, and 
should not necessarily be seen as a reason for better immune status. 
 
The results of previous investigations indicated increased prevalence and persistence of 
cervical dysplasia in women living with HIV infection, but that the risk for progression and 
persistence of cervical dysplasia may be reduced by improving immunity during treatment 
with HIV-suppressing antiretroviral therapy regimens. 
 
Previous studies on the effect of antiretroviral therapy on HPV infection have, however, 
lacked both power and detail, and many failed to show any effect of such treatment.  A 
possible reason for the lack in statistical power experienced could be the simplification of 
chosen outcomes of HPV infection, as was probably required for the statistical methods 
available at that time. Also, authors could have chosen to adopt the familiar terminology from 
cervical dysplasia research. Clinical endpoints, although easy to understand in such a setting, 
do not adequately entertain the statistical effect of repeated measures in a group of women. 
The simplification also ignores the time-dependency of factors that influence HPV detection, 
such as the change in CD4 count and sexual activity during follow-up. We therefore chose to 
apply multivariate GEE analysis using the logistic regression model with detection of HPV 
infection as the primary outcome. The primary predictors were chosen as cART status, time 
on cART and CD4 count<200 in separate analyses. Sexual activity was included as a time-
dependent variable and age as a non-time-dependent variable. 
 
We were also curious as to the possible statistical weakness created by grouping subtypes as 
low-risk (LR) and high risk (HR), or only HR types analysed, thereby ignoring possible 
differences between genotypes in the studies previously done.  A concern was that the 
subtypes could be influenced differently by exposure to cART and immune reconstitution. 
We have therefore also applied multivariate GEE analysis using HPV-16 subtype detection as 
our main outcome, and cART as the main predictor, with other covariates the time-dependent 
variables CD4 count, HIV-RNA level, and days since excision treatment. Here again, age 
was included as a non-time-dependent variable, since the time of follow-up was relatively 
short. Multivariate GEE analysis incorporates a random effect to adjust not only for within-
participant correlation, but can compare the HPV genotypes as a ratio of the odds ratio of as 
base HPV type, in our case we chose HPV16. 
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Due to this study design- not that of a randomized study, but of a prospective design where 
every woman serves as her own control, women who did not start on cART were different 
from those that did. Mostly, the differences reflect the more advanced HIV disease in women 
who needed to initiate treatment. They had lower CD4 counts and higher viral set points. This 
is also reflected in the significant older age and sexual age for the cART treated group, as 
they had possibly lived with HIV infection a longer time. Poorer health might also have 
reduced sexual activity at the time of entering the study for women who did need cART. It is 
possible that the shorter follow-up time for women who did not receive cART reflects at least 
some of the women who died due to complications of immunosuppression, or moved 
elsewhere for medical care. A further consequence of the separate Colposcopy clinic 
enrolment stream was that the cytopathology status at study entry was more LSIL and HSIL 
in the women who did not need to initiate cART, as many women who present at Colposcopy 
do so for evaluation of LSIL and diagnostic biopsy for exclusion of HSIL. This was not a 
concern, as women served as their own controls in follow-up. 
 
There were important similarities between the women regardless of whether cART was 
initiated. Excision treatment, which is usually done for high-grade dysplasia, was done at the 
same prevalence, for the same indication and with similar completeness for the women who 
did initiate cART than those who did not. Although excision treatment may clear HPV 
infection, it does not always eradicate HPV infection and subtypes may persist afterwards, 
especially in immune compromised women. The women who underwent excision treatment 
were thus not excluded from the analysis, but we chose to retain the effect of excision 
treatment as a time-dependent covariate influencing the detection of HPV subtypes. 
 
Having concluded that the decision-making towards initiation of cART was based on immune 
status, and that the basic protocol for excision treatment of dysplastic lesions was applied 
equally regardless of ART or immune status, we proceeded to examine the effect of ART on 
the detection of HPV types. We included in the analysis two time-dependent variables as 
indicators of ART administration. The first, a binary variable, was indicative of receiving 
cART, which was determined by self-reporting (adherence) of ART use, the other that of the 
viral load at the visit. The latter was important, as the HIV-RNA level, even though mostly 
strongly correlated to cART use, may under certain exceptional conditions not be an honest 
reflection of drug use, such as in resistance to cART regimen dispensed. 
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Because the effect of cART may be longer-lived than the actual administration status of the 
medication, we chose to include another time-dependent variable, time-since-cART-first 
started, which depicts the months from the cART initiation date. This variable would 
therefore be independent of cART adherence or interruptions (and the HIV-RNA level). This 
variable harbours a memory effect of immune reconstitution, maybe even on local cervical 
level of indicators not measured, or which may not be reflected by the CD4 count in the 
blood. 
 
As described in some other centres (140), in spite of telephonic outpatient visit reminders and 
intensive tracing, we had some difficulty in maintaining contact with some study subjects. 
Besides reasons of poverty and poor health, a number of non-SA residents without the 
required permits were apprehensive of deportation. Failure to complete study follow-up is 
however not a concern in mixed model effect analyses, as all visits may be included, with no 
resulting bias due to lost to follow-up status. For the same reason, observations for patients 
who died could still be included for the visits completed before such event. 
 
Most prospective observational studies, no matter how rigorous the data collection is, will 
have to deal with missing data points. In this study, all outcome variables (HPV results) were 
complete. Only two variables, namely that of CD4 count and plasma HIV-RNA level, had 
missing values. Because of the complete un-randomness of missing values, that is, they 
represent tests that were intentionally omitted at visits where there could be a very accurate 
prediction of what their value would be, we decided not to implement statistical methods 
such as multiple imputations to calculate values based on population averages.  Instead, for 
CD4 counts, we calculated the average of the preceding and following values, a common 
method to deal with missing such values. For the missing viral load values, single 
imputations according to maximum likelihood of value were used. The viral load imputations 
represent fewer than 5% of the total data sets. 
 
We tested 1101 samples for each of the 37 HPV genotypes. The most frequent oncogenic 
type, as found in other Southern African countries, was HPV16. High-Risk Types were found 
in the majority of women – 94.3% in our cohort had a HR type at some point. The frequency 
of HR is types is higher than reported by Firnhaber (82) in Soweto in 2010, but this may be 
ascribed to the fact that our study purposefully targeted HIV infected women known with 
cervical dysplasia from the Colposcopy clinic as part of the enrolment stream. Also, our 
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figures represent a period of follow-up over a year and are therefore not comparable as 
reflection of prevalence. Nevertheless, the 83% HR prevalence found by Firnhaber, also 
having used Roche Linear Array HPV genotyping, in their once-off screening at their cART 
treatment clinic, corresponds with our high number of HR positive results. 
 
We found that the detection of most HPV genotypes was not specifically associated with 
abnormal cytopathology, except oncogenic types HPV16, -31, 33, -35 and -39 and non-
oncogenic types, HPV6, -42, -70 and – 84. From this, we conclude that detection of many 
HPV subtypes tend to be equally likely in women with normal cytopathology results than 
abnormal results. This remained so when adjusted for the covariates, but excision treatment 
had a significant contribution in reducing this association.  Similarly, the association with 
HSIL was not significant for the presence of most HPV subtypes, except for oncogenic types 
HPV16, -31, 33, -35, -39, -56, -58, -59 and -82 and non-oncogenic types, HPV69, and -70. 
This means that detection of most HPV types is just as likely in the presence of HSIL as in 
the absence thereof. 
 
The lack of exclusive association of subtypes with cervical dysplasia, together with the 
presence of multiple subtypes in most women, moved us to the decision that we needed to 
examine the effect of cART treatment on each subtype, and not just those that can cause 
cancer. Most genotypes can contribute to cervical dysplasia. We did not, therefore, analyse 
the proportional distribution of HPV subtypes associated with lesions. Indeed, the 
oncogenicity of HPV genotypes been described extensively in literature. Also, the purpose of 
this study was not to identify which one of the multiple types detected in a patient was 
causing the lesion that might progress to HSIL. We were seeking to investigate the effect of 
antiretroviral therapy on the presence of HPV on the cervix, because it is this presence that 
may cause the abnormal Pap smear. This is also important on a larger scale of cervical 
disease burden in our HIV population in rural South Africa, where many women have limited 
access to colposcopy clinics and certainly no availability of HPV genotyping tests. 
 
From our analysis we learned that cART exposure reduced the risk of detection of any HPV 
type by 47%. When adjusted for covariates, time of exposure to cART and CD4 count had a 
stronger effect.  Every month since the treatment was first started, reduced the risk detection 
of any HPV type with 7%.  The effect was also significant on HPV16 alone. All non-
oncogenic subtypes were influenced similarly or more strongly than HPV16, as well as the 
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oncogenic type HPV52. Only one oncogenic subtype, HPV39, was influenced marginally less 
(ratio of OR 0.95, CI 0.90-0.99, p=0.04). 
 
We included age, whether the patient was sexually active and time since excision treatment as 
covariates in all analyses, and as expected, the effect of all was significant. Increasing age 
was associated with higher risk of HPV detection, and excision treatment reduced the risk. 
There was a weak association with sexual status, with a marginally increased risk of HPV 
detection. 
 
The effect of cART seemed to be immunology-driven. There was an increased risk for any 
HPV detection at CD4 count<200 (OR 1.63, 1.50-1.77), but when adjusted, the time of cART 
exposure again remained the strongest predictor of risk. There was a weak association of 
HPV-16 with very low CD4 count, with no other HPV genotype significantly less influenced 
and several types more strongly associated with CD4 count<200.  
 
Interestingly, there was a lack of association of HPV detection with HIV-RNA level in our 
adjusted models. This also supports the stronger effect of time of cART exposure than cART 
status at a particular observation point, with the cART exposure time as a mirror of immune 
reconstitution and cART status reflected by the HIV-RNA level. 
 
As described earlier, we were curious to know why previous reports on the effect of cART on 
cervical HPV infection have been so conflicting, with several studies failing to show any 
effect. Firstly, we postulated that HPV subtype differences could have contributed to the 
confusion. It has become possible to test for an increasing number of subtypes over the past 
15 years. Because we were not just interested in the prevention of cervical cancer alone, but 
the impact on cervical dysplasia, we applied the Roche Linear Array Method which can test 
for the largest number of HPV genotypes. We also included all subtypes separately in our 
analyses, and did not just analyse the HR types together as a group. From the similar impact 
of cART on the detection of all subtypes, we could however exclude subtype differences of 
the effect of cART on HPV as a major factor contributing to the authors’ different published 
results. 
 
Our ability to show the impact of cART on HPV infection, where some studies have failed, 
could however be ascribed to several other factors.  We used robust statistical methods that 
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included all study visit observations, avoiding loss of valuable data and statistical power. 
Also, we rejected artificial clinical end points such as prevalence, incident detection and 
persistence in our analyses. These, although applicable and efficient enough in large cohort 
studies of cervical dysplasia, can be fraught with simplifications, and are not suitable for 
interpreting HPV results. Deciding when detection of a HPV subtype is part of prevalence, 
persistence or an incident detection can be subjective, and in any case ignores pre-study 
infection; if we do not really know whether the presence of the virus is due to reinfection or 
reactivation at time points during follow-up, more value would not derived from including 
those definitions in the analysis, however accustomed we have become to them in our 
research of cervical dysplasia. Using them would have led to omission of a large quantity of 
data points. Instead, snapshot detections of HPV presence led to full utilization of 
observations, which again contributed to statistical power. We therefore conclude that the 
combination of using repeated measurement analysis and of using the most applicable binary 
outcome of HPV detection as the reason for our success. 
 
Finally, it can be said that cART reduces cervical HPV infection in a time-dependent and 
immunology-driven manner. In contrast, severe immunosuppression as measured by the CD4 
count, is not independently associated with increased HPV detection.  Because ARVs as 
antiviral medication have no direct anti-HPV effect, one question still remains:  could 
residual cervical HIV replication, in spite of undetectable HIV-RNA levels in the blood, play 
a role? If not, we may have to assume that there are immune deficiencies or immune 
reconstitution effects occurring more on a local cervical level, which may not be reflected in 
the CD4 count, or at least not before the CD4 count dips to below 200. 
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Chapter 5:  Cervical HIV infection and HPV detection  
 
Background 
 
We have previously concluded that cART reduces cervical HPV infection in a time-
dependent and immunology-driven manner. Time since cART first started was found to be a 
stronger predictor of risk for HPV detection than the CD4 count, but even more so than the 
HIV RNA plasma level. We therefore hypothesized that the mechanism by which the reduced 
cervical HPV infection occurs is an early immune reconstitution effect in the cervical 
mucosa. 
 
The life cycle of HPV is entirely intra-epithelial, and the virus can infect no other cells. 
Cervical infection first occurs in the basal keratinocytes via micro-abrasions. From here, the 
life cycles follow closely the path of the keratinocytes as they migrate to the surface 
epithelium, from where viral assembly occurs and mature virions are released.  The HPV, 
however, for most of its replicative life, does not cause cell death; there is no viremia and 
little exposure of its antigens to start the cascade of cytokine release and adaptive immune 
response. This cunning ability to remain invisible to the innate immune defences is witnessed 
as the early persistence of the infection even in non-immunocompromised women (141). 
Eventually, after some months, there is evidence of an immune response against HPV. 
Spontaneous regression of HPV-associated lesions is seen in almost all cases. Clearance of 
the infection is associated with large infiltrates of T cells (both CD4+ and CD8+) and 
macrophages. This cell-mediated Th1 biased response is characterized by the release of pro-
inflammatory cytokines IL-12, IFN-γ and TNF-α (101). In response to HPV infection, there 
is an associated concentration of T-lymphocytes subsets, NK cells and macrophages in the 
transformation zone of the cervix, in contrast to the normal vaginal mucosa, where there are 
few T cells and antigen-presenting cells (APCs) (142).  
 
In contrast to HPV, HIV is capable of infecting more than one cell type. Physical abrasions 
during sexual intercourse puts the virus into close contact with susceptible cells. Virions 
interact and travel through the epithelium along several cellular pathways, which are not all 
associated with productive infection. Cervical cell types that are known to be infected by HIV 
are epithelial cells, CD4 T+ cells, Langerhans Cells (LCs), Dendritic Cells (DCs), 
macrophages and Natural Killer Cells (143-148) (figure 23).   
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Figure 23 Early host invasion by HIV 
(Reprinted with permission from (145)) 
 
 
In women with chronic HIV infection, measured cervical immune markers (CD4 cells, 
macrophages, Langerhans cells, neutrophils, NK cells, and expression of interferon-γ and 
regulatory cytokines) are lower (149-152). The decreased local cervical immunity does not 
appear to be influenced by the CD4 count or plasma HIV RNA load (152). There is reduced 
maturation of HIV-infected monocytes, which may cause decreased antigen presentation 
capacity and generalized lowered T Cell responses (153) at mucosal level. Even worse, it has 
been shown that a subset of activated cervical CD4+ T cells, responsible for production of 
IFN-γ and IL-17 normally associated with the clearance of HPV infection, is almost entirely 
depleted in vivo during HIV infection (154). This could explain, even though not all 
mechanisms have been understood, the increased persistence and multiple HPV subtype 
infection in the same anatomical milieu in women living with HIV/HPV co-infection. There 
is already evidence that cervical HPV infection may increase the risk for contracting HIV 
infection (155-157) due to the high density of HIV-susceptible cells in the cervix. 
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There seems to be a good correlation between plasma and genital HIV viral loads. An 
observational study that followed women after acute infection, saw both measurements 
decrease in parallel after the early period to a viral set point (158). Similarly, initiation of 
cART was found to not only cause a rapid decrease of plasma HIV-RNA levels, but also to a 
dramatic drop, within days (159), in HIV-RNA levels in cervicovaginal samples (160, 161), 
with good correlation between plasma HIV-RNA and cervical HIV-DNA (162). 
 
Despite this, it  has been shown that in as many as half of women who have reached 
undetectable levels of plasma HIV-RNA, detection of HIV-RNA in cervicovaginal lavage 
specimens was still possible (163, 164). Even more so, mutant virus that was different from 
the virus in the blood has been detected in the genital tract of women who were taking non-
suppressive therapy (165-167), indicating ongoing viral production in a separate anatomical 
(i.e. cervical) compartment. Importantly, antiretroviral drug concentrations in the female 
genital tract have been shown to vary (168-170). Most worrying, however, are the extremely 
low concentrations of efavirenz reported in all studies. Almost all women enrolled to our 
prospective study received an efavirenz-containing regimen when initiating cART. 
 
Few studies have been done that have examined the association between HIV infection and  
HPV detection in cervical samples, and these have had conflicting results (162, 171-175). It is 
obvious that evidence for an association between the cervical HIV-Viral Load and the 
presence HPV infection is lacking. From the current research related to eradication efforts of 
the HIV, we think that observations taken from the blood compartment possibly do not 
accurately represent what is happening in the cervical compartment. We therefore proceeded 
to perform an ad hoc sub-analysis, using ultrasensitive HIV DNA qPCR method, to 
investigate if an association between the cervical HIV proviral DNA load and HPV DNA 
detection can be identified. 
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Methods 
 
Study Design, Population, Setting and Outcomes Definition 
This ad hoc sub-analysis was done on the same cohort as described in Chapter 4. The 
prospective study had enrolled women known with HIV infection and were cART naïve or 
had recently (<1 month) initiated cART. Antiretroviral therapy use, CD4 count,  HIV-RNA 
plasma level and HPV Genotyping had been recorded as described in the previous chapter. 
 
HIV DNA Analysis 
HIV DNA copy numbers were measured by the  real-time quantitative PCR method (qPCR) 
on the DNA extracted from the cervical specimens for the HPV analysis, as previously 
described (176). Primers and probes were obtained from Integrated DNA Technologies 
(South Africa) and included parts of the HIV-1 LTR-gag fragment (figure 24). Briefly, The 
iTaqTM universal probe supermix were used (Bio-Rad Laboratories, Inc.) for the PCRs. 
Primers were used in a final concentration of 300nM, while probes were used in a final 
concentration of 150nM (CCR5: Forward ATGATTCCTGGGAGAGACGC, Probe VIC-
AACACAGCCACCACCCAAGTGATCA, Reverse AGCCAGGACGGTCACCTT; HIV-1: 
Forward TACTGACGCTCTCGCACC, Probe FAM-CTCTCTCCTTCTAGCCTC, Reverse 
TCTCGACGCAGGACTCG). The HIV-1 copy number was determined by using the pMJ4 
plasmid copy number as reference (177). The cell numbers were calculated by using pc-
CCR5 (obtained from the NIH AIDS reference reagent laboratory) as a reference for cellular 
copy number. Negative- and positive-control DNA were included in all reactions. Samples 
were run in duplicate on a CFX96 TouchTM Real-Time PCR Detection system (Bio-Rad 
Laboratories, Inc.), at 950C for 15 min, 40 cycles of 950C for 1 minute and 600C for 1 minute. 
Analyses were completed using CFX ManagerTM software.  Data graphs and tables were 
exported to Microsoft Excel for further analysis. The copy numbers of each sample gene 
were analysed against the standard curves and the HIV DNA per 106 cells extrapolated as 
described (174). The threshold of detection of real-time PCR for HIV-1 cellular provirus 
DNA was 10 copy/106 cells, and therefore the lower limit of detection was 1.0 log10/106 
cells. 
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Figure 24 HIV-1 Region detected by the proviral DNA qPCR assay 
Reprinted with permission from (176) 
 
Statistical analysis 
We used  GEE regression analysis to determine the association between the cervical HIV-
DNA level with the plasma HIV-RNA level and in a separate analysis with the detection of 
cervical infection of each HPV subtype respectively. All models were adjusted, using time-
dependent variables, for the CD4+ cell count, plasma HIV-RNA level, the time since cART 
was first started and cART treatment status. P-Values reported were two-tailed and alpha 
level 5%. For the purpose of the analysis, plasma HIV-RNA levels <50 copies/ml were 
reported as 49 copies/ml. Only women whose cervical smears had successful qPCR HIV-
DNA determination performed, were included, leaving on 290 study subjects and the final 
study observations at 1036. 
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Results 
 
Exploratory descriptive analysis: HIV-RNA and -DNA results 
There were more than 100 observations at quarter 0, 2, and 4 after cART was first started, indicating 
adequate representation of ART- exposed subjects in the analysis. The large sample size taken during 
quarter zero represents women at baseline as well as those samples taken during the time initiators 
were still naïve to cART. The small sample sizes at quarter 1, 3, and 5 represent subjects that had to 
initiate cART between the scheduled 6 monthly study visits. Since follow-up for this study was 18 
months, there are very few observations taken after quarter 6 of ART (figure 25). 
 
 
Figure 25 Number of Observations at observation points for quarters 1-10 after cART was first started. 
 
Results plasma HIV-RNA levels 
There was a rapid decrease in the log HIV-RNA level for observations for each quarter after cART 
was initiated (figure 26). 
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Figure 26 Log plasma HIV-RNA level at each quarter after cART first started. 
 
Observations taken at quarter 0 had wide range of log plasma HIV-RNA determinations, with the 
largest share falling in the range of 4-5 log RNA copies/ml. At each quarter 1-6 after ART was first 
started, the % observations that obtained a log value <2.0 exceeded or was close to 80%. This 
indicates a maintained response for most study subjects during the period after initiation of cART. At 
quarters 7-10, the number of observations was smaller and this could have contributed to the aberrant 
distribution. Also, some of the observations quarter 7-10 were repeat samples in women who had 
interrupted cART or developed virological failure (figure 27). 
 
Figure 27 Distribution of Log Plasma HIV-RNA Level Results at observation points for quarters 1-10 since 
cART was first started. 
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Results: Cervical HIV-DNA pVL 
There appears to be a slow decrease in Log Cervical HIV-DNA pVL at each quarter after cART 
initiation date, with the range of values becoming smaller over time since cART was first started 
(figure 28). 
 
Figure 28 Cervical HIV-DNA pVL at each quarter after cART first started. 
 
There was a loss of % extreme HIV-DNA pVL observations (log HIV-DNA >3.0) through quarter 1-
6, with a decrease from approximately 30% to 10% (figure 29). The response appears slower than 
observed for HIV-RNA determination results (figure 27). 
 
Figure 29 Distribution of Log Cervical HIV-DNA pVL at observation points  
for quarters 1-10 since cART was first started. 
 
As to whether observations were done when the study subject was receiving or not on that day, there 
appears to be a dramatic difference in plasma HIV-RNA level. In contrast, there is no difference in the 
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cervical HIV-DNA level when comparing the observations done on cART with not on ART. The log 
HIV-RNA and log HIV-DNA was 4.31±1.05 and 2.43± 1.10 for observations done when not 
receiving cART, and 1.96±0.78 and 2.29±0.99 when receiving cART (figure 30).  
   
Figure 30 Effect of cART on log plasma HIV-RNA levels vs cervical HIV-DNA pVL 
 
Correlation of Cervical HIV-DNA pVL with plasma HIV-RNA level 
When using a scatterplot to compare the relationship of log cervical HIV-DNA pVLwith plasma log 
HIV-RNA levels at each observation, there is a wide cluster of blue points of which the majority fall 
within a range of log HIV-RNA 4-5, representing observations taken during ART naive time. There 
appears to be no monotonic relationship between the values and we therefore did not calculate a 
Spearman Rho value. The range of log HIV-DNA pVL for patients with plasma HIV-RNA<50 
copies/ml (log=1.79) is large, indicating that a low log HIV-RNA level may coincide with from low 
to high cervical HIV-DNA pVL. There were twenty (20) observations with no HIV-DNA pVL 
detected (Figure 31). These samples were representative from different plate runs and all had tested 
positive on our CCR5-DNA positive control gene. Although we were uncertain as to why at these 
observations showed no HIV presence in spite of detectable plasma-RNA levels, we considered it 
possible that the samples represented an HIV subtype not detected by our HIV-DNA probe. However, 
after scrutinizing the samples that had cervical HIV-DNA=0 but plasma HIV-RNA> log 2, only two 
subjects* (no 9 and 14) had more than one sample with no HIV-DNA detected. Also, although twelve 
of the negative HIV-DNA pVL observations had correspondingly low plasma-RNA levels of under 
20,000 copies/ml, five had higher levels. The cytopathology results were also not uniform (i.e. normal 
or abnormal for all). We therefore could find no pattern to explain our negative cervical HIV-DNA 
pVL  results in these 20 observations, other than to conclude that they are very few of the total 
observations of 1036 (table 32). 
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Blue: Not receiving cART   Red: Receiving ART 
Figure 31 Correlation of visit log plasma HIV-RNA with log cervical HIV-DNA 
 
Figure 32 Subjects with negative HIV-DNA pVL observations and corresponding detectable plasma HIV-
RNA levels  
Study 
Subject 
Age 
ART on 
study 
RNA pre-
ART 
On ART 
Days since 
cART started 
CD4 RNA Log RNA DNA Cytopathology 
1 48 yes 775990 yes 491 465 159 2.20 0 Normal 
2 40 yes 100000 yes 168 668 166 2.22 0 Normal 
3 65 yes 846899 yes 538 147 327 2.51 0 Normal 
4 21 no 573 no 0 813 573 2.76 0 LSIL 
5 44 no 981 no 0 372 981 2.99 0 Normal 
6 24 no 1402 no 0 785 1402 3.15 0 Normal 
7 27 yes 75000 yes 175 238 3428 3.54 0 LSIL 
8 41 yes 5006 yes 532 212 3659 3.56 0 Normal 
9* 27 no 6100 no 0 230 6100 3.79 0 LSIL 
10 30 yes 26551 yes 575 305 8411 3.92 0 Normal 
11 29 no 13000 no 0 370 13000 4.11 0 Normal 
12 21 no 14312 no 0 536 14312 4.16 0 ASCUS 
13 45 yes 51719 no 0 169 51719 4.71 0 Normal 
14* 22 no 87688 no 0 464 87688 4.94 0 HSIL 
15 35 yes 170000 no 0 235 170000 5.23 0 LSIL 
16 33 yes 173653 no 0 177 173653 5.24 0 Normal 
17 44 yes 200000 no 168 321 200000 5.30 0 Normal 
18 37 yes 339457 no 642 79 434828 5.64 0 HSIL 
(* had two observations) 
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Association of plasma HIV-RNA level with Cervical HIV-DNA Proviral Load  
 
During the unadjusted GEE population-averaged model analysis of the cervical log HIV-
DNA pVL of >1.0, >2.0 and >3.0, there was no association with the log plasma HIV-RNA 
level. After adjusting for the other covariates, only the time since cART was first started had a 
significant effect, which appeared stronger for higher HIVDNA pVL (table 27-29). 
Table 27 Association of plasma HIV-RNA level with Cervical HIV-DNA pVL >1.0/copies/106 cells 
Variable OR  (95%CI) p-value 
Unadjusted 
Log plasma HIV-RNA level 1·10  (0·95-1·27) 0·22 
Adjusted 
Log plasma HIV-RNA level 0·95  (0·77-1·32) 0·06 
CD4  count 0·99  (0·99-1·00) 0·15 
cART Status 1·33  (0·54-3·27) 0·54 
Months since cART first started 0·96  (0·92-0·99) 0·04 
Months Since Excision Treatment 1·00  (0·97-1·03) 0·82 
 
Table 28 Association of plasma HIV-RNA level with Cervical HIV-DNA pVL >2.0/copies/106 cells 
 
Unadjusted 
Log plasma HIV-RNA level 0·95  (0·87-1·04) 0·24 
Adjusted 
Log plasma HIV-RNA level 0·90  (0·77-1·05) 0·19 
CD4  count 0·99  (0·99-1·00) 0·52 
cART Status 1·51  (0·88-2·60) 0·13 
Months since cART first started 0·95  (0·93-0·98) <0·001 
Months Since Excision Treatment 1·00  (0·97-1·02) 0·97 
 
Table 29 Association of plasma HIV-RNA level with Cervical HIV-DNA pVL>3.0/copies/106 cells 
Unadjusted 
Log plasma HIV-RNA level 1·05  (0·95-1·15) 0·33 
Adjusted 
Log plasma HIV-RNA level 0·96  (0·81-1·13) 0·61 
CD4  count 0·99  (0·99-1·00) 0·40 
cART Status 1·50  (0·84-2·70) 0·17 
Months since cART first started 0·94  (0·91-0·97) <0·001 
Months Since Excision Treatment 1·98  (0·96-1·01) 0·21 
 
  
Stellenbosch University http://scholar.sun.ac.za
 106 | P a g e  
 
Association ART Status with Cervical HIV-DNA Proviral Load 
 
Again applying GEE analysis, now with cART status as the main predictor, time that had 
passed since cART was first started was the strongest predictor of risk, with a 5% reduction 
in risk for the cervical log HIV-DNA level to be >1.0, >2.0 or >3.0 for each month that had 
elapsed. Unadjusted, there was no association of cART status with cervical HIV-DNA pVL 
(table 30-32). 
Table 30 Association of ART Status with Cervical HIV-DNA pVL>1.0/copies/106 cells 
Variable OR  (95%CI) p-value 
Unadjusted 
cART Status 0·77  (0·50-1·19) 0·24 
Adjusted 
cART Status 1·33  (0·54-1·27) 0·54 
CD4  count at visit 0·99  (0·99-1·00) 0·15 
Log plasma HIV-RNA level 1·01  (0·77-1·32) 0·95 
Months since cART first started 0·96  (0·92-0·99) 0·04 
Months Since Excision Treatment 1·00  (0·97-1·04) 0·82 
 
Table 31 Association of ART Status with Cervical HIV-DNA pVL >2.0/copies/106 cells 
Unadjusted 
cART Status 1·10  (0·85-1·43) 0·45 
Adjusted 
cART Status 1·51  (0·88-2·60) 0·13 
CD4  count at visit 0·99  (0·99-1·00) 0·52 
Log plasma HIV-RNA level 0·90  (0·77-1·05) 0·19 
Months since cART first started 0·95  (0·93-0·98) <0·001 
Months Since Excision Treatment 1·00  (0·98-1·02) 0·97 
 
Table 32 Association of ART Status with Cervical HIV-DNA pVL>3.0/copies/106 cells 
Unadjusted 
cART Status 0·83  (0·63-1·10) 0·20 
Adjusted 
cART Status 1·50  (0·84-2·70) 0·17 
CD4  count at visit 0·99  (0·99-1·00) 0·40 
Log plasma HIV-RNA level 0·96  (0·81-1·13) 0·61 
Months since cART first started 0·94  (0·91-0·97) <0·001 
Months Since Excision Treatment 0·98  (0·96-1·01) 0·21 
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Association Time since ART Started with Cervical HIV-DNA Proviral Load 
 
GEE analysis was repeated, now with Time Since cART was first started as main predictor, and it was 
associated with a 4%, 5% and 6% reduction in risk for the cervical HIV-DNA pVL >1.0, >2.0 and 
>3,0, respectively, for each month that had elapsed since the ART initiation date. In the adjusted 
models, no other covariate had a significant influence (table 33-35). 
Table 33 Association of Months since cART started with Cervical HIV-DNA pVL>1.0/copies/106 cells 
Variable OR  (95%CI) p-value 
Unadjusted 
Months since cART first started 0·97  (0·95-0·99) 0·02 
Adjusted 
Months since cART first started 0·96  (0·92-0·99) 0·04 
CD4  count at visit 0·99  (0·99-1·00) 0·15 
Log plasma HIV-RNA level 1·01  (0·77-1·32) 0·95 
cART Status 1·33  (0·54-3·23) 0·54 
Months Since Excision Treatment 1·00  (0·97-1·04) 0·82 
 
Table 34 Association of Months since cART started with Cervical HIV-DNA pVL >2.0/copies/106 cells 
Unadjusted 
Months since cART first started 0·98  (0·97-0·99) 0·04 
Adjusted 
Months since cART first started 0·95  (0·93-0·98) <0·001 
CD4  count at visit 0·99  (0·99-1·00) 0·52 
Log plasma HIV-RNA level 0·90  (0·77-1·05) 0·19 
cART Status 1·51  (0·88-2·60) 0·13 
Months Since Excision Treatment 1·00  (0·98-1·02) 0·97 
 
Table 35 Association of Months since cART started with Cervical HIV-DNA pVL >3.0/copies/106 cells 
Unadjusted  
Months since cART first started 0·96  (0·94-0·98) <0·001 
Adjusted 
Months since cART first started 0·94  (0·91-0·97) <0·001 
CD4  count at visit 0·99  (0·99-1·00) 0·40 
Log plasma HIV-RNA level 0·96  (0·81-1·13) 0·61 
cART Status 1·50  (0·84-2·70) 0·17 
Months Since Excision Treatment 0·98  (0·96-1·01) 0·21 
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Association of Cervical HIV-DNA Proviral Load with HPV Detection 
 
During the unadjusted GEE regression analysis of the association of the cervical log HIV-DNA pVL 
with HPV detection, there was an increased risk for the detection of any HPV subtype with higher 
HIV-DNA pVL. The unadjusted association was also significant for the detection of HPV 16 and/or 
HPV 18, but less so for any HR HPV. The association remained significant when adjusting for the 
other covariates, but not for HR HPV. There was also a significant association with the time that had 
elapsed since cART was first started. For HR HPV and HPV 16/18, excision treatment was associated 
with reduced risk of detection.  The plasma HIV-RNA level was not a predictor of risk (table 36-38). 
 
Table 36 Association of Cervical HIV-DNA pVL with Detection of Any HPV Type 
Variable OR  (95%CI) p-value 
Unadjusted  
Log Cervical HIV-DNA pVL 1·42  (1·16-1·71) <0·001 
Adjusted 
Log Cervical HIV-DNA pVL 1·30  (1·08-1·57) 0·007 
CD4  count at visit 0·99  (0·99-1·00) 0·19 
Log plasma HIV-RNA level 1·05  (0·80-1·38) 0·71 
cART Status 0·49  (0·20-1·19) 0·11 
Months Since ART First Started 0·95  (0·93-0·98) 0·003 
Months Since Excision Treatment 0·98  (0·96-1·01) 0·21 
 
Table 37 Association of Cervical HIV-DNA pVL with Detection of any HR HPV Type 
Unadjusted  
Log Cervical HIV-DNA pVL 1·17  (1·03-1·33) 0·02 
Adjusted 
Log Cervical HIV-DNA pVL 1·07  (0·93-1·22) 0·34 
CD4  count at visit 0·99  (0·99-1·00) 0·13 
Log plasma HIV-RNA level 0·99  (0·83-1·20) 0·99 
cART Status 0·69  (0·38-1·26) 0·22 
Months Since ART First Started 0·95  (0·93-0·97) <0·001 
Months Since Excision Treatment 0·98  (0·96-1·00) 0·08 
 
Table 38 Association of Cervical HIV-DNA pVL with Detection of HPV 16 and/or HPV 18 
Unadjusted  
Log Cervical HIV-DNA pVL 1·23  (1·10-1·39) <0·001 
Adjusted 
Log Cervical HIV-DNA pVL 1·19  (1·05-1·33) 0·005 
CD4  count at visit 1·00  (0·99-1·00) 0·13 
Log plasma HIV-RNA level 1·10  (0·93-1·31) 0·25 
cART Status 0·95  (0·54-1·67) 0·86 
Months Since ART First Started 0·95  (0·93-0·98) 0·002 
Months Since Excision Treatment 0·96  (0·93-0·99) 0·01 
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Association of Multiple HPV Detection with Cervical HIV-DNA Proviral Load 
 
Applying Gaussian GEE regression, there was a significant positive association between the number 
of HPV types detected and HIV-DNA pVL. This remained significant when adjusting for other 
covariates. There was a highly significant negative association of time that had elapsed since cART 
initiation and the cervical HIV-DNA pVL detected (table 39). 
 
Table 39 Association of Number of HPV types with Cervical HIV-DNA pVL 
Variable Coeff  (95%CI) p-value 
Unadjusted  
Number of HPV Types Detected 0·04  (0·02-0·06) <0·001 
Adjusted 
Number of HPV Types Detected 1·03  (1·01-1·05) 0·01 
CD4  count at visit 0·99  (0·99-1·00) 0·24 
Log plasma HIV-RNA level 0·96  (0·89-1·04) 0·30 
cART Status 1·09  (0·85-1·41) 0·50 
Months Since ART First Started 0·98  (0·96-0·98) <0·001 
Months Since Excision Treatment 0·99  (0·99-1·01) 0·64 
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Discussion 
 
We have previously found that cART reduces risk for cervical HPV detection by almost 50%, 
but that it occurs in a time-dependent manner, and that this effect possibly precedes CD4 
recovery or may even not be reflected by the CD4 count in the blood. We also failed to show 
an adjusted association between the plasma HIV-RNA levels with the risk for cervical HPV 
detection, where the time since cART was started was always a stronger predictor of risk. We 
were therefore performed an ad hoc sub-analysis to investigate if there exists an association 
of cervical HIV- pVL with the risk of HPV detection. From our prospective study of the 
effect of cART on HPV detection described in Chapter 4, we used stored DNA samples and 
performed real-time PCR to determine the level of HIV-DNA copies per million cells present 
in each cervical smear. We found that, in contrast to plasma HIV-RNA levels, increased 
cervical HIV-DNA pVL is associated with an increased risk in HPV detection. Of note, this 
association remained significant when adjusted for the time that had elapsed since cART was 
first started. 
 
As this was an exploratory study into a field where little evidence exists as to the events on a 
cervical level in the time shortly after cART is initiated, we did preliminary descriptive 
investigative analyses, before moving on to reporting regression results. When we looked at 
the distribution of plasma HIV-RNA observations, while still ignoring subject relationships, 
we saw that receiving cART led to a rapid decrease in values that was sustained throughout 
the observation period. In contrast, cervical HIV-DNA levels showed no significant 
difference if the observation was taken at a study visit whilst receiving cART or not. The 
change in observed levels is small and slow, with loss only of the highest HIV-DNA pVL 
measurements, here noted as a log HIV-DNA >3.0, during the first 18 months after initiating 
cART.  
 
When exploring the relationship of plasma HIV-RNA levels with cervical HIV-DNA pVL, 
we  found a wide range of cervical HIV-DNA pVL for women who are receiving cART and 
have plasma HIV-RNA levels <50 copies (log HIV-RNA=1.79). This contrasts with previous 
reports: initiation of cART was found to not only cause a rapid decrease of plasma HIV-RNA 
levels, but also to a dramatic drop, within days (159), in HIV-RNA levels in cervicovaginal 
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samples (160, 161), with good correlation between plasma HIV-RNA level and cervical HIV-
DNA pVL (162, 173).  
 
We applied GEE regression analyses to our longitudinal observation sets to include intra-
participant relationships in our results. We found that there is no association between plasma 
HIV-RNA levels and cervical HIV-DNA pVL. Instead, time since cART started was 
associated strongly with a reduction in risk for the cervical HIV-DNA pVL to be >1.0, and it 
became stronger for log HIV-DNA >2.0 and >3.0. This confirmed our suspicion that cervical 
HIV-DNA burden decreases more slowly than the plasma HIV-RNA load. 
 
We repeated the analyses with cART status and time since cART was started as primary 
predictors separately. Again, it confirmed our suspicion that cervical HIV-DNA pVL was not 
significantly determined by whether a patient was receiving cART at the observation point, 
but how much time had elapsed since she started receiving it. 
 
Finally, we used regression to investigate the association of cervical HIV-DNA pVL with 
HPV detection. There was an increased risk of detection of any HPV type, as well as HPV16 
and/or HPV18, with higher HIV-DNA pVL from the cervix. This remained significant when 
adjusting for the time that had passed since cART was started. However, the effect of HIV-
DNA pVL was not as strongly associated with HR-HPV, but time since cART was started 
still was a strong predictor of risk. Interestingly, excision treatment also became a significant 
predictor for the HR HPV and HPV 16/18, which relates to these subtypes as being more 
prevalent in high-grade CIN and the need for excision biopsy treatment. 
 
As explained in Chapter 4, we chose not to investigate HPV viral load measurements or HPV 
mRNA expression. These have been done before, and persistent high HPV viral loads and 
HPV mRNA were linked to the severity of CIN and development of cancer (83). In this sub-
analysis, we wanted to look at the interaction of the amount of HIV infection in the cervix on 
the risk for HPV infection, as the focus of this research was to investigate the behaviour of 
HPV associated disease in HIV-infected women. 
 
We could now show that the slow decrease in cervical HIV-shedding mirrors the reduction in 
HPV infection experienced during the time of cART.  This is in contrast to the faster HIV-
RNA reductions observed in blood. This is an early indication that the cervical milieu 
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behaves as a separate anatomical HIV compartment. This slow decrease in cervical HIV-
DNA pVL may still be mainly due to a continued seeding of HIV to the cervical 
compartment in response to the presence of HPV. However, there exists the possibility that 
ongoing viral replication is occurring which is largely isolated from the blood compartment, 
especially since some antiretroviral agents have very low penetration in cervical tissues. Viral 
sequencing studies to compare the evolution of the virus between cervical and blood samples 
are therefore planned. Sequencing may also assist us in gaining further understanding into the 
reason for the negative HIV-DNA pVL results in the twenty observations. 
Stellenbosch University http://scholar.sun.ac.za
 113 | P a g e  
 
 Chapter 6:  Final Conclusions 
 
Cervical intraepithelial dysplastic lesions are caused by infection with HPV.  Persistence of 
HPV infection, particularly with oncogenic HPV types, is linked to an increased risk for 
development of cancer. Women who are co-infected with HPV and HIV have higher 
persistence of cervical HPV, which would make them at higher risk for the development of 
cancer of the cervix than their HIV-uninfected counterparts. It has been postulated that the 
high mortality due to AIDS initially prevented a noticeable increase of cervical cancer in 
Africa. It was also feared that the rollout of HIV treatment programmes could subsequently 
cause a re-emergence of cervical cancer due to increased longevity in women living with 
HIV-infection. Indeed, during the time that we have been engaged in this research, some 
evidence has emerged as to the increased risk of HIV infected women for development of 
invasive cervical cancer. This increase was observed in younger women (<40 years) and 
women with more severe immunosuppression (178-180). In the larger of the investigative 
studies, 132 women with cervical cancer and 120 with normal cytology were included, and of 
these women, 89.4% and 31.1% respectively, tested HPV HR positive. The authors report 
that HIV infection was associated with cervical cancer in the women who were HPV high-
risk positive (OR 4.5, 95% CI 1.5-13.6) (181). However, a rise in cervical cancer cases 
amongst HIV-infected women has not yet been observed in developed countries, and this is 
why the question first arose if immune recovery as seen in HIV treatment programs has been 
responsible for the protection against development of the said cancer. 
 
HIV infection is a largely manageable disease. Many Sub-Saharan countries, where the 
prevalence of both HIV and HPV infection is endemic, have well-established antiretroviral 
treatment programs. Certainly, we have found that women who are on antiretroviral treatment 
have a lower risk of progression and reduced persistence of dysplastic lesions. cART also  
improves excision treatment outcome by reducing post-excision recurrence. This has been 
confirmed by other authors. The question remained, as we know that HPV causes cervical 
disease, why have previous studies that measured directly the effect of cART on HPV 
infection been so conflicting?  
 
We developed two theories that could explain the differences. Firstly, the few studies that had 
been done covered more than two decades of technical development and epidemiological 
changes. Very few patients were enrolled to the earlier studies, or too few of the study 
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subjects actually received cART. With the advancement of detection methods to include 
more HPV types, we postulated that it could also have been possible that not all types were 
influenced equally by the immune restoration offered by cART. Interestingly, outcomes had 
been simplified over time to cope with the expanding spectrum of HPV detection capability, 
and women were observed as having “any HR type present”, without distinguishing between 
individual subtype effects. 
Secondly, in the analysis of outcomes, investigators remained loyal to terminology adopted 
from research methodology in the field of Cervical Dysplasia, with the outcomes being 
persistence, clearance, recurrence and incident detection. Not only do these artificial 
outcomes ignore the previous history during assumptions or generalizations made at time 
zero, but the effects of changes in other factors that could influence the outcomes are ignored. 
Logistic regression, setting binary outcomes at a chosen interval, or survival analysis testing 
time to a specified end point, were performed. The weaknesses of applying such methods are 
that most data sets or observation points in a patient’s follow-up time are ignored and that a 
left-sided truncation of time is afforded. Also, women who were lost to follow-up, or were 
followed for shorter periods of time, had to be excluded. This led to loss of statistical power 
and created bias in ignoring the women likely to have more advanced immunosuppression. 
  
This is again evident in a very recent paper published at the time that this dissertation is 
submitted. Although longitudinal data was collected on 326 HIV-infected women, HPV types 
were grouped as oncogenic type, HPV16 or HPV type other than HPV16/18. The authors 
used a 2-state Markow model, a type of survival analysis, to assess the effect of HAART, 
CD4 and other covariates on acquisition and clearance of HPV infection. HAART was 
identified as yes/no, but the time that it had been administered was not taken into account. 
Also, sexual activity was identified as life-time partners, which is a time-independent 
variable. Nevertheless, they did find that HAART increased the likelihood of clearance of 
oncogenic types other than HPV16/18 (HR 2.2 p=0.01) (182). 
 
In contrast, we chose to maximize statistical power by using all available data sets in a 
clustered or repeated measures design. Each woman served as her own control, was not 
excluded due to earlier drop-out, and each covariate incorporated as a time-dependent 
variable. Also, we abandoned the artificial end points (e.g. persistence), rather restricting 
HPV test results to what they were designed to reflect: the detection of HPV infection at a 
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certain time point. We were able to show that cART reduced the chance of detecting any 
HPV type on a cervical smear by almost 50%. Moreover, the effect was time-dependent, in 
that the time since cART was started was the strongest predictor of risk, even stronger than 
the CD4 recovery measured in blood. According to our knowledge, this was the first 
expression, as an odds ratio, of reduced risk of cervical HPV infection associated with 
initiation of antiretroviral treatment. Moreover, we could show that almost all HPV subtypes 
were affected at least as strongly by the initiation of cART than our chosen base type, 
HPV16. We attributed prior conflicting study results to research methodology, and not to 
HPV subtype differences, as cause for these differing reports. 
 
Paradoxically, even though the time that elapsed since cART was first started was the 
strongest predictor of HPV detection, we found that plasma RNA levels were not 
significantly associated with the HPV detection risk. This was unexpected, as we know that 
cART reduces plasma HIV-RNA levels. We therefore performed a sub-analysis to investigate 
the role of amount of cervical HIV infection in the risk for HPV detection. Higher cervical 
HIV-DNA pVL was significantly associated with the increased HPV detection risk. This 
cannot simply be viewed as a causative relationship, however. The higher cervical HIV-DNA 
pVL could also be due concomitant processes in the cervix.  We suggest that the cervix is 
behaving more like a separate anatomical compartment, where the inflammatory environment 
of HPV-infected mucosa is populated by HIV-vulnerable cells. We are concerned about the 
effect of possible continuing HIV replication in the cervix contributing to viral evolution and 
efavirenz resistance. Therefore, we plan to use more sophisticated methods to explore the 
mechanism by which cART reduces cervical HPV infection, including cellular immune 
markers and HIV sequencing. 
 
To the Clinician, our research already has delivered had some important messages. During 
the years we have been actively involved in studying cervical dysplasia and the effect of 
cART on cervical HPV infection, we have observed the improved Pap screening efforts. 
Indeed, it has been integrated into the HIV management protocol as a standard screening visit 
procedure, regardless of the woman’s age. Referral protocols have been improved, both from 
our IDC and Colposcopy Clinic. These efforts will be maintained. Importantly, HIV testing 
has become a standard screening test at the Colposcopy Clinic. 
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For the Gynaecologist, there are specific lessons learned. Women living with HIV–infection 
have much higher failure of excision treatment of HSIL. Moreover, initiating cART before 
excision treatment of HSIL will improve the outcome and lower the recurrence. However, the 
importance of excision treatment of HSIL, and not just providing cART, was again 
demonstrated and it remains indicated in women who are receiving cART.  
For the HIV Clinician, apart from the awareness of the importance of screening for cervical 
disease and providing cART, we need to engage in further study of the impact of cervical 
HIV infection on the viral evolution and resistance development.  
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Appendix 6:  Participant Information Leaflet and Consent Form 
 
Title of research project: 
A  Prospective Descriptive study of the Effect of Highly Active Antiretroviral Therapy on Human 
Papilloma Virus Infection and Cervical Cytological Abnormalities and in HIV Infected Women 
 
Principal Investigator: 
Dr MD Zeier 
 
Address: 
Room 77 
Infectious Diseases Clinic 
C8A East 
Tygerberg Hospital 
Parow 7505 
 
Contact number: 
Tel: +27-21-9385230 
Cell: +27827846605 
Fax: +27-86-5032614 
 
 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study staff 
or doctor any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and how 
you could be involved.  Also, your participation is entirely voluntary and you are free to decline to 
participate.  If you say no, this will not affect you negatively in any way whatsoever.  You are also 
free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University and 
will be conducted according to the ethical guidelines and principles of the international Declaration 
of Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council 
(MRC) Ethical Guidelines for Research. 
What is this research study all about? 
This study will be conducted at the colposcopy clinic on the third floor and the Infectious Diseases 
Clinic on the eighth floor at Tygerberg Hospital. There are no other sites. There will be approximately 
one hundred and fifty participants recruited (this number may vary according to the findings of the 
study). The study will continue for approximately two years.  
There is evidence that HIV positive women with HPV infection (the virus that causes warts) may be 
more likely to develop cancer of the Cervix (mouth of the womb). Therefore we advise all women 
with HIV infection to undergo regularly testing for early lesions of this cancer. This is called Pap 
smear testing. More sensitive tests are now available where we can also test for this HPV directly, in 
the same way we would normally do a PAP smear. We are trying to find out if providing HIV women 
with antiretroviral treatment protects them from the HPV infection or helps them to get rid of it 
more quickly.  
Why have you been invited to participate? 
You have been identified as being a carrier of the Human Immunodeficiency Virus, or as it is usually 
called, as being HIV positive. HIV infection causes weakening of the immune system over some 
years, with the result that your body may lose its ability to protect you against certain infections, 
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such as infection with certain viruses. It may be that the HPV may cause you to develop early forms 
of cancer of the mouth of the womb. Normally, the only way we can find out if you already have this 
infection, is to do a Pap smear to see if the virus has caused these lesions to develop. In this study, 
we can do other more sensitive tests for the HPV virus that causes cancer of the cervix. We will 
follow normal procedure and refer you for antiretroviral therapy (this is used to limit the activity of 
the HIV) to the Infectious Diseases Clinic in Tygerberg Hospital, or if you have already been seen 
there, refer you for Pap smear and HPV testing. 
What will your responsibilities be? 
You will have to undergo a Pap smear screening every six months, which will include the HPV tests, 
every six months, for a period of 18 months. 
Will you benefit from taking part in this research? 
You will benefit from this study because we will be able to offer you an additional test for HPV 
infection. Because there is conflicting evidence if antiretroviral therapy may help you to get rid of 
HPV infection, it is not yet known whether treatment with ARV will protect you from developing 
cervical cancer.  
Are there in risks involved in your taking part in this research? 
There is minimal risk involved. You may developed some bleeding or infection after the HPV smear is 
taken, in the same way this may happen after a Pap smear. 
If you do not agree to take part, what alternatives do you have? 
If you do not take part in the study you will have access to standard management of abnormal Pap 
smear results which will include referral to the colposcopy clinic and removal of these lesions as 
prescribed by standard management protocols, but this will not include the HPV test. The HIV 
infection and treatment will be provided regardless if you take part or not, according to the 
Government Roll-out Programme of antiretroviral treatment. 
Who will have access to your medical records? 
All information will remain strictly confidential and will be protected. The members of the research 
team on the study are all also members of the staff at the Infectious Diseases Clinic and the 
Colposcopy Clinics at Tygerberg Hospital and they will be the only people that have access to the 
information. During the data analysis phase, all participants will remain anonymous and then there 
will be no way of identifying the participants. The anonymous information from this study will be 
used to compile a document which will be published. 
What will happen in the unlikely event of some form injury occurring as a direct result of 
your taking part in this research study? 
There will be no injury as the additional test, the HPV tests, are done in the same manner as a 
routine Pap smear and will be done during the same procedure. 
 
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid to take part in the study. Your will be reimbursed for the cost of your 
transport to the hospital for each visit, to assist you with attending your outpatient clinic for the 
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specific study-related appointments. The funding for the study is provided by the HIV Research Unit 
of the Stellenbosch University as well as PEPFAR (US President's Emergency Plan for AIDS Relief ). 
 
Is there anything else that you should know or do? 
You can contact Dr MD Zeier at tel. (021) 9385230/0827846605 if you have any further queries or 
encounter any problems. 
You can contact the Committee for Human Research at (021) 9389207 if you have any concerns or 
complaints that have not been adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own records. 
 
 
 
 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study entitled: 
 A  Prospective Descriptive study of the Effect of Highly Active Antiretroviral Therapy on 
Human Papilloma Virus Infection and Cervical Cytological Abnormalities in HIV Infected 
Women. 
I declare that: 
I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. 
I have had a chance to ask questions and all my questions have been adequately answered. 
I understand that taking part in this study is voluntary and I have not been pressurized to take 
part. 
I may choose to leave the study at any time and will not be penalized or prejudiced in any way. 
I may be asked to leave the study before it has finished, if the study doctor or researcher feels it 
is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20….. 
 
 
.........................................................................   ................................................................  
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
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I explained the information in this document to ………………………………….. 
I encouraged her to ask questions and took adequate time to answer them. 
I am satisfied that she adequately understands all aspects of the research, as discussed above 
I did/did not use a translator.  (If a translator is used then the translator must sign the declaration 
below). 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20. 
 
.........................................................................   ................................................................  
Signature of investigator Signature of witness 
 
 
 
 
 
Declaration by translator 
 
I (name) ……………………………………………..……… declare that: 
 
I assisted the investigator (name) ………………………………………. to explain the information in this 
document to (name of participant) ……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
We encouraged her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
I am satisfied that the participant fully understands the content of this informed consent document 
and has had all her questions satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
.........................................................................   ................................................................  
Signature of translator      Signature of witness 
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Appendix 4:   Participant Information Leaflet and Consent Form, 
Addendum 7 June 2011 
 
 
Title of research project: 
A  Prospective Descriptive study of the Effect of Highly Active Antiretroviral Therapy on Human 
Papilloma Virus Infection and Cervical Cytological Abnormalities and in HIV Infected Women 
 
Principal Investigator: 
Dr MD Zeier 
 
Address: 
Room 77 
Infectious Diseases Clinic 
C8A East 
Tygerberg Hospital 
Parow 7505 
 
Contact number: 
Tel: +27-21-9385230 
Cell: +27827846605 
Fax: +27-86-5032614 
 
 
 
You completed 18 months enrolment to this research project.  Please take some time to read the 
information presented here, which will explain the details of this addendum.  Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand.  It is 
very important that you are fully satisfied that you clearly understand what this research entails and 
how you could be involved.  Also, your participation is entirely voluntary and you are free to decline 
to participate.  If you say no, this will not affect you negatively in any way whatsoever.  You are also 
free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University and 
will be conducted according to the ethical guidelines and principles of the international Declaration 
of Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council 
(MRC) Ethical Guidelines for Research. 
 
What is this addendum all about? 
This addendum does not replace or change any part of the original consent form you have signed. 
We would like to offer you to continue participation in this project by one more year (two more 
visits) if  you have not yet cleared the HPV viral infection on your Pap smears, i.e. your last test was 
still positive. At the two extra visits, we will do the same procedures as with all other follow-up visits:  
a Pap smear, a HPV test on that smear and a CD4 count (if not done at your local clinic). 
We also want to ask you permission to do a special test on the samples we collected at the first visit. 
This is similar to the HPV test, where we characterized the HPV virus as being one of the oncogenic 
(cancer) types or not, but we also want to test which type of HIV you have in your blood and in the 
Pap smear. We will not do any tests on your own (human) DNA.  Please indicate on the signature 
page if you agree to this test. 
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Is there anything else that you should know or do? 
You can contact Dr MD Zeier at tel. (021) 9385230/0827846605 if you have any further queries or 
encounter any problems. 
You can contact the Committee for Human Research at (021) 9389207 if you have any concerns or 
complaints that have not been adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own records. 
 
 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study entitled: 
 A  Prospective Descriptive study of the Effect of Highly Active Antiretroviral Therapy on 
Human Papilloma Virus Infection and Cervical Cytological Abnormalities in HIV Infected 
Women. 
 
I declare that: 
I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. 
I have had a chance to ask questions and all my questions have been adequately answered. 
I understand that taking part in this study is voluntary and I have not been pressurized to take 
part. 
I may choose to leave the study at any time and will not be penalized or prejudiced in any way. 
I may be asked to leave the study before it has finished, if the study doctor or researcher feels it 
is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 I agree or     I DO NOT agree 
to have a test done on the sample taken at the first visit  to have a test done on the samples 
taken at the first visit which will determine the type of HIV I have. 
 I want to     I DO NOT want to 
 
continue participation in the study for a further year (two visits).  
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 201…..    
 
 
Signature of participant...................................Signature of witness......................................... 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
I explained the information in this document to ………………………………….. 
I encouraged her to ask questions and took adequate time to answer them. 
I am satisfied that she adequately understands all aspects of the research, as discussed above 
I did/did not use a translator.  (If a translator is used then the translator must sign the 
declaration below). 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 201 
 
.........................................................................   ................................................................  
Signature of investigator Signature of witness 
 
 
 
 
 
 
 
Declaration by translator 
 
I (name) ……………………………………………..……… declare that: 
 
I assisted the investigator (name) ………………………………………. to explain the information in this 
document to (name of participant) ……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
We encouraged her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
I am satisfied that the participant fully understands the content of this informed consent document 
and has had all her questions satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 201 
 
.........................................................................   ................................................................  
Signature of translator      Signature of witness 
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Appendix 5:  CCR5 and HIV-DNA standardization Curves 
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Appendix 6:  Sample HPV-DNA Results 
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Appendix 7:  Samples of Patient HPV-DNA Results 
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